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Abstract 
The aim of this project was to determine the best materials and surface treatments for 
soft tissue repair and to enhance our understanding of material / cell interactions by 
comparing the response of human cells growing on a selection of currently approved 
and novel biomaterials.  This study focused on comparing the materials and also 
investigated the effect of modifying the surfaces using gas plasma and other 
treatments with the aim of enhancing cell growth.  In addition, chitosan was studied 
to examine the reported bacteriostatic effect and promotion of human cell growth. 
 
Chitosan has many properties but this research focused on its reported acceleration of 
wound healing haemostatic and bacteriostatic properties.  To examine the 
bacteriostatic properties of chitosan, a number of experimental designs were used.  
The bacteriostatic study led onto a selection of means to incorporate chitosan 
into/onto some of the biomaterials being tested.   
 
A selection of biomaterials were examined for their ability to support tissue growth in 
native and surface modified forms (plasma treatment/ chitosan treatment).  Cells were 
seeded on the samples and the growth of the cells was measured at weekly intervals. 
 
The outcome of this research was that the optimal material for soft tissue repair was 
found to be polyurethane with an ammonia plasma treatment.  This can be made into 
a mesh prosthesis for hernia repair and can be coated with chitosan to inhibit bacterial 
colonisation if required. 
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Definitions 
Aliphatic 
“Pertaining to any member of one of the two major groups of organic compounds, 
those with branched or chain structure.” 
(Dorland, 2009) 
Alloplast 
“An inert foreign body used for implantation into tissue.”  
(Dorland, 2009). 
Antibiotic 
“Antibiotics are a class of natural and synthetic compounds that are able 
selectively and at low concentrations to destroy or inhibit the growth of other 
organisms, especially microorganisms.” 
(Oxford Dictionary of Biochemistry and Molecular Biology, 2000). 
Ångström 
A unit of length equal to one hundred-millionth of a centimetre (10
-10
 meter). 
(The Oxford Dictionary, Thesaurus and Wordpower Guide, 2001) 
Apoptosis 
“Cell death as a result of an intracellular “suicide” programme.  It is a normal 
and essential event during development generally and within the immune system.  
Apoptosis does not lead to lysis of cells and thus avoids damage to neighbouring 
tissue.  Alt. Programmed cell death.” 
(Henderson's Dictionary of Biology, 2008) 
 
 
 
viii 
Biocompatibility 
“The ability of a material to perform with an appropriate host response in a 
specific application”  
(Definitions in Biomaterials, 1986).   
This is the preferred definition, commonly referred to as the Williams definition of 
biocompatibility (The Williams Dictionary of Biomaterials, 1999). 
“Comparison of the tissue response produced through the close association of the 
implanted candidate material to its implant site within the host animal to that 
tissue response recognised and established as suitable with control materials”  
(ASTM International, 2008).  This is a specific definition as it refers solely to 
implanted devices and the local tissue response. 
Biomimetic material 
“Any material that is structurally or chemically analogous to a component of 
plant or animal tissue and which can be incorporated into any product whose use 
is based on the characteristics of that tissue component.” 
(The Williams Dictionary of Biomaterials, 1999) 
Bactericidal 
“Causing the death of bacteria.” 
(Henderson's Dictionary of Biology, 2008) 
Bacteriostatic 
“Inhibiting growth but not killing bacteria.” 
(Henderson's Dictionary of Biology, 2008) 
 
 
 
ix 
Chitin 
“Insoluble, linear polysaccharide forming the principal constituent of arthropod 
exoskeletons and found in some plants, particularly fungi.” 
(Dorland, 2009) 
Cytotoxic 
“Attacking or destroying cells.” 
(Henderson's Dictionary of Biology, 2008) 
Extrusion 
“To shape a material such as metal or plastic by forcing it through a die. “  
(The Oxford Dictionary, Thesaurus and Wordpower Guide, 2001) 
Fibroblast 
“Flattened, irregular-shaped connective tissue cell, ubiquitous in fibrous 
connective tissue. It secretes components of the extracellular matrix, including 
type 1 collagen and hyaluronic acid.” 
(Henderson's Dictionary of Biology, 2008) 
Fistula 
“An abnormal passage between two internal organs or from an internal organ to 
the body surface.” 
(Dorland, 2009) 
Granuloma 
“Inflammatory tissue nodule containing proliferating lymphocytes, fibroblasts, 
giant cells and epithelioid cells, which forms in response to chronic infection or 
persistence of antigen.” 
(Roitt and Delves, 1994). 
x 
Hernia  
“Protrusion of a portion of an organ or tissue through an abdominal opening.” 
(Dorland, 2009) 
Abdominal hernia 
“One through the abdominal wall, either a congenital defect or a complication of 
pregnancy or a surgical incision.”  
(Dorland, 2009) 
Diaphragmatic hernia 
“Hernia through the diaphragm.” 
(Dorland, 2009) 
Incisional hernia 
“One through an old abdominal incision.” 
(Dorland, 2009) 
Inguinal hernia 
“Hernia into the inguinal canal.” 
(Dorland, 2009) 
Cystocele 
“Hernial protrusion of the urinary bladder, usually through the vaginal wall.” 
(Dorland, 2009) 
Enterocele 
“An enterocele is essentially a vaginal hernia in which the peritoneal sac 
containing a portion of the small bowel extends into the rectovaginal space 
between the posterior surface of the vagina and the anterior surface of the 
rectum.” 
(Diagnosing and Treating an Enterocele, 1999). 
xi 
Rectocele 
“Hernial protrusion of part of the rectum into the vagina.” 
(Dorland, 2009) 
Mechanotransduction 
“Mechanotransduction refers to the many mechanisms by which cells convert 
mechanical stimulus into chemical activity.” 
(Katsumi et al., 2004, Liu et al., 1996). 
Nosocomial 
“Hospital acquired, in relation to infections.”  
(Henderson's Dictionary of Biology, 2008) 
Osteoblast 
“Bone forming cell that secretes the bone matrix.” 
(Henderson's Dictionary of Biology, 2008) 
Parastomal 
“Para- indicating beside or near.  Stoma (stomal) mouth-like opening, 
particularly an incised opening which is kept open for drainage or other 
purpose.” 
(Dorland, 2009) 
Plasma (gas) 
“Plasma, the 4
th 
state of matter, is a partially ionised gas containing ions, 
electrons, atoms and neutral species.” 
(Palmers, 1999) 
xii 
Prolapse  
“1. ptosis; the falling down, downward placement, of a part of the viscus.  2. To 
undergo such displacement.” 
(Dorland, 2009) 
Uterine; 
“Downward displacement of the uterus so that the cervix is within the vaginal 
orifice (first degree prolapse), the cervix is outside the orifice (second degree 
prolapse), or the entire uterus is outside the orifice (third degree prolapse).” 
(Dorland, 2009) 
Pelvic Floor 
 
Fig i (Stanford University, 2008) 
“The pelvic floor or pelvic diaphragm is composed of muscle fibres of the levator 
ani, the coccygeus and associated connective tissue which span the area 
underneath the pelvis.  The pelvic diaphragm is a muscular partition formed by 
the levators ani and coccygei, with which may be included the parietal pelvic 
fascia on their upper and lower aspects.  The pelvic floor separates the pelvic 
cavity above from the perineal region (including perineum) below.” 
(Stanford University, 2008) 
xiii 
Kegel exercises 
“A Kegel exercise, named after Dr. Arnold Kegel, consists of contracting and 
relaxing the muscles which form part of the pelvic floor (sometimes called the 
"Kegel muscles").” 
(Wikipedia, 2008). 
Seroma 
“A seroma is a pocket of clear serous fluid that sometimes develops in the body 
after surgery.  When small blood vessels are ruptured, blood plasma can seep out; 
inflammation caused by dying injured cells also contributes to the fluid.” 
(Roitt and Delves, 1994) 
Somatic 
“Adjective of soma.  Soma; The body: The body of an animal or plant excluding 
the germ cells.” 
(20th Century Dictionary, 1983) 
Stability 
“Ability of a substance or material to resist chemical change” 
(The Williams Dictionary of Biomaterials, 1999) 
Thrombogenicity 
“Property of a material which induces and/or promotes the formation of a 
thrombus” 
(Definitions in Biomaterials, 1986) 
Thrombus 
“A stationary blood clot along the wall of a blood vessel, frequently causing 
vascular obstruction.” 
(Dorland, 2009) 
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Chapter 1 – Introduction 
1.1 Research Aims  
 To review the advantages and disadvantages of materials used in soft tissue 
repair and to review potentially alternative materials.  
 To investigate in depth a limited selection of these alternative materials.  
 To investigate the value of gas plasma treatment on the ability of these 
materials to support tissue growth in vitro.  
 To investigate the reported benefits of using chitosan in relation to medical 
device applications 
 
One aim of this project was to perform an in depth study into surgical devices used 
for soft tissue repair (e.g. hernias and prolapses)  
 
The next aim was to evaluate a selection of materials chosen because they are in 
common use or because they have potential as surgical biomaterials and to explain 
their advantages and disadvantages, review the potential alternative materials and 
attempt to demonstrate the efficacy of some alternative materials / surface treatments 
as tissue scaffolds.  
 
The third aim was to examine how a small selection of surface treatments (gas 
plasma and chitosan coating) affects their properties as tissue scaffolds (Angelova 
and Hunkeler, 1999, Chandra and Rustgi, 1998, Guidoin et al., 2000). 
 
By examining how well fibroblasts grew on these materials, biomaterials can be 
developed that will become incorporated into healthy tissue rather than “scar plates” 
thus avoiding the negative consequences and therefore this work sought to clarify the 
potential of a selection of biomaterials based on their ability to support tissue growth 
in vitro. 
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In addition to this core body of work, this project aimed to examine the role chitosan 
can play in biomaterials.  By examining the bacteriostatic effect of chitosan and 
techniques to incorporate chitosan into biomaterials, it was postulated that the 
biomaterials would incorporate the benefits of containing chitosan, while retaining 
the properties of the material the chitosan is combined with. 
 
1.2 Current Situation 
Polymers are a promising class of biomaterials that can be engineered to meet 
specific end-use requirements (Angelova and Hunkeler, 1999).  They can be selected 
according to key “device” characteristics such as mechanical resistance, 
degradability, permeability, solubility and transparency but the currently available 
polymers need to be improved by altering their surface and bulk properties. 
 
There are many examples of materials that have been used for medical implants that 
have elicited undesired responses.  Current mesh prostheses are made of 
polypropylene (PP), polyethylene terephthalate (PET) or polytetrafluoroethylene 
(PTFE), though all of them reveal some disadvantages (Klinge et al., 2002a).  The 
extended implantation of alloplastic material in the flexible frame of muscles and 
fascial tissue is known to cause specific mesh-related complications like restriction of 
the abdominal wall mobility (McLanahan et al., 1997, Vestweber et al., 1997), 
induction of intra-abdominal adhesions with erosion of adjacent organs or 
consecutive fistula formation (Schneider et al., 1979, Fitzgerald and Walton, 1996), 
to the bladder (Houdelette et al., 1991, Gray et al., 1994, Hume and Bour, 1996), 
bowel (DeGuzman et al., 1995, Kaufman et al., 1981, Soler et al., 1993, Miller and 
Junger, 1997), blood vessels (Schumpelick and Kingsnorth, 1999) and ductus 
deferens (Silich and McSherry, 1996).  Next to an unavoidable inflammatory foreign 
body reaction (FBR) the prosthesis usually is embedded into a fibrous scar plate, 
which is responsible for a considerable shrinkage of the mesh area of about 40% 
(Amid, 1997, Meddings et al., 1993).  
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Hernias and prolapses are caused by a weakness or defect in the supportive tissues 
that contain the bodily organs (Morris-Stiff and Hughes, 1998).  A hernia (also called 
a rupture), is a general term referring to a protrusion of a tissue through the wall of 
the cavity in which it is normally contained.  In more specific terms, hernia is usually 
used to describe a protrusion of the abdominal contents through the abdominal wall.  
This is usually treated surgically by the implantation of a polypropylene mesh over 
the defective part of the abdominal wall. 
 
A prolapse is a type of hernia that occurs exclusively in women (Creighton and 
Lawton, 1998).  It is characterised as a failure in the pelvic floor, causing the descent 
of the uterus.  This often presents itself as stress incontinence or in more severe cases, 
the uterus can descend so far that it protrudes through the vagina.  Treatments for 
prolapses can range from pessaries (which act to provide internal support for the 
uterus), the implantation of a „sling‟ to support the urethra, to hysterectomies (the 
complete removal of the uterus and ovaries) 
 
1.2.1 Hernia repair 
Abdominal Hernia 
Abdominal wall hernia repairs are performed over 990,000 times each year in the 
USA, which makes it second only to cataract procedures, the most common surgical 
procedure performed in the USA (Rutkow, 1997).  
 
Although surgical techniques in hernia surgery have improved, recurrence used to be 
a common complication (Engelsman et al., 2007).  Therefore, the idea of increasing 
the strength of the abdominal wall by implanting a mesh was explored with the 
introduction of a polypropylene (PP) mesh in 1962 by Uscher (Uscher, 1962). 
 
The strength of the abdominal wall depends on the collagen fascia layers, which are 
the structures to be replaced by a mesh (Engelsman et al., 2007).  From a mechanical 
point of view, abdominal wall implants should become an integral part of the 
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abdominal wall.  This requires complete incorporation of the mesh into the fascial 
margins of the defect.  In the repair of abdominal wall defects, surgical meshes can 
either be placed fully intra-abdominally (on the surface of the peritoneal lining) or in 
between different anatomical layers of the abdominal wall.  In both situations, the 
aim of the treatment is to consolidate a musculo-fascial defect without tension on the 
surrounding tissues. 
 
The most common mesh material used for hernia repair is still polypropylene (PP), 
although there are alternatives.  Trostle et al (Trostle, 1994) mentions polypropylene, 
expanded polytetrafluoroethylene (ePTFE) polyethylene terephthalate polyglactin 
910 (PET) and polyglycolic acid (PGA).  These materials vary from rigid strong non-
absorbables like PP, to moderately strong very pliable absorbables like PGA. 
 
Vaginal Vault Prolapse 
Women face an 11% lifetime risk of surgery for pelvic organ prolapse or urinary 
incontinence (Olsen et al., 1997).  Prolapse and prolapse related conditions account 
for nearly a quarter of women waiting for routine gynaecological surgery (Creighton 
and Lawton, 1998).  The condition is rarely life threatening but can cause 
considerable discomfort and stress.  Patients with pelvic prolapses commonly have a 
general state of „pelvic relaxation‟, with stress incontinence and some degree of 
vaginal prolapse coexisting in many patients (Cespedes, 2002).  These prolapse 
conditions include urethral hypermobility, cystocele, rectocele, enterocele and uterine 
prolapse. 
 
The pelvic floor acts as a support for the pelvic organs and a prolapse occurs when 
this support fails due to a weakness in the musculo-fiberous tissue (Creighton and 
Lawton, 1998).  The main support for the pelvic viscera is provided by a group of 
muscles collectively known as the levator ani (Cespedes, 2002).  An intact pelvic 
floor allows the pelvic and abdominal viscera to „rest‟ on the levator ani, significantly 
reducing the tension on the fascia and supporting ligaments.  The pelvic ligaments are 
not true ligaments and are simply condensations of endopelvic fascia covering the 
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pelvic structures.  The vagina can be anatomically divided into the proximal, middle 
and distal regions.  The proximal segment is also called the vault or cuff and is 
stabilised by the cardinal and uterosacral ligaments.  Uterine and vault prolapse are 
associated with damage to these supportive structures. 
 
Treatments recommended for the different types of prolapse depend on the severity 
of the condition.  Preventative treatments include strengthening of pelvic floor 
muscles using Kegel exercises (Visco and Figuers, 1998). Cespedes (Cespedes, 2002) 
mentions that in mild cases of asymptomatic prolapse in which no other procedures 
are anticipated, the patient will not require surgery.  For the elderly patient with 
severe total vault prolapse who no longer desires sexual intercourse or in whom a 
short procedure is required because of medical conditions, a vaginal closure or 
colpocleisis can be performed. 
 
Common techniques available for uterine and vaginal suspension (transvaginal 
procedure) require drawing each side of the fault together causing restriction of 
movement.  The concept of tension free surgery (the use of a mesh) avoids the need 
to draw the two sides together and leads to improved wellbeing for the patient with 
little to no restriction on their movement but the complications must be addressed.  
 
For the repair of vaginal vault prolapses, one of the popular techniques is to suspend 
the vaginal vault by attaching it to the sacrum using a mesh or cadaverous fascia.  
This procedure is ideal for young women with severe vault prolapses wishing to 
retain their fertility or wishing to maintain their sexual activities.  Transabdominal 
suspension using a mesh or cadaverous fascia is a relatively morbid procedure with 
results comparable to a transvaginal procedure (Nichols, 1991, Kovac and 
Cruikshank, 1993). 
 
There are other techniques involving permanent suturing of the uterus to alternative 
support structures, but they are not much better (Cespedes, 2002).  The choice of 
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technique is a difficult one and can dramatically affect the quality of life for the 
patient.  
 
1.2.2 Complications 
To reduce complications, first one must analyse them and the mechanisms behind 
them. Klosterhalfen et al (Klosterhalfen et al., 1998)  report that while there are 
undisputed advantages to using polypropylene meshes, reports of complications after 
implantation are increasing.  Serious complications such as perforation and fistula 
formation are rare but minor and local complaints such as seromas, misfeelings and 
decreased abdominal wall mobility are observed in about half of the patients.  A 
recent paper (Steele et al., 2003) showed complications in 36% of patients from a 
population of 58 patients requiring Parastomal hernia repair, with complications 
including recurrence (26%), surgical bowel obstruction (9%), prolapse (3%), wound 
infection (3%), fistula (3%) and mesh erosion (2%). No patient required extirpation 
of the mesh.  Of the 15 patients with recurrence, 7 underwent successful repair for an 
overall success rate of 86%. 
 
Morris-Stiff et. al. (Morris-Stiff and Hughes, 1998) mention that despite the reported 
low tissue reactivity and long term maintenance of tensile strength associated with PP 
mesh, they had seen four patients in whom these properties failed during long term 
follow up of forty patients in a single unit.  The four patients included three with 
dense adhesions (one with severe infection) and one with primary mesh failure, all 
requiring re-operation.  It is mentioned that complications of non-infected wounds are 
notably absent from current literature (1998) and suggests that these complications 
may occur more often than is reported.  The reasons proposed are short periods of 
follow up, a lack of association between the complications and the mesh or reluctance 
to report them.  
 
PP and PET fibre meshes can cause tissue damage including; reduced mobility, 
severe adhesion formation causing bowel obstruction, subsequent erosion and 
formation of fistulas when placed in direct contact with the intestine and the 
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incorporation of the prosthesis into a fibrous scar plate which in turn can cause the 
mesh to shrink up to 40% (U.Klinge et al., 2002, Law and Ellis, 1988, Klinge et al., 
2002b).  Therefore, its application is avoided when the mesh may be in direct contact 
with the intestines. 
 
In addition to problems with adhesion, when polymeric biomaterials are implanted 
within the body, the immune system responds.  This reaction is caused by a foreign 
body reaction (Coleman et al., 1974, Marchant and Anderson, 1986, Marchant et al., 
1986).  Foreign body reactions are characterised by an initial acute inflammatory 
reaction.  A chronic granulomatous (see Granuloma in Chapter 1) tissue reaction may 
persist, even after encapsulation has occurred.  The foreign body reaction seems to be 
induced by continuous chemical or mechanical stimuli arising from the biomaterial 
implants (Coleman et al., 1974).  Morphological analysis of this reaction reveals the 
presence of a large number of macrophages, which generally attempt to phagocytose 
the material.  Usually the foreign body is much larger than individual macrophages 
and is not easily degraded.  Some of the macrophages then merge their cytoplasm to 
become multinucleated giant cells also called foreign body giant cells.  If the foreign 
body cannot be degraded by phagocytes, granulation tissue is formed to isolate the 
implant from the rest of the body tissues.  The foreign body reaction may be assessed 
in a semi-quantitative way by the enumeration of inflammatory cells, namely, 
polymorphonuclear leukocytes (PMN) and activated macrophages or giant cells 
found either at the surface of the implanted biomaterials in the inflammatory 
exudative fluid elicited by implants (Coleman et al., 1974, Marchant and Anderson, 
1986, Marchant et al., 1986). 
 
The contribution of phagocytic cells to the foreign body reaction may involve two 
closely related mechanisms (Vaudaux et al., 1994).  In the first, the neutrophils or 
macrophages phagocytose the smaller fragments of the biodegraded or corroded 
metallic or plastic implants.  These fragments cannot be degraded further and they 
may persist intracellularly in the neutrophils or macrophage for a prolonged period of 
time or may be ingested by other phagocytes if cell death does occur.  In the second 
reaction also called “frustrated phagocytosis,” phagocytic cells are confronted with 
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foreign particles such as nylon wool, glass, cotton, polysulfone fibres, polystyrene or 
polypropylene materials too large to be ingested (Henson, 1971, Johnston and 
Lehmeyer, 1976, Klock and Bainton, 1976, Wright and Gallin, 1979, Yanai and 
Quie, 1981).  Phagocytes coming into contact with this non-phagocytosable foreign 
material become permanently activated in a way similar to phagocytes containing the 
smaller fragments of non-degradable foreign particles; each kind of phagocyte may 
separately or in concert secrete or passively release several important inflammatory 
mediators (Coleman et al., 1974, Marchant et al., 1986), including acidic or neutral 
hydrolases, activated complement components, tumour necrosis factor (TNF), 
interleukins, prostaglandins, plasminogen activator and coagulation factors (Vaudaux 
et al., 1994).  The respective roles and the relative importance of these secreted 
factors in the control and maintenance of acute and chronic phase of the 
inflammatory response to implants are not yet well defined (Baggiolini, 1982, 
Coleman et al., 1974, Gallin, 1984). 
 
1.3 Prosthesis Related Infections 
Infections are one of the most frequent and serious complications associated with 
indwelling medical devices (Vaudaux et al., 1994).  
 
Infections of biomaterial applications, including surgical meshes, are especially 
troublesome as a biofilms can be formed on the mesh.  Biofilms are formed when 
micro-organisms colonise a surface and excrete a polysaccharide matrix.  Micro-
organisms in this biofilm are protected against the host immune response and 
antimicrobial attack (An and Friedman, 1998, Zimmerli et al., 1984).  The body 
continues to try to clear the microorganisms and this ends up causing damage to the 
surrounding tissue.  This will often lead to major complications which can be 
potentially life-threatening and will in the majority of cases result in removal of the 
mesh (Costerton et al., 1999).  Bacteria look for a permanent surface to bind to as it 
affords them greater protection against the body‟s immune system, so a non-
permanent implant should circumvent that problem. 
 
9 
1.3.1 Incorporation of antimicrobials into medical prostheses 
To avoid the problem of biomaterial related infections, one can try to incorporate 
antibiotic or bacteriostatic compounds into the material.  Most published data for 
antimicrobial textiles and fibres are generated by placing a fabric on an inoculated 
nutrient agar plate and measuring the inhibition zone (stanford.edu, 2008).  This 
procedure depends on diffusion of the antimicrobial agent in the agar.  Further work 
is usually required to discover the mechanism of the antimicrobial properties.  This is 
required if one wishes to discover if the compound being tested is bacteriocidal or 
bacteriostatic.  The difference between bacteriocides and bacteriostats is subtle.  
Antibiotics have been widely used and antibiotic pathogens have developed as a 
result, but the inhibition of growth using bacteriostats is less common and could be 
used as a prophylactic alternative to antibiotics.  With an appropriate antimicrobial 
incorporated into a biomaterial, it is anticipated that this would significantly reduce 
the chances of post operative infection and potential biofilm production 
 
1.4 Tissue Engineering 
The desired effect of any tissue engineering is to restore, maintain or improve the 
function of human tissues.  
 
The tissue engineering paradigm is to isolate specific cells through a small biopsy 
from a patient, to grow them on a three-dimensional biomimetic scaffold under 
precisely controlled culture conditions, to deliver the construct to the desired site in 
the patient‟s body and to direct new tissue formation into the scaffold that can be 
degraded over time (Lee and Mooney, 2001).  Tissue engineering (TE) merges many 
aspects of engineering and life sciences, aiming towards the primary understanding of 
cell functions and the advancement of biological substitutes (Wiria et al., 2007). 
 
Degradable materials are less susceptible to infection and intend to cause less of a 
foreign body response (Badylak et al., 2001).  However, the lack of strength over 
time is a concern for certain clinical applications where adequate tensile properties 
are necessary and required.  
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“Tissue engineering concepts of producing a lattice for the ingrowth of cells in vivo 
to lay down the appropriate matrix have been used very successfully for the skin and 
for the repair of the facia in hernias.  The approach used by researchers has been to 
assume that cells and their accompanying matrix need a scaffold to enter, adhere to 
and proliferate in an ordered manner.  The three features of the tissue-engineered 
scaffold are the overall architecture and porosity, the fibre morphology and the 
surface chemistry.  The use of knitted polyester meshes with pore sizes many orders 
of magnitude larger than the repair matrix requires can result in a tissue response that 
is inadequate.  Pore sizes of between 10-50 µm and overall porosity of 85-90% with a 
multifilament fibre yarn with fibre diameters of 1-10 µm appear to be the most ideal 
for tissue ingrowth.”  (Minns, 1999)  
 
Other papers claim slightly different values for the “optimal” pore size. In a recent 
paper, the author conducted a study where he developed polycaprolactone scaffolds 
with varied pore sizes using a centrifugation method and therefore studied how 
different pore sizes suit different applications.  The scaffold section with 380–405 µm 
pore size showed better cell growth for chondrocytes and osteoblasts, while the 
scaffold section with 186–200 µm pore size was better for fibroblasts‟ growth.  The 
scaffold section with 290–310 µm pore size showed faster, new bone formation than 
those of other pore sizes (Oh et al., 2007). 
 
In cartilage tissue remodelling in response to mechanical forces, (Grodzinski et al., 
2000) Grodzinski, mentions recent studies which suggest that mechanotransduction is 
critically important in vivo in the cell mediated feedback between physical stimuli 
and the resulting macroscopic biomechanical properties of the tissue.  This should be 
an important consideration when selecting materials, especially degradable materials 
intended to regenerate damaged tissue.  
 
Another important consideration, often overlooked, is how the regenerating tissue 
reacts with the prosthesis.  The material used should elicit no negative effects on the 
growing cells.  This can be difficult to measure, but testing the cells for Heat Shock 
Protein (an indicator of macrophage stress) (Henze et al., 1996) and produced by 
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other cells growing in a stressful environment) is potentially an effective way of 
quantifying cellular stress.  A simpler approach may be to measure how well cells 
grow on a sample.  This approach may not be so accurate, but should indicate a 
cellular preference for a particular material/ surface that can then be followed up by 
more elaborate testing.  
 
1.5 Reasons for Improvement 
These papers indicate the need for a new type of mesh implant for the repair of 
incisional hernias and vaginal prolapses. In discussion with Dr Fotheringham (PhD 
Supervisor) and Dr Browning (Gynaecologist), it became apparent that instead of 
trying to produce a new permanent implant, the market would soon be ready for an 
absorbable implant that could encourage the patient‟s tissue to repair the fault and 
then dissolve so there is no surface for bacteria to adhere to and the problem 
adhesions and encapsulation would be avoided, as these are a host response to a 
foreign material placed within the body.  With permanent implants, the immune 
system takes the material as a threat and when bacteria bind the implant and bind to 
it, this amplifies the problem.  By having an implant that is constantly dissolving, the 
problem of the macrophages trying to engulf the entire implant is avoided.  Instead, 
the immune system is able to encapsulate the small fragments of dissolving material.  
The bacteria do not have a permanent surface to adhere to which will reduce the 
chance of infection at the implant site in the long term.  With a permanent implant, 
even if the surgery is performed perfectly, the chance of infection at the implant site 
is still dramatically increased.  
 
1.5.1 Niche 
There is demand in the medical profession for a new generation of medical implants.  
They are looking for implants for repairing hernias and prolapses that will avoid the 
problems that current mesh technologies cannot.  This review is one of several 
indicating the problems associated with the current permanent meshes on the market.  
 
12 
The ultimate solution would be a re-absorbable implant that would encourage new 
tissue to grow over the implant to eventually replace it, one that would not antagonise 
the immune system and inhibit bacterial growth/ adhesion.  An implant that satisfies 
these parameters would find many applications. 
 
Therefore a strategy would be to take the body as a template and try to mimic the 
body‟s original structure.  The main obstacle to determining the characteristics 
required for such a design is the fact that there is little research into the mechanical 
properties of the pelvic floor and even less on how the body subconsciously controls 
it.  An implant could be designed to mimic the mechanical properties, but little will 
be known about how successful it will be without the necessary somatic control.  
With this in mind, it would be sensible to make sure that this implant will exceed 
requirements. 
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Chapter 2 - Material Review 
In the process of selecting materials, there are several requirements a biomaterial 
must meet.  The most important of these is biocompatibility.  It must not illicit an 
undesired response when placed within the body.  The ideal material should be; 
 
biocompatible 
stable 
biomimetic 
 
The material should maintain strength as long as required. It should have strength and 
bear load in a manner homologous with the tissue it is to emulate but it should not be 
so strong that it restricts the mobility of the patient, or damage surrounding tissue 
under stress.  
 
In the case of biodegradables for soft tissue repair, one is looking for a material that 
will transfer load from the device to the tissue as it is regenerating (Grodzinski et al., 
2000) so that the repaired tissue will be strong enough when the material has 
degraded. 
 
In addition, the device should not be prohibitively expensive. Therefore if the 
medical device cost is kept to a reasonable level, it will be a viable option for more 
patients and be better placed to compete with its competing products. 
 
The choice of material(s) is of vital importance to the success of an implant but there 
are so many aspects that need to be examined.  The ideal implant should inhibit 
adverse reactions and bacterial growth/attachment yet promote healthy, controlled 
tissue regeneration.  Unless cloned tissue is used, there is little chance there will be a 
single material that can emulate the native tissue, therefore a combination of 
materials and treatments may be necessary. 
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The materials used in this project shall be a selection of materials that fit three 
criteria. They will be either 1. Currently approved materials, 2. Available novel 
materials and 3. Modifications of these materials. 
 
2.1 Potential Materials 
The materials selected for this study shall be selected for the following reasons; they 
should be either currently used as medical prostheses (in the case of the permanent 
materials), or potentially suitable for medical use (in the case of the resorbable 
materials) and they should be available to the researcher. 
 
There are two objectives for this study.  One is to evaluate a range of permanent and 
degradable materials as scaffolds for tissue regeneration.  The other aim is to evaluate 
a selection of surface treatments for their ability to enhance biocompatibility and 
tissue regeneration whilst maintaining their bulk properties. 
 
2.1.1 Material selection 
Polymers used as biomaterials can be naturally occurring, synthetic or a combination 
of both. (Angelova and Hunkeler, 1999) 
 
Naturally derived polymers are abundant and usually biodegradable (Chandra and 
Rustgi, 1998).  Their principal disadvantage lies in the development of reproducible 
production methods, because their structural complexity often renders modification 
and purification difficult.  Additionally, significant batch-to-batch variations occur 
because of their „biopreparation‟ in living organisms (plants, crustaceans) (Angelova 
and Hunkeler, 1999) . 
 
Synthetic polymers are available in a wide variety of compositions with readily 
adjusted properties.  Processing, copolymerization and blending provide 
simultaneous means of optimizing a polymer‟s mechanical characteristics and its 
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diffusive and biological properties.  The primary difficulty is the general lack of 
biocompatibility of the majority of synthetic materials, although poly (ethylene 
oxide) (PEO) and poly (lactic-co-glycolic acid) are notable exceptions.  Synthetic 
polymers are therefore often associated with inflammatory reactions, which limit 
their use to solid, unmoving, impermeable devices (Angelova and Hunkeler, 1999). 
 
With these considerations in mind the next stage is to narrow the field of prospective 
materials through a process of elimination.  
 
In „functional assessment and tissue response of short- and long-term absorbable 
surgical meshes‟ (Klinge et al., 2001) it is mentioned that while non-absorbable 
devices usually tend to produce fistulas in direct contact with the bowels, the 
interposition of short-term absorbable meshes result in large incisional hernias in 
almost all cases.  The study investigated the functional and histological consequences 
of a short-term polyglactin 910 (Vycryl®, loss of 50% of its mechanical stability 
within three weeks) and a long-term absorbable mesh polylactide (LTS, preserved 
>50% of its stability for over one year).  The PG-mesh initially revealed a 
pronounced inflammatory reaction and a significantly increased formation of 
connective tissue in the interface mesh/recipient tissues correlated to an increased 
stiffness of the abdominal wall compared to the sham-group (The sham-group 
consists of incisions sutured together with no implanted mesh).  However, a loss of 
mechanical stability and an increase in elasticity could be detected three weeks after 
implantation, which may be explained by the rapid absorption of the mesh material.  
In contrast to PG, the LTS mesh indicated a decreased but persisting inflammatory 
reactions in the interface mesh/recipient tissues and significantly reduced induction of 
connective tissue.  Although the formation of scar tissue was diminished compared to 
PG, the LTS mesh preserved its mechanical stability after 180 days.  The results 
indicate that the frequent development of incisional hernias with short-term 
absorbable meshes (PG) might be due to the decreased mechanical stability and 
dilation of the newly formed connective tissue after 2-3 weeks.  Moreover extensive 
scar tissue formation may promote adhesion formation. 
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To decide which of the many biomaterials to study, one must make out a list of 
potential materials and weigh up the criteria for and against.  This will not be a 
complete list, as there are many exotic biomaterials being developed and therefore it 
will contain materials that are readily available. 
 
Natural Polymers 
Proteins and protein based polymers 
Collagen 
Collagen is expensive and suffers from large batch-to-batch and source-to-source 
variations typical of natural extracts (Angelova and Hunkeler, 1999).  Collagen 
would be an ideal material if complications such as variation and potential for disease 
transfer could be circumvented.  In addition, tissue sources that have origins from 
other humans or animals remain problematic mainly due to immunogenic responses 
by the patients (Shin et al., 2003). 
 
Koob (Koob and Hernandez, 2002) published research data on the modification of 
native collagen to produce re-synthesised collagen fibre. The outcome of this work 
was a biologically based tendon bio-prosthesis with mechanical properties equivalent 
to native tendon.  Ultimate tensile strength of the NDGA cross-linked fibre was 
greater than that of native tendon, while the elastic modulus and strain at failure were 
comparable to those of tendon fibres. 
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Polysaccharides and derivatives 
Chitin / Chitosan 
Chitin is one of the most abundant natural amino-polysaccharides and is estimated to 
be produced annually almost as much as cellulose.  Its immunogenicity is low, in 
spite of the presence of nitrogen (Majeti and Kumar, 2000).  Its purity can vary as a 
result of its origin (e.g. (crab shell chitin = low purity, Squid chitin = higher purity.)  
It can also vary in molecular weight (e.g. squid chitin = high molecular weight) and 
these factors can affect the properties of the chitin.  Another variable for chitin is the 
degree of deacetylation.  Chitosan is a deacetylated form of chitin and by varying the 
degree of deacetylation, its biodegradability and solubility can be modified. Chitosan 
biodegrades hydrolytically and this is enhanced by the presence of lysozyme (Lee et 
al., 1995).  The susceptibility to lysozyme of chitin derivatives is controlled by the 
degree of acetylation at the C2-position and/or by the introduction of various 
substituents at the 6-0-position of the N-acetylglucosamine residue (Nishimura et al., 
1985). 
 
Chitosan has many possible applications, but the applications of most interest for this 
study are its tissue culture properties and its bacteriostatic effect.  Chitosan has some 
level of antimicrobial activity and fibres made from chitosan are available in the 
marketplace (stanford.edu, 2008).  Coatings of chitosan on conventional fibres or 
films appear to be a more realistic prospect for development of this material 
(Broughton et al., 2001).  
 
 
Fig 2.1 - Chemical formula of chitosan in Haworth‟s projection (Murúg, 2007). 
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Chitosan In relation to medicine 
In a paper by Hwang (Hwang et al., 2000) it is mentioned that nitric oxide (NO) 
contributes towards cytotoxicity in cell proliferation during inflammation of wound 
healing.  NO is a highly reactive free radical and is employed by the immune system 
to respond to inflammatory agents such as LPS (lipopolysaccharide derived from 
bacterial cell walls) and interferon-gamma that activate macrophages and stimulate 
them to produce NO. Chitin and chitosan show a significant inhibitory effect on NO 
production by the activated macrophages.  This would help explain the beneficial role 
that chitin and the deacetylated derivatives have on wound healing. 
 
Deacetylated chitin derivatives such as 70% deacetylated chitin (DAC-70) and 30% 
deacetylated chitin (DAC-30) have potent immunological activities for activation of 
peritoneal macrophages in vivo, suppression of Meth-A tumour cells in syngenic 
BALB/c mice and stimulation of non-specific host resistance against Escherichia coli 
infection in mice (Nishimura et al., 1984).  Chitin and chitosan are also effective for 
the protection of host against infection with Candida albicans and Staphylococcus 
aureus and against growth of Ehrlich and Sarcoma 180 ascites tumour (Suzuki et al., 
1982, Suzuki et al., 1984).  All deacetylated derivatives of chitin are reported to 
enhance the activity of natural killer (NK) cells as well (Nishimura et al., 1985).  
 
Because chitin and its deacetylated derivatives do not provoke an unfavourable 
immunological response, chitin derivatives have been suggested for bandages, 
sutures and other items placed in the human body (Brown, 1999) although purity will 
be an issue in these applications (Broughton et al., 2001).  
 
One issue with using chitin and chitosan for medical devices is the difficulty in 
producing useable fibres. The poor tensile strength of chitosan fibres, especially in 
the wet state, is a key deficiency (Notin et al., 2006).  This is part of the reason why 
there are so few products using chitin or chitosan on the market with the exception of 
wound dressings (Niekraszewicz, 2005, Ong et al., 2008).  This is being addressed by 
scientists working on novel extrusion techniques or via the use of additives during 
extrusion (Notin et al., 2006, Qin et al., 2002). 
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Synthetic Polymers 
Polyanhydrides 
Polyanhydrides are a group of polymers with two sites in the repeating unit 
susceptible to hydrolysis (Angelova and Hunkeler, 1999). Polyanhydrides are useful 
materials for drug delivery.  The degradation rates can be altered with changes in the 
polymer backbone.  Aliphatic polyanhydrides degrade within a few days while 
aromatic polyanhydrides can degrade slowly over a period of several years.  
 
Aliphatic polyesters 
Almost the only high molecular weight compounds shown to be biodegradable are 
the aliphatic polyesters.  The reason for this is the extremely hydrolysable backbone 
found in these polyesters (Angelova and Hunkeler, 1999). 
 
Poly-ε-Caprolactone (PCL) 
Poly(ε-caprolactone) (PCL) has been studied as a substrate for biodegradation and as 
a matrix in controlled-release systems for drugs and its slow rate of degradation in 
vivo makes it suitable for devices with longer working lifetimes (1–2 years) (Chandra 
and Rustgi, 1998). 
 
This material is primarily being developed as a bone substitute for use in 
maxillofacial reconstructive surgery.  However, it could be adapted to other areas 
where bioabsorbable composite materials may be used (Corden et al., 2000). 
 
In vitro biocompatibility of both the in situ polymerised PCL and commercially 
available PCL (Solvay‟s CAPA 6400) material has been assessed using osteoblasts 
derived from human craniofacial bone cells.  The material is highly biocompatible 
with these cells which will attach and spread on both the PCL types.  
 
20 
The main factor influencing cell behaviour seems to be the surface topography of the 
polymer samples (Corden et al., 2000).   A tendency of cells to group, showing zones 
with more cellular density, was observed on PCL films, although these nuclei of 
growth disappeared when cultures reached confluence (Serrano et al., 2005).  
 
Polyglycolic acid  
Polyglycolic acid or PGA is the simplest linear aliphatic polyester, with repeat units –
OCH2CO- and is a readily degradable highly crystalline polymer used for sutures and 
other implantable devices (The Williams Dictionary of Biomaterials, 1999). 
 
The advantage of poly-glycolic acid is the degradability by simple hydrolysis of the 
ester backbone in aqueous environments such as body fluids.  Furthermore, the 
degradation products are ultimately metabolized to carbon dioxide and water or are 
excreted via the kidney (Chandra and Rustgi, 1998). 
 
Although poly-glycolic acid is a commonly used biomaterial in medical devices, it is 
a short term resorbable polymer which eliminates it as a structural component of a 
tissue repair mesh for connective tissue, although it is often used as a copolymer to 
increase the degradation rate. 
 
Poly-l-lactic acid  
PLA is a relatively hydrophobic linear aliphatic polyester, with repeat units 
OCHCH3CO.  PLA has similar properties to polyglycolic acid except that 
degradation occurs more slowly.  PLA exists in two stereoregular forms, D-PLA and 
L-PLA and in the racemic D,L-PLA (The Williams Dictionary of Biomaterials, 
1999). 
 
Polymeric scaffolds including synthetic materials such as poly(L-lactic acid) have 
attracted significant interest in the tissue engineering community as a consequence of 
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their biocompatibility, ease of processing into three-dimensional structures, their 
established safety as suture materials and the versatility that they offer for producing 
chemically defined substrates for graft matrices  (Kanczler et al., 2007). 
 
Aromatic polyesters 
Polyethylene terephthalate is an aromatic polyester (aromatic polyesters are often just 
termed polyester).  The sample used in this project was donated by Vascutek Ltd in 
the form of an arterial prosthesis and has therefore been tested to ensure its 
biocompatibility and anti-thrombogenicity.  
 
Aliphatic-aromatic polyesters 
Solanyl Flexibilitis component (or Eastar Bio GP copolyester) 
Aliphatic-aromatic co-polyester the name of Solanyl
®
 is derived from Solanum 
Tuberos.  The polymer is made from by-products of potato processing, the potato 
peels (Rodenburg Biopolymers, 2004). 
 
Having seen this material, the Flexibilitis grade appears to have very good 
mechanical properties and it would be interesting to find out how human cells react to 
it.  For the purpose of this work, it shall be referred to as Solanyl. 
 
Polypropylene 
Polypropylene is a thermoplastic homopolymer, made by the chemical industry and 
used in a wide variety of applications including medical devices such as Marlex
® 
which is a commercially available hernia repair patch.  Polypropylene has many 
advantages and disadvantages but the material has a long history in medical devices 
and therefore it is important as a control.  Experiments were conducted in this thesis 
to determine if tissue response could be improved. 
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PTFE (Polytetrafluoroethylene) (Teflon
®
) 
PTFE is a chemically inert homopolymer, with a very low coefficient of friction 
(Young and Lovell, 1991) and as such, has found numerous applications in 
biomedical devices.  PTFE is commonly used in vascular grafts and tendon repair, 
both applications where low friction and hydrophobicity are an advantage, but this is 
a disadvantage when looking for cell adhesion and tissue regeneration.  Therefore 
this material is not ideal for this study as it is so hydrophobic. 
 
Thermoplastic polyurethanes 
Polyurethanes are a large family of polymers in which urethane bonds are formed in 
the backbone of molecule chains by the reaction between a polyol and an isocyanate 
and can be either thermoplastic or thermosets. 
 
Among synthetic materials, polyurethanes have been considered to be the most 
suitable material in various biomedical applications, which is connected to their 
biocompatibility, biodegradability and controlled microstructure and properties 
(Corneillie et al., 1998).  They also have excellent mechanical properties which 
makes them well suited to biomedical applications. 
 
Carbon fibre 
Carbon fibre initially appears to be a very suitable material as described by R.J. 
Minns (Minns, 1999).  In his paper, Tissue engineered Synthetic Scaffolds for Tissue 
repair– a textile approach to implant design he states that individual carbon fibres 
appear to present an attractive surface, morphologically and chemically, to the 
attachment of fibroblasts which eventually produce a collagenous framework within 
the implant scaffold at the sites desired. 
 
During questioning at the MedTex conference in 2003 (Bolton, UK), when R.J. 
Minns was presenting, Royston Dawber raised an issue, mentioning that he was 
aware of an autopsy on a 60 year old woman who had died and it was discovered that 
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a carbon fibre from a tendon repair had migrated through her body and been 
discovered in her brain.  This news was enough to discount this material as a 
potential prosthesis for this project. Incidentally, there have not been any recent 
papers proposing the use of carbon fibre for soft tissue repair. 
 
2.1.2 Chosen Materials  
Polypropylene 
Polypropylene was chosen partially because it is widely used for medical prostheses, 
therefore would act as a reference material.  In addition it would be of value to see if 
altering its surface properties would improve the tissue reaction. 
 
Polyurethane 
Chosen for its biocompatibility, biodegradability and mechanical properties. 
 
Polyester (Vascutek) 
This material is an example of a vascular prosthesis. As it is currently used in 
surgery, examining the way cells proliferate on this material and how the cells react 
to the material is of great interest.  This was used as the gold standard control and to 
demonstrate how well cells should grow on a biomaterial.  It was also examined to 
see if the cell material interaction can be improved by plasma treatment.  
 
Poly-ε-Caprolactone 6400 
Chosen because it is biocompatible, flexible, biodegradable and has a large body of 
published work relating to medical use.  
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Solanyl 
Chosen for its mechanical properties, biodegradability and lack of published work. 
 
Poly lactic acid 
Chosen because it is biocompatible, biodegradable and has a large body of published 
work relating to medical use.  
 
In addition to the reasons stated above, another selection criterion for these materials 
was that they were available in sufficient quantities to perform this research project. 
 
2.2 Potential Treatments for Materials 
2.2.1 Chitosan/ chitin coating 
As mentioned earlier by R. Broughton (Broughton et al., 2001) coatings of chitosan 
on conventional fibres or films appears to be a more realistic prospect for 
development of this material although development of a fibre would be very useful.  
To make this idea a commercial reality, a method needs to be developed of applying 
a uniform coating of chitosan to a material.  There is a concept of spray application 
that could have many applications in the medical sphere.  Some materials may need 
surface alteration to make the material wetable before any lasting chitosan coating 
can be applied.  In a preliminary study into the effect of chitosan-coated material on 
MRSA and Staphylococcus epidermis, the coated polypropylene performed poorly, 
whilst the chitosan-coated cotton cloth had an observable effect.  This indicated that 
the material needed to be wetable for the chitosan coating to adhere sufficiently to the 
material to be useful (Method 3c in the results section).  
 
Another potential approach to incorporating chitosan to a polymer would be to use 
gas plasma to cross link the chitosan to the polymer surface.  It would be interesting 
to compare the various methods of chitosan coating. 
25 
2.2.2 Low Pressure Plasma Treatment 
Low pressure plasma treatment can be used to alter a materials hydrophobicity / 
hydrophilicity, sterilise materials without the problems associated with other methods 
and to erode the surface to enhance roughness of a material (Palmers, 1999).  This 
can be achieved in a reproducible manner by ionising the gas in a controlled and 
qualitative way within a vacuum vessel (pumped down to a pressure in the range of 
10
-2
 to 10
-3
 mbar).  The gas is ionised with the help of a high frequency generator.  
The highly reactive particles react with the surface of the substrate.  The gas used can 
be altered, the power used and length of exposure can be altered to promote the 
desired effect (ablation, crosslinking, activation or deposition).  The formed reactive 
particles react in a direct way with the surface without damaging the bulk properties 
of the treated material as the surface modification is limited to the outermost 10 to 
1000A (Ångström) of the substrate.   
 
The lifetime of the treated polymer surface can be a concern.  A disadvantage of 
polymer surface treatments is that the modified surfaces undergo surface 
restructuring with time (Yang et al., 2002) owing to the mobility of the polymer chain 
in the amorphous regions (Murakami et al., 1998, Kim et al., 2003), which is driven 
by thermodynamic need to lower the overall interfacial energy of the system 
(Koberstein et al., 1998). 
 
Oxygen Plasma 
Oxygen plasma treatment is an effective means of enhancing the hydrophilicity of a 
polymer‟s surface.  This enables polymers that would normally be unsuitable for 
tissue growth to be able to support the attachment of cells.  According to Van-Kooten 
(van-Kooten et al., 2004), the improved wettability of oxygen plasma treated 
materials was related to improved cell proliferation, increased fibronectin surface 
coverage and increased expression of adhesion related proteins. 
 
There also appear to be other advantages to oxygen plasma treatment.  In adhesion of 
Pseudomonas aeruginosa strains to untreated and oxygen-plasma treated poly (vinyl 
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chloride) (PVC) from endotracheal intubation devices by K. Triandafillu 
(Triandafillu et al., 2003) they mention that oxygen plasma treatment has a beneficial 
effect against the bacterial colonization of a Oxygen plasma treated PVC, reporting a 
70% reduction in adhering bacteria although they concede that this reduction is 
however unlikely to be sufficient to prevent P. aeruginosa colonization of 
endotracheal intubation devices.   
 
This would be an attractive surface treatment to examine, as it appears to yield 
promising results.  Unfortunately technical problems conspired to make this 
treatment unavailable for the majority of the materials. 
 
Argon Plasma 
Argon is an inert gas, so while it will ablate the surface of the polymer and improve 
the hydrophilicity, it will not create a functional group on the surface of the polymer. 
 
Ammonia Plasma 
It is hypothesised that plasma treatment with ammonia would improve tissue growth 
along a biomaterial more than argon plasma treatment.  This was suggested as 
ammonia is made of nitrogen and hydrogen, which are the building blocks of proteins 
(Proteins are built from amino acids and amino acids are so called because they 
contain an amine group (NH2)).  Therefore it was suggested that a material presenting 
nitrogen and hydrogen on its surface would mimic a protein and therefore encourage 
cell binding and greatly enhance its biocompatibility.  
 
Fluorine Treatment 
Fluorine is the most electronegative and reactive of all elements (Fessenden and 
Fessenden, 1990).  Treatment of polyester with a solution of fluoropolymer 
(polyvinylidene fluoride) has been shown to reduce thrombogenicity (Maini, 1999).  
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Due to this lower thrombogenicity, this biomaterial is now used for vascular 
prostheses with a diameter of 6mm.  
 
2.2.3 Hyaluronic acid 
In a paper by D. Girotto (Girotto, 2003) it is reported that the re-differentiation 
capabilities of human articular and chick embryo sternal chondrocytes were evaluated 
by culture on HYAFF-11 and its sulphate derivative, HYAFF-11-S, polymers derived 
from the benzyl esterification of hyaluronate.  Initial results showed that the HYAFF-
11-S material promoted the highest rate of chondrocytes proliferation. 
 
2.2.4 Laser pitting 
Prof Duncan Hand at Heriot-Watt University in Edinburgh developed a technique 
using lasers to introduce pits of controllable size into a material (Fotheringham et al., 
2004).  It was thought that this would be useful for encouraging cells to grow on the 
proposed implant.  This was discussed and while material could be pitted for tissue 
culture study, the technology was prohibitively expensive and slow in its current 
incarnation.  
 
2.2.5 Micro-grooves 
In a paper by E.T. den Braber (Braber, 1996), planar and micro-textured silicon 
substrata were produced and made suitable for cell culture by radio frequency glow 
discharge treatment and media were produced with grooves with widths of 2μm, 5μm 
and 10μm and depth of 0.5μm.  Cell counts proved that neither the presence of the 
surface grooves nor the dimensions of the grooves had an effect on cell proliferation, 
although cells grown on the 2μm and 5μm wide grooves were elongated and aligned 
parallel to the surface grooves.  It was also shown that cells on the 10 µm grooves 
were almost comparable with the control with no grooves.  Finally, it was also 
observed that cells on the micro-textured substrates were capable of spanning the 
surface grooves. 
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It was also mentioned that these results contradict the work reported by Green (Green 
et al., 1994) and Ricci (Ricci, 1994).  It goes on to mention that a response to surface 
topography is dependent on cell type, which would account for the discrepancies 
between this and other studies. 
 
2.2.6 Chosen treatments for materials 
Given more time and resources, one could compare all of these surface treatments 
and develop treatment combinations but unfortunately, only a few treatments could 
be analysed, due to the aforementioned limitations. 
 
The treatments chosen were plasma treatment and chitosan coating and a 
combination of plasma treatment and chitosan coating. 
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Chapter 3 - Methodology       
The experimental studies can be split into two distinct groups. The first is the 
examination of chitosan as a bacteriostat and the second is the production and testing 
of biomaterial samples.  
 
3.1 Examination of Chitosan as a Bacteriostat 
This series of experiments was designed to examine the bacteriostatic effects of 
chitosan on common hospital bacteria.  The bacteria chosen were methicillin resistant 
Staphylococcus aureus (MRSA 9551) and Staphylococcus epidermis (Staphylococcus 
epidermis).  
 
3.1.1 Materials 
Nutrient agar (NA) 
Nutrient broth (NB) 
Plate Count Agar (PCA) 
Petri dishes (~10 cm) 
Culture bottles (~25ml) 
Inoculation loop 
Bunsen burner 
Scissors 
Tweezers 
Ethanol (100%) 
Distilled Water 
Methylene blue 
Acetic Acid (2M) 
Sodium Hydroxide (2M) 
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Chitosan (Purisan  squid chitosan – high molecular weight) 
Cotton cloth (unbleached) 
Neubauer Improved Haemocytometer (Vol = 1/400 ml per small square) 
Incubator (37 C & 20 C) 
Autoclave 
Gilson pipettes (20μl – 1ml) 
 
Chitosan Materials (Various Production Methods) 
All chitosan work was performed using Purisan™ PB-103 squid chitosan, high 
molecular weight from Sigma Aldrich (made by Technology Resource International 
Corporation).  The 2M acetic acid was made from glacial acetic acid (reagent grade, 
Acacia). 
 
All of these samples were autoclaved (sterilised) prior to use in the experiment, at 
121 C for 15 minutes unless stated otherwise.  This produced some discolouration in 
the chitosan coated cotton cloth and the chitosan film sample and it also softened the 
film sample, making it supple rather than the rigid film that it was before autoclaving. 
Chitosan Gel 
Chitosan samples were prepared by dissolving 1g, 0.1g, 0.01g or 0.001g (+/– 
0.0001g) of chitosan in 10 mls acetic acid (2M, pH5).  The 1g sample was so thick it 
needed heating to 70 ºC to fully dissolve.  
 
Chitosan Suspension 
To 1g, 0.1g or 0.01g chitosan was added to 10mls of distilled water.  The chitosan did 
not dissolve and thus needed constant agitation to keep the chitosan powder in 
suspension. 
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Chitosan Film 
Chitosan was dissolved in acetic acid (2M, pH5) and the acid was allowed to 
evaporate, leaving a film of chitosan (and traces of un-evaporated acetic acid).  No 
attempt was made to remove acetic acid residues.  For materials coated in chitosan, 
materials were dipped in 0.1% (w/v) chitosan in acetic acid solution and then allowed 
to hang dry in a fume cupboard for 12 hrs. 
 
Chitosan Coated Cotton cloth 
The chitosan-coated cotton cloth was made by dipping woven cotton cloth (made at 
Heriot-Watt University) first in chitosan solution (0.1g chitosan dissolved in 100mls 
acetic acid (2M, pH5)) and then transferred into a NaOH bath (0.1M pH 13 in excess) 
to neutralise the acid and precipitate the chitosan and then the excess chitosan was 
squeezed out of the material using a glass rod on a glass plate.  The samples were 
then washed under cold water and hung on an aluminium bar to dry at ~20 C (room 
temperature) for 24hrs. 
 
The control was cotton cloth treated in acetic acid without the chitosan and 
neutralised in sodium hydroxide and washed in water then dried in the same way.  
 
Chitosan Fibre 
Attempts were made to try to produce useable chitosan fibres but these were not 
entirely successful, although this could yield more success with a suitable investment 
of time.  Initial attempts yielded some success but within the project there was neither 
the time nor more importantly, the equipment available to yield useful results.  
 
1g of chitosan was added to 20mls dilute acetic acid (2M, pH5) and mixed using a 
glass rod.  This was then left for half an hour to dissolve.  The resulting thick gel was 
then filtered through a Buchner funnel and extruded using a syringe with a 1ml 
pipette tip attached into a 2M NaOH bath.  The fibre was then collected from the 
NaOH bath and dried on a glass rod. 
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Culture Media 
Standard Nutrient Agar (NA) plates 
This process was scaled to make the required quantity of NA plates. To make 5 NA 
plates (containing approx 20mls of agar each), 2.8g NA powder and 100mls distilled 
water were measured out.  The NA powder was added to the distilled water in a glass 
bottle and swirled to mix.  A cap was placed on the bottle (loosely, to prevent the 
bottle exploding inside the autoclave) and autoclaved in a Dixons Vario 2228 
autoclave at 121 C for 15 minutes.  When the autoclaved solution was cool enough to 
handle, the solution was removed from the autoclave and Swirled until no 
concentration haze was observable at the bottom of the bottle.  The mixture was then 
allowed to cool to ~ 60ºC.  When the solution had cooled, approx 20mls of NA 
solution was poured onto each Petri dish (10 cm) and then allowed to set.  The NA 
plates were then left for 24 hours at around 20ºC before use to remove excess 
moisture.  As a rule, more NA plates were produced than were required to allow for 
unforeseen circumstances. 
 
Chitosan NA plates 
This process was scaled to make the required quantity of chitosan NA plates. To 
make 3 NA plates containing each acetic acid solution (containing approx 20mls of 
agar each), 2.8g NA powder and 90mls distilled water were measured out into 5 
different bottles.  5 bottles of 10 mls acetic acid were prepared with varying 
quantities of chitosan powder added to each of the 5 bottles (1g, 0.1g, 0.1g, 0.001g 
chitosan or no chitosan for the control).  The 5 bottles were swirled to mix.  A cap 
was placed on each bottle (loosely, to prevent the bottle exploding inside the 
autoclave) and autoclaved in a Dixons Vario 2228 autoclave at 121 C for 15 minutes.  
When the autoclaved solutions were cool enough to handle, the solutions were 
removed from the autoclave and Swirled until no concentration haze was observable 
at the bottom of the bottle.  The mixtures were then allowed to cool to ~ 60ºC.  When 
the solutions had cooled, approx 20mls of each solution was poured onto 3 Petri 
dishes and then allowed to set.  The plates were then left for 24 hours at around 20ºC 
before use to remove excess moisture.   
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Standard Nutrient Broth (NB)  
This process was scaled to make the required quantity of NB. To make 10 bottles of 
NB (containing 10mls of NB each), 2.5g NB powder and 100mls distilled water were 
measured out.  The NB powder was added to the distilled water in a glass bottle and 
swirled to mix.  A cap was placed on the bottle (loosely, to prevent the bottle 
exploding inside the autoclave) and autoclaved in a Dixons Vario 2228 autoclave at 
121 C for 15 minutes.  When the autoclaved solution was cool enough to handle, the 
solution was removed from the autoclave and Swirled until no concentration haze 
was observable at the bottom of the bottle.  The mixture was then allowed to cool to 
~ 60ºC.  When the solution had cooled, 10mls of NB solution was dispensed into 10 
sterilised 25ml Culture bottles (universal bottles or universals).  The NB bottles were 
then allowed to cool to room temperature (20ºC). 
 
Chitosan NB  
This process was scaled to make the required quantity of chitosan NB. To make 3 NB 
universals containing each acetic acid solution (containing approx 10mls of broth 
each), 5g NB powder and 200mls distilled water were added to a bottle.  The bottle 
was swirled to mix.  5 bottles of 10 mls of distilled water were prepared with varying 
quantities of chitosan powder added to each (1g, 0.1g, 0.1g, 0.001g chitosan or no 
chitosan for the control). A cap was placed on each bottle (the NB solution, the 
chitosan suspensions, the control and 15 universals) with the caps attached loosely (to 
prevent the bottles exploding inside the autoclave) and autoclaved in a Dixons Vario 
2228 autoclave at 121 C for 15 minutes.  When the autoclaved solutions were cool 
enough to handle, the solutions were removed from the autoclave and the NB 
solution was swirled until no concentration haze was observable at the bottom.  The 
NB solution, the chitosan suspensions and the 15 universals were then allowed to 
cool to ~ 60ºC.  When the solutions had cooled, 9mls of NB solution was dispensed 
into each of the 15 universals.  1 ml of each chitosan suspension was added to 3 
universals (vortexing the suspensions prior to extracting the suspension using a 
vortex mixer).  1ml of distilled water was added to the 3 remaining universals 
(vortexing the water prior to extracting the suspension for consistency).  The NB 
mixtures were allowed to cool to room temperature (20ºC) prior to use. 
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Chitosan Film Plates 
As for standard NA plates but with chitosan film added to plate after inoculation with 
bacteria.  Any air pockets under chitosan film were squeezed out. 
 
Chitosan Coated Material Plates 
As for chitosan film plates, but with the chitosan film having a material embedded 
(cotton cloth or polypropylene mesh). 
 
3.1.2 Methods 
Examination of Chitosan as a Bacteriostat 
Methodology 
The experimental methods for the chitosan study were derived from discussions with 
academic staff after an extensive review of the available literature.  The methods 
were designed primarily to examine the bacteriostatic effect of chitosan in relation to 
hospital pathogens and evolved into a study that examined how the quantity of 
chitosan available and the form in which the chitosan was presented affected the 
bacteria. 
 
Cell Count 
Using the Gilson 20µl pipette, take 10µl of cells.  Stain cells using methylene blue 
(10µl methylene blue to 10µl cell suspension).  Place methylene blue stained cells on 
Haemocytometer (improved Neubauer BS748, depth 0.01mm, 1/400mm
2
) and place 
cover slip on top of the drop of cells.  Place Haemocytometer on microscope.  Count 
cells in 10 random squares. Cells are counted when in the middle of the square (not 
touching the lines) and when in contact with the bottom and left sides of the square.  
Cells touching the top and left sides are excluded from the cell count figure.  Get the 
average of the 10 cell counts.  Divide the average by 16, then multiply by 4. multiply 
that figure by 10
6
 and you have the cells per ml.   
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Method 1 - Chitosan dissolved in dilute acetic acid incorporated into nutrient agar 
Vs MRSA 9551 and Staphylococcus epidermis 
This experiment was designed to examine the growth of MRSA 9551 and 
Staphylococcus epidermis on nutrient agar plates containing chitosan gel. 
 
Obtain cultures of MRSA 9551 and Staphylococcus epidermis and culture the 
Staphylococcus epidermis on nutrient agar and the MRSA 9551 on DST agar for 24 
hrs.  Dissolve 1g chitosan in 10mls acetic acid (2M).  Dissolve 0.1g chitosan in 10mls 
acetic acid (2M).  Add 1g chitosan in 10mls acetic acid (2M) to 90mls nutrient agar.  
Add 0.1g chitosan in 10mls acetic acid (2M) to 90mls nutrient agar.  Add 10mls 
acetic acid (2M) to 90mls nutrient agar.  Prepare 100 ml nutrient agar.  Prepare 2x 
10mls 0.9% saline solution.  Autoclave the prepared nutrient agars and saline 
solutions at 121ºC for 15 minutes.  Shake (swirl) autoclaved agars well without 
producing bubbles, allow to cool to 40-50ºC and pour into Petri dishes 
(approximately 20mls each) and allow to cool to room temperature.   
 
Take the 24 hour culture of MRSA and inoculate an inoculation loop full of MRSA 
into 10mls 0.9% saline and use a vortex mixer to ensure through mixing.  Take the 24 
hour culture of MRSA and inoculate an inoculation loop full of MRSA into 10mls 
0.9% saline and use a vortex mixer to ensure through mixing.  Perform cell count of 
the saline inoculums using Neubauer improved haemocytometer.  Add 100mls of 
MRSA inoculum to the control (NA), the control containing acetic acid (NA + acetic 
acid), the NA + 1g chitosan in 10 ml acetic acid, NA + 0.1g chitosan in 10 ml acetic 
acid and spread the inoculum across the plates with sterile glass beads.  Add 100mls 
of Staphylococcus epidermis inoculum to the control (NA), the control containing 
acetic acid (NA + acetic acid), the NA + 1g chitosan in 10 ml acetic acid, NA + 0.1g 
chitosan in 10 ml acetic acid and spread the inoculum across the plates with sterile 
glass beads.  Inoculate 2 NA plates, one with MRSA and the other with 
Staphylococcus epidermis and spread the inoculum across the plate with sterile glass 
beads, then add a 1cm square of chitosan film to each.  Incubate at 37 C for 48hrs 
and then examine for signs of growth. 
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Method 1b - Modified method 
This method is a modified version of method 1.  By neutralising the acetic acid 
control and using only the 1g chitosan and 0.1g chitosan samples, all of the agar 
plates would be solid enough to inoculate.  In addition, the plates were inoculated 
using a sterile swab of saline inoculum instead of an inoculation loop (to increase the 
quantity of inoculum). 
 
Obtain cultures of MRSA 9551 and Staphylococcus epidermis and culture 
Staphylococcus epidermis on nutrient agar and MRSA 9551 on DST agar for 24 hrs.  
Dissolve 1g chitosan in 10mls acetic acid (2M).  Dissolve 0.1g chitosan in 10mls 
acetic acid (2M).  Add 1g chitosan in 10mls acetic acid (2M) to 90mls nutrient agar.  
Add 0.1g chitosan in 10mls acetic acid (2M) to 90mls nutrient agar.  Add 10mls 
acetic acid (2M) (neutralised to pH 7 using NaOH) to 90mls nutrient agar.  Prepare 
100 ml nutrient agar.  Autoclave the prepared nutrient agars and saline solutions at 
121ºC for 15 minutes.  Shake (swirl) autoclaved agars well without producing 
bubbles, allow to cool to 40-50ºC and pour into Petri dishes (approximately 20mls 
each) and allow to cool to room temperature.   
 
Take a sterile swab and dip it in sterile saline solution (0.9%) then take a swab of 
MRSA and inoculate the control (NA) making sure to cover the entire plate.  Repeat 
this process for the control containing acetic acid (NA + acetic acid), the NA + 1g 
chitosan in 10 ml acetic acid, NA + 0.1g chitosan in 10 ml acetic acid.  Take a sterile 
swab and dip it in sterile saline solution (0.9%) then take a swab of Staphylococcus 
epidermis  and inoculate the control (NA) making sure to cover the entire plate. 
repeat this process for the control containing acetic acid (NA + acetic acid), the NA + 
1g chitosan in 10 ml acetic acid, NA + 0.1g chitosan in 10 ml acetic acid.  Take a 
sterile swab and dip it in sterile saline solution (0.9%) then take a swab of MRSA and 
inoculate a nutrient agar making sure to cover the entire plate and then add a 1cm 
square of chitosan film.  Take a sterile swab and dip it in sterile saline solution 
(0.9%) then take a swab of MRSA and inoculate a nutrient agar making sure to cover 
the entire plate and then add a 1cm square of chitosan film.  Incubate at 37 C for 
48hrs and then examine for signs of growth.   
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Method 2 - Chitosan dissolved in acetic acid added to nutrient broth Vs MRSA 9551 
and Staphylococcus epidermis  
Method 2 was redesigned so that the experiment would be performed using nutrient 
broth and measuring the growth of the bacteria spectrophotometrically using a LKB 
Biochrom Ultrospec II.  With this study, all of the samples and the control contained 
acetic acid.   
 
Obtain cultures of MRSA 9551 and Staphylococcus epidermis and culture on 
Staphylococcus epidermis nutrient agar and MRSA 9551 on DST agar for 24 hrs.  
Add 1g chitosan to 10mls acetic acid (2M).  Add 0.1g chitosan to 10mls acetic acid 
(2M).  Add 0.01g chitosan to 10mls acetic acid (2M).  Make 100 ml nutrient broth 
(2.5g nutrient broth powder + 100mls distilled water).  Make 4 x 110 ml chitosan 
nutrient broth (2.5g nutrient broth powder + 100mls distilled water) +; (1g chitosan + 
10 ml acetic acid (2M)), (0.1g chitosan + 10 ml acetic acid (2M)), (0.01g chitosan + 
10 ml acetic acid (2M)) and (10 ml acetic acid (2M)).  Autoclave the prepared 
nutrient broth and 0.9% saline solution and 10 glass culture bottles (~25ml) at 121ºC 
for 15 minutes.  Shake (swirl) autoclaved broth well and allow to cool to room 
temperature.  Dispense 2 (x10mls) of each media into a universal (2x NB, 2x NB 
+10mls acetic acid (2M), 2x NB +10mls acetic acid (2M) + 1g chitosan, 2x NB 
+10mls acetic acid (2M) + 0.1g chitosan and 2x NB +10mls acetic acid (2M)+ 0.01g 
chitosan).   
 
Take the 24 hour culture of MRSA and inoculate an inoculation loop full of MRSA 
into 10mls 0.9% saline and use a vortex mixer to ensure through mixing.  Take the 24 
hour culture of Staphylococcus epidermis and inoculate an inoculation loop full of 
MRSA into 10mls 0.9% saline and use a vortex mixer to ensure through mixing.  
Perform cell count of the saline inoculums using Neubauer improved 
haemocytometer.  Add 0.5ml of MRSA to one of each of the nutrient broth.  Add 
0.5mls of Staphylococcus epidermis one of each of the nutrient broth.  Incubate at 
37 C.  After 2 hours take 1 ml of bacterial broth from each culture and add each 
sample to a 1ml spectrophotometry curvette.  Measure the absorbance of the samples 
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at AD550nm. Examine every 2 hours for 8 hours using the spectrophotometer and 
then once after 24 hours. 
 
Method 2b - Modified method - Chitosan added to nutrient broth Vs MRSA 9551 
and Staphylococcus epidermis 
In this method, the chitosan powder was not dissolved in acetic acid. Instead, it was 
suspended in distilled water.  This was to study how colloidal chitosan affected 
bacterial growth and to remove any effect the pH may have on bacterial growth. 
  
Obtain cultures of MRSA 9551 and Staphylococcus epidermis and culture on 
Staphylococcus epidermis nutrient agar and MRSA 9551 on DST agar for 24 hrs.  
Prepare 1g chitosan in 10mls distilled water.  Prepare 0.1g chitosan in10mls distilled 
water.  Prepare 0.01g chitosan in 10mls distilled water.  Make 5 x 110 ml nutrient 
(2.5g nutrient broth powder + 100mls distilled water +; (1g chitosan + 10mls distilled 
water), (0.1g chitosan + 10mls distilled water), (0.01g chitosan + 10mls distilled 
water) and Prepare 100 ml nutrient broth.  Autoclave the prepared nutrient broth and 
0.9% saline solution and 12 glass culture bottles (~25ml) at 121ºC for 15 minutes.  
Shake (swirl) autoclaved broth well and allow to cool to room temperature.  Dispense 
3 (x10mls) of each media into a universal vortexing each time to resuspend chitosan 
(3x NB, 3x NB + 1g chitosan, 3x NB + 0.1g chitosan and 3x NB + 0.01g chitosan).   
 
Take the 24 hour culture of MRSA and inoculate an inoculation loop full of MRSA 
into 10mls 0.9% saline and use a vortex mixer to ensure through mixing.  Take the 24 
hour culture of Staphylococcus epidermis and inoculate an inoculation loop full of 
MRSA into 10mls 0.9% saline and use a vortex mixer to ensure through mixing.  
Perform cell count of the saline inoculums using Neubauer improved 
haemocytometer.  Add 0.5ml of MRSA to one of each of the nutrient broth.  Add 
0.5mls of Staphylococcus epidermis one of each of the nutrient broth.  Incubate all of 
the samples (including the sterile controls) at 37 C and examine every hour for 4 
hours using spectrophotometer at AD550nm and then once after 24 hours.   
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Method 2c - Modified method - Chitosan added to nutrient broth Vs MRSA 9551 
and Staphylococcus epidermis 
This method is a further refinement of method 2b.  In method 2b the nutrient broths 
were stationary when in the incubator.  This method includes the use of a platform 
shaker to encourage the chitosan powder to remain in suspension while in the 
incubator.  The platform shaker agitated the chitosan powder into suspension 
therefore it was necessary to let the chitosan powder to settle before 
spectrophotometer readings to prevent the chitosan suspension from influencing the 
absorbance readings.  An absorption wavelength of 550nm was used for the 
spectrophotometer as is it the optimal wavelength for bacterial turbidity readings. 
 
Obtain cultures of MRSA 9551 and Staphylococcus epidermis and culture on 
Staphylococcus epidermis nutrient agar and MRSA 9551 on DST agar for 24 hrs.  
Prepare 1g chitosan in 10mls distilled water.  Prepare 0.1g chitosan in10mls distilled 
water.  Prepare 0.01g chitosan in 10mls distilled water.  Prepare 5 x 110ml nutrient 
(2.5g nutrient broth powder + 100mls distilled water +; (1g chitosan + 10mls distilled 
water), (0.1g chitosan + 10mls distilled water), (0.01g chitosan + 10mls distilled 
water) and Prepare 100ml nutrient broth.  Autoclave the prepared nutrient broth and 
0.9% saline solution and 8 glass culture bottles (~25ml) at 121ºC for 15 minutes.  
Shake (swirl) autoclaved broth well allow to cool to room temperature.  Dispense 3 
(x10mls) of each media into a universal (2x NB, 2x NB + 1g chitosan, 2x NB + 0.1g 
chitosan and 2x NB + 0.01g chitosan).   
 
Take the 24 hour culture of MRSA and inoculate an inoculation loop full of MRSA 
into 10mls 0.9% saline and use a vortex mixer to ensure through mixing.  Take the 24 
hour culture of Staphylococcus epidermis and inoculate an inoculation loop full of 
MRSA into 10mls 0.9% saline and use a vortex mixer to ensure through mixing.  
Add 0.2ml of MRSA to one of each of the nutrient broth.  Add 0.2mls of 
Staphylococcus epidermis one of each of the nutrient broth.  Incubate all of the 
samples (including the sterile controls) at 37 C on a platform shaker and examine 
every hour for 4 hours using spectrophotometer at AD550nm and then once after 24 
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hours (allow the chitosan suspension to settle ~15mins to before taking 
spectrophotometer readings). 
 
Method 3 - Testing of Chitosan treatment of Cotton cloth 
This experiment was designed to examine the efficacy of chitosan coatings on a 
material (cotton cloth) to inhibit bacterial growth of MRSA 9551 and Staphylococcus 
epidermis.  This method is a development of the chitosan film sample tested in 
method 1. 
 
Obtain cultures of MRSA 9551 and Staphylococcus epidermis and culture 
Staphylococcus epidermis and MRSA 9551 in nutrient broth for 24 hrs.  Prepare 120 
ml nutrient agar and 60mls 0.9% saline solution.  Autoclave the prepared nutrient 
agars, saline solution and cotton cloth samples at 121ºC for 15 minutes.  Shake 
(swirl) autoclaved agars well without producing bubbles, allow to cool to 40-50ºC 
and pour into 6 Petri dishes (approximately 20mls each) then allow to cool to room 
temperature.   
 
Take a sterile swab and dip it in sterile saline solution (0.9%) then take a swab of 
MRSA and inoculate a nutrient agar making sure to cover the entire plate.  Take a 
sterile swab and dip it in sterile saline solution (0.9%) then take a swab of MRSA and 
inoculate a nutrient agar making sure to cover the entire plate, then add a 1cm square 
of untreated cotton cloth.  Take a sterile swab and dip it in sterile saline solution 
(0.9%) then take a swab of MRSA and inoculate a nutrient agar making sure to cover 
the entire plate, then add a 1cm square of chitosan coated cotton cloth.  Take a sterile 
swab and dip it in sterile saline solution (0.9%) then take a swab of MRSA and 
inoculate a nutrient agar making sure to cover the entire plate.  Take a sterile swab 
and dip it in sterile saline solution (0.9%) then take a swab of Staphylococcus 
epidermis and inoculate a nutrient agar making sure to cover the entire plate, then add 
a 1cm square of untreated cotton cloth.  Take a sterile swab and dip it in sterile saline 
solution (0.9%) then take a swab of Staphylococcus epidermis and inoculate a 
nutrient agar making sure to cover the entire plate, then add a 1cm square of chitosan 
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coated cotton cloth.  Incubate at 25 C for 72 hrs and then examine for signs of 
growth.   
 
Method 3b - Modified method - Testing of Chitosan treatment of Cotton cloth 
This method is a refined version of method 3.  The samples were covered in 
aluminium foil to maintain the sterility while cooling down from the autoclave cycle 
and instead of using a swab to inoculate the agar plates, 20 µl of inoculum was used 
to standardise the quantity of bacteria on each agar plate. 
 
Obtain cultures of MRSA 9551 and Staphylococcus epidermis and culture 
Staphylococcus epidermis and MRSA 9551 in nutrient broth for 24 hrs.  Prepare 120 
ml nutrient agar.  Autoclave the prepared nutrient agars, saline solution and cotton 
cloth samples at 121ºC for 15 minutes. Cotton cloth samples were wrapped in 
aluminium foil during the autoclave cycle.  Shake (swirl) autoclaved agars well 
without producing bubbles, allow to cool to 40-50ºC and pour into 6 Petri dishes 
(approximately 20mls each) and allow to cool to room temperature.   
 
Dispense 20µl of MRSA broth onto a nutrient agar and spread around the NA using a 
Bunsen sterilised inoculation loop making sure to cover the entire plate, then add a 
1cm square of untreated cotton cloth using Bunsen sterilised tweezers and squeeze 
out any air bubbles under the samples.  Dispense 20µl of MRSA broth onto a nutrient 
agar and spread around the NA using a Bunsen sterilised inoculation loop making 
sure to cover the entire plate, then add a 1cm square of chitosan coated cotton cloth 
using Bunsen sterilised tweezers and squeeze out any air bubbles under the samples.  
Dispense 20µl of Staphylococcus epidermis broth onto a nutrient agar and spread 
around the NA using a Bunsen sterilised inoculation loop making sure to cover the 
entire plate, then add a 1cm square of untreated cotton cloth using Bunsen sterilised 
tweezers and squeeze out any air bubbles under the samples.  Dispense 20µl of 
Staphylococcus epidermis broth onto a nutrient agar and spread around the NA using 
a Bunsen sterilised inoculation loop making sure to cover the entire plate, then add a 
1cm square of chitosan coated cotton cloth using Bunsen sterilised tweezers and 
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squeeze out any air bubbles under the samples.  Incubate at 25 C for 72 hrs and then 
examine for signs of growth.   
 
Method 3c - Modified method - Testing of Chitosan treatment of Cotton cloth & 
polypropylene 
This method is a modified version of method 3.  The method is the same as for 
method 3 with the addition of a chitosan coated polypropylene mesh.  In addition, the 
samples were placed in glass bottles (with lids) to prevent the moisture in the 
autoclave from effecting the chitosan coating and to maintain the sample sterility 
until they were used.  
 
Obtain cultures of MRSA 9551 and Staphylococcus epidermis and culture 
Staphylococcus epidermis and MRSA 9551 in nutrient broth for 24 hrs.  Prepare 200 
ml nutrient agar and 100mls 0.9% saline solution.  Autoclave the prepared nutrient 
agars, saline solution and cotton cloth samples at 121ºC for 15 minutes. Cotton cloth 
and polypropylene samples were placed in “universal” bottles during the autoclave 
cycle to keep them dry (as the samples were dry after the autoclave, they would need 
moistening with 0.9% saline so they would adhere to the agar).  Shake (swirl) 
autoclaved agars well without producing bubbles, allow to cool to 40-50ºC and pour 
into 6 Petri dishes (approximately 20mls each) and allow to cool to room 
temperature.   
 
Take a sterile swab and dip it in sterile saline solution (0.9%) then take a swab of 
MRSA and inoculate a nutrient agar making sure to cover the entire plate, then add a 
2cm square of untreated cotton cloth (sterilised) using Bunsen sterilised tweezers and 
squeeze out any air bubbles under the samples.  Take a sterile swab and dip it in 
sterile saline solution (0.9%) then take a swab of MRSA and inoculate a nutrient agar 
making sure to cover the entire plate, then add a 2cm square of chitosan coated cotton 
cloth (sterilised) using Bunsen sterilised tweezers and squeeze out any air bubbles 
under the samples.  Take a sterile swab and dip it in sterile saline solution (0.9%) 
then take a swab of MRSA and inoculate a nutrient agar making sure to cover the 
43 
entire plate, then add a 2cm square of chitosan coated cotton cloth (non-sterilised) 
using Bunsen sterilised tweezers and squeeze out any air bubbles under the samples.  
Take a sterile swab and dip it in sterile saline solution (0.9%) then take a swab of 
MRSA and inoculate a nutrient agar making sure to cover the entire plate, then add a 
2cm square of chitosan coated polypropylene mesh (sterilised) using Bunsen 
sterilised tweezers and squeeze out any air bubbles under the samples.   
 
Take a sterile swab and dip it in sterile saline solution (0.9%) then take a swab of 
Staphylococcus epidermis and inoculate a nutrient agar making sure to cover the 
entire plate, then add a 2cm square of untreated cotton cloth (sterilised) using Bunsen 
sterilised tweezers and squeeze out any air bubbles under the samples.  Take a sterile 
swab and dip it in sterile saline solution (0.9%) then take a swab of Staphylococcus 
epidermis and inoculate a nutrient agar making sure to cover the entire plate, then add 
a 2cm square of chitosan coated cotton cloth (sterilised) using Bunsen sterilised 
tweezers and squeeze out any air bubbles under the samples.  Take a sterile swab and 
dip it in sterile saline solution (0.9%) then take a swab of Staphylococcus epidermis 
and inoculate a nutrient agar making sure to cover the entire plate, then add a 2cm 
square of chitosan coated cotton cloth (non-sterilised) using Bunsen sterilised 
tweezers and squeeze out any air bubbles under the samples.  Take a sterile swab and 
dip it in sterile saline solution (0.9%) then take a swab of Staphylococcus epidermis 
and inoculate a nutrient agar making sure to cover the entire plate, then add a 2cm 
square of chitosan coated polypropylene mesh (sterilised) using Bunsen sterilised 
tweezers and squeeze out any air bubbles under the samples.  Incubate at 25 C for 72 
hrs and then examine for signs of growth.   
 
Method 4 - Chitosan suspended in nutrient broth Vs MRSA 
Prepare 3 litres of plate count agar and 2 litres of 0.9% saline solution.  Sterilise the 
plate count agar and 0.9% saline solution in the autoclave at 121ºC for 15 minutes.  
Shake (swirl) autoclaved agars well without producing bubbles, allow to cool to 40-
50ºC and pour into and poured into 200 Petri dishes (approximately 20mls each) and 
allow to cool to room temperature.  Once the plate count agars have cooled, store for 
1 week to dry out a little (so that when they are inoculated, there isn‟t excess 
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moisture enabling the bacteria to spread).  Obtain culture of MRSA 9551 and culture 
on nutrient agar for 24 hrs.  Accurately weigh out 1g chitosan and add to 10 ml of 
distilled water in to a “universal” bottle (25ml).  Accurately weigh out 0.8g chitosan 
and add to 10 ml of distilled water in to a “universal” bottle (25ml).  Accurately 
weigh out 0.6g chitosan and add to 10 ml of distilled water in to a “universal” bottle 
(25ml).  Accurately weigh out 0.4g chitosan and add to 10 ml of distilled water in to 
a “universal” bottle (25ml).  Accurately weigh out 0.2g chitosan and add to 10 ml of 
distilled water in to a “universal” bottle (25ml).  Sterilise 200 „Universals‟.  Dispense 
9mls of 0.9% saline solution into 150 „universals‟.  Dispense 10 ml of distilled water 
in to a “universal” bottle (25ml) (the control).  Prepare 100mls of nutrient broth.  
Prepare 3x 10mls 0.9% saline solution in “universal” bottles (25ml).  Sterilise the 
chitosan samples, nutrient broths and saline solution in saline in the autoclave at 
121ºC for 15 minutes.  Take 1ml of the chitosan/ distilled water mixture (mix by 
pipetting 3x first) and add to 9mls of nutrient broth).   
 
Take the 24 hour culture of MRSA and inoculate an inoculation loop full of MRSA 
into 10mls 0.9% saline and use a vortex mixer to ensure through mixing.  Perform 
cell count of the saline inoculum using Neubauer improved haemocytometer.  Add 
200mls of MRSA inoculum to the control (NB + 1ml distilled water), the NB + 1g 
chitosan, NB + 0.1g chitosan, NB + 0.01g chitosan.  Incubate at 37 C for 48hrs on a 
platform shaker and then examine for signs of growth.  Take 1ml of each sample and 
add to 9mls 0.9% saline, vortex mix, then take 1ml of the inoculated saline and 
inoculate it into 9mls 0.9% saline. Repeat a further 5 times for 10
-6
 dilution and 7 
times for 10
-8
 dilution.  The 48hr samples should be diluted to 10
-8
 and 10
-6
, 10
-7
 & 
10
-8
 samples should be used to inoculate plate count agars. (100ul per plate count 
agar, spread across the plate count agar using sterile glass beads).  Return cultures to 
platform shaker in 37ºC incubator after the dilutions have been performed.  The 72hr 
Samples should be taken and diluted to 10
-8
 and 10
-6
, 10
-7
 & 10
-8
 samples should be 
used to inoculate plate count agars. (100ul per plate count agar, spread across the 
plate count agar using sterile glass beads). Return cultures to platform shaker in 37ºC 
incubator after the dilutions have been performed.  The plate count agars had the 
colonies counted 24 - 48 hours after inoculation and the results were noted.   
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Method 4b - Modified method 
This method is a refined version of method 4.  The concentrations of chitosan (and 
the control) are performed in triplicate (e.g. control 1, control 2 and control 3).  In 
addition, the dilutions performed have been expanded to 10
-9
 on certain days in order 
to have plate count agars containing countable numbers of colonies. 
 
Prepare 4 litres of plate count agar.  Sterilise the plate count agar in the autoclave at 
121ºC for 15 minutes.  Shake (swirl) autoclaved agars well without producing 
bubbles, allow to cool to 40-50ºC and pour into and poured into 200 Petri dishes 
(approximately 20mls each) and allow to cool to room temperature.  Once the plate 
count agars have cooled, store for 1 week to dry out a little (so that when they are 
inoculated, there isn‟t excess moisture enabling the bacteria to spread).  Obtain 
culture of MRSA 9551 and culture on nutrient agar for 24 hrs.  Accurately weigh out 
1g chitosan and add to 10 ml of distilled water in to a “universal” bottle (25ml).  
Accurately weigh out 0.8g chitosan and add to 10 ml of distilled water in to a 
“universal” bottle (25ml).  Accurately weigh out 0.6g chitosan and add to 10 ml of 
distilled water in to a “universal” bottle (25ml).  Accurately weigh out 0.4g chitosan 
and add to 10 ml of distilled water in to a “universal” bottle (25ml).  Accurately 
weigh out 0.2g chitosan and add to 10 ml of distilled water in to a “universal” bottle 
(25ml).  Dispense 10 ml of distilled water in to a “universal” bottle (25ml) (the 
control).  Sterilise 200 „Universals‟ and prepare 2 litres of sterile 0.9% saline 
solution.  Dispense 9mls of 0.9% saline solution into 150 „universals‟.  Prepare 
100mls of nutrient broth.  Prepare 3x 10mls 0.9% saline solution in “universal” 
bottles (25ml).  Sterilise the chitosan samples, nutrient broths and saline solutions in 
the autoclave at 121ºC for 15 minutes.  Take 1ml of the chitosan/ distilled water 
mixture (mix by pipetting 3x first) and add to 9mls of nutrient broth).   
 
Take the 24 hour culture of MRSA and inoculate an inoculation loop full of MRSA 
into 10mls 0.9% saline and use a vortex mixer to ensure through mixing.  Add 
100mls of MRSA inoculum to the control (NB + 1ml distilled water), the NB + 0.1g 
chitosan, NB + 0.08g chitosan, NB + 0.06g chitosan, NB + 0.04g chitosan, NB + 
0.02g chitosan (Perform this stage in triplicate). Perform cell count of the saline 
46 
inoculum using Neubauer improved haemocytometer.  Incubate at 37 C for 48hrs on 
a platform shaker and then examine for signs of growth.   
 
Dilution procedure; 
take 1ml of each sample and add to 9mls 0.9% saline, vortex mix, then take 1ml of 
the inoculated saline and inoculate it into 9mls 0.9% saline.  Repeat a further 5 times 
for 10
-6
 dilution and a further 7 times for 10
-9
 dilution, ensuring to vortex mix each 
dilution. 
 
Samples should be taken and diluted to 10-8 after 48 hours and 10
-6
 - 10
-8
 samples 
used to inoculate plate count agars. (100ul per plate count agar, spread across the 
plate count agar using sterile glass beads). Once dilutions are performed, wash the 
universals and repeat step 11 and 12 so that the salines are ready for the next day.  
Samples should be taken and diluted to 10-9 after 72 hrs and 10
-7
 - 10
-9
 samples used 
to inoculate plate count agars (100ul per plate count agar, spread across the plate 
count agar using sterile glass beads). Once dilutions are performed, wash the 
universals and repeat step 11 and 12 so that the salines are ready for the next day.  
Samples should be taken and diluted to 10-8 after 96 hours and 10
-6
 - 10
-8
 samples 
should be used to inoculate plate count agars. (100ul per plate count agar, spread 
across the plate count agar using sterile glass beads).  The plate count agars should 
have the colonies counted ~48 hours after inoculation and the results should be noted. 
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3.2 Production of Biomaterial Samples  
Table 3.1 Sample summary.  
 
Table 3.1 illustrates the source and production methods used to produce the samples 
used in the experiments. 
 
3.2.1 Extrusion 
Polypropylene tape 
Materials 
Polypropylene pellets MFI-19 (borealis polypropylene) 
ESL vertical extruder (model 250) 
          Material 
 
Details 
Poly-ε-
Caprolactone 
6400 
Solanyl Polylactic acid Polyester Polypropylene Tuftane 
Polyurethane 
Source Solvay Rodenburg 
Biopolymers 
Cargill Dow Vascutek Borealis 
polypropylene 
Lord 
Corporation 
Grade 6400 Flexibilitis N/A VP1200K 
Virgin grade 
N/A N/A 
Method of 
 fabrication 
Extrusion Extrusion Film casting - 
dissolved in 
dichloromethane 
(DCM) 
Extrusion 
followed by 
knitting 
Extrusion extrusion 
Melting Point 
(°C) 
62.5 112.5 168 257.5 151 149.5 
Extrusion 
Temperature 
(°C) 
76 125 @280psi N/A N/A 235 N/A 
Tape / sample 
 width (mm) 
1.33 0.97 1.13 2 1.4 1 
Tape / sample 
 thickness 
(mm) 
0.09 0.19 0.01 0.9 0.16 0.05 
Additional 
notes 
Hand drawn 
over 47°C roller 
 Unable to 
extrude a useful 
tape, therefore 
prepared as a 
film 
Obtained in the 
form of pre 
fabricated 
vascular graft 
 Obtained as a 
pre fabricated 
sheet 
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Fig 3.2 (Younes et al., 2009) - Diagram of ESL vertical extruder illustrating the extruder screw, die head 
(in green), the air quench chamber and winding apparatus. The barrel heaters are divided into zones so 
that the temperature of the molten polymer can be controlled from where it enters the extruder screw 
through to the die head.  The extruder screw forces the polymer through the barrel, increasing the pressure 
of the molten polymer until it reaches the die head. 
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Method 
The polypropylene tape was produced with the following extruder settings. 
Extruder 
Zone 1 Zone 2 Zone 3 
180°C 180°C 185°C 
Pump Die Head 
193°C Zone 1 Zone 2 
208°C 211°C 
Melt Extruder screw speed  
212°C 19.6-18.7 rpm 
Pre pump pressure Die Head Pressure 
769-860psi 514psi 
Metering Pump Air Quench Winder 
4.1rpm 23% 3rpm 
Polymer Draw Frame 
Roller No1 Roller No2 Roller No4 
34mpm 80mpm 158mpm 
80ºC 80ºC 80ºC 
Table 3.3 polypropylene extrusion parameters.  These setting were determined by Stewart Wallace, the 
extrusion technician at Heriot-Watt University. 
 
Solanyl 
Materials 
Solanyl Flexibilitis pellets 
ESL Laboratory Extrusion, Melt Spinning and Draw Equipment. Labspin 892 
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Fig 3.4 ESL Laboratory Extrusion, Melt Spinning and Draw Equipment. Labspin 892. 
 
 
Method 
The Solanyl tape was produced with the following extruder settings 
Material Details 
Source Rodenburg Biopolymers 
Grade  Flexibilitis 
Method of fabrication  Extrusion 
Melting Point (°C) 119.2 
Extrusion Temperature (°C) 125 @280psi 
Tape / sample width (mm) 0.97 
Tape / sample thickness (mm) 0.19 
Table 3.5 Solanyl extrusion parameters.  These setting were determined by Stewart Wallace, the extrusion 
technician at Heriot-Watt University. 
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Solanyl + 2% Chitosan Powder (W/W) 
This was extruded as per Solanyl but was mixed with chitosan powder at 2% w/w 
prior to extrusion.   
 
Poly-ε-caprolactone 6400 tape 
Materials 
Solvay poly-ε-caprolactone 
Bradford University Research Ltd. Small Scale Ram Extruder 
 
Fig. 3.6 Bradford University Research Ltd. Small Scale Ram Extruder 
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Method 
The poly-ε-caprolactone tape was produced with the following extruder settings. 
Extruder 
Zone 1 Zone 2 Zone 3 
80°C 80°C 80°C 
Pump Die Head 
105°C Zone 1 Zone 2 
105°C 105°C 
Melt Extruder screw speed  
105°C 19.6-18.7 rpm 
Pre pump pressure Die Head Pressure 
769-860psi 514psi 
Metering Pump Quench Tank Winder 
1.5rpm 10.8% 3rpm 
Table 3.7 poly-ε-caprolactone extrusion parameters.  These setting were determined by Stewart Wallace, 
the extrusion technician at Heriot-Watt University. 
3.2.2 Film Casting 
PLA film  
Perform all work using Dichloromethane in a fume cupboard.  1g of PLA (Cargill 
Dow) fibre is placed in a 200ml Pyrex glass beaker.  Add 30mls Dichloromethane 
(DCM) (Acros Organics).  Wait for the PLA to dissolve completely.  Pour solution 
on glass sheet and place in rack for glass plates.  Wait for the DCM to evaporate 
(takes about 4 hours but can be left longer).  Collect the film.  Place the film in an 
airtight bag and squeeze out any air and store it at room temperature in the bag until 
required.   
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3.2.3 Plasma Treatment 
Materials 
Polypropylene 
Tuftane polyurethane 
Polyester (Vascutek polyester VP1200K™) 
Poly-ε-Caprolactone 6400 tape 
Solanyl  
PLA 
 
Plasma treatment at Riccarton campus (Nanotech) 
Equipment 
Argon gas 
Ammonia gas 
Pirani 10 Pressure gauge 
Thruline Watt meter (model 43, Biro Electronic Corporation, Cleveland Ohio) 
Parallel plate plasma equipment (pressure chamber parallel plates and purge 
system by Nanotech, model PE250, serial 115) 
Vacuum pump 
RF generator (solid state power generator, Eni Powersystems Inc, model OEM-6, 
serial 729) 
Fume cupboard (to vent the spent gases) 
Silane calibrated flow meter to be used for argon gas (therefore actual gas flow 
rate = output reading x [flow factor for new gas/flow factor for the calibrated gas] 
= output reading x 1.4 [1.4 is the argon conversion factor] /0.4 [0.4 is the silane 
conversion factor]) 
Ammonia calibrated flow meter 
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Method 
Recommended settings 
Pressure  10
-1
Torr 
Power   50-100W  
Zero flow (for silane calibrated flow meter) registers as 0.5cc (therefore all flow 
readings will be compensated for by removing the 0.5cc 
Recommended gas flow (valves open) is 20cc 
Electrode gap  2.5cm 
 
Safety checks 
Check the cooling water for the RF unit is running.  Check the RF power is off when 
the chamber is open.  For Argon treatment - Set the regulator on the gas cylinder to a 
maximum of 5 bar. 
 
Procedure 
Before first run (warm up) 
Before any treatment takes place, the following need to be performed to prepare the 
equipment (argon gas is the vent/purge gas) 
Close the plasma chamber and turn on the vacuum pump.  Flush the system with 
argon gas to purge out any other gases (open the needle valve and turn on the electric 
valve).  Set flow meter to 20 cubic centimetres (cc).  Adjust the pressure to 
recommended levels (10
-1
Torr).  Turn on RF and tune for 0 reflected power (by 
adjusting input and load controls) and record forward power.  Turn power off.  Turn 
gas off.  Vent gas. 
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For Argon treatment 
Fume cupboard should be checked to make sure it is on before anything else to vent 
any waste gases.  Open argon cylinder (5 bar max).  Turn on vacuum pump.  Purge 
gas lines and plasma chamber with Argon.  Turn on water-cooling for RF generator.  
Turn on the rest of the equipment (gauges, valves).   Perform dummy run to ensure 
RF generator and gas flow are set to desired specifications.  Pump out the chamber to 
about 10
-1
 Torr (open the valve to the pump) and periodically vent the chamber with 
argon (will partially release the vacuum) and repeat at least 5 times to ensure air has 
been removed (displaced by the argon).  Pump down chamber for trial treatment to 
10
-1
 Torr (no sample).  Adjust gas flow (for treatment gas) until the pressure within 
the chamber is 20
-1
 Torr and record the gas flow.  Turn on the RF generator and 
adjust the power to desired level.  Check the Watt meter and adjust settings until 
there is 0 reflected power (all the power is going forward).  Equipment should be set 
now for your samples so, close the valve to the pump and fill the chamber with argon 
to return the pressure to atmospheric pressure.  Place samples on lower plate.  Pump 
down chamber for treatment to 10
-1
 Torr.  Open the treatment gas valve (the flow rate 
is already set).  When ready, turn on the RF generator (power level already set) and 
administer RF power for a measured time (for the treatment used, the time is 1 
minute).  When time has expired, turn off the RF generator.  Vent the chamber to 
atmospheric pressure (close the pump valve and admit argon to the chamber to 
relieve the vacuum).   
For Ammonia gas treatment 
Prior to commencing the ammonia gas line needs to be vented with argon (as the gas 
line is shared with other gases) the rest of the procedure is the same as for argon, 
except for the addition of step 15. 
 
For potentially toxic or malodorous treatment gases, add more vent/ pump down 
cycles after step 14 to remove treatment gas completely from the chamber prior to 
relieving the pressure to atmospheric pressure and opening the treatment chamber.  
 
Flow rates (excess gas used for both gases) 
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 Argon  mean flow rate = 28.35cc 
 Ammonia mean flow rate = 9.8cc 
 (Operating pressures were the same = 20
-1
 Torr) 
RF time = 1minute 
 
Fig. 3.8 
Nanotech plasma chamber  
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Fig. 3.9 
View of the plasma chamber during warm up showing the high energy plasma 
 
Europlasma Plasma Treatment 
Equipment 
Argon Gas 
Oxygen Gas 
Europlasma Surface Treatment CD400PC MHz System  
 
The following settings were used (settings were stored as file mike2) 
Gas Flow 0.4 SLM (standard Litres per Minute) 
Power 300W 
RF Time 5Mins 
Pressure 200Mtorr 
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Method 
Place sample to be treated in the plasma chamber.  Load configuration file “mike2” 
and allow the process to run.  Collect and store sample in an airtight bag at room 
temperature. 
 
Fig. 3.10 
Europlasma plasma treatment machine showing the computerised controls on the left hand 
side and the plasma chamber on the right hand side 
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3.3 Sample Characterisation 
3.3.1 Differential scanning calorimetry (DSC) Analysis 
All standard materials (untreated) were analysed by DSC (Mettler DSC 12E). This 
was done to determine the melting point.  Samples were placed in aluminium 
crucibles and heated.  The temperature increased at 5ºC per minute. 
 
3.3.2 SEM Analysis 
The electron microscope was used to examine the standard materials and plasma 
treated materials to determine if there was any observable physical change to the 
material surface due to plasma treatment. 
 
The materials first needed to be splutter coated for 60 seconds using a Polaron sc7620 
splutter coater before being examined in a Hitachi S-530 scanning electron 
microscope.   
 
Method 
Instrument Switch On 
Turn on the cooling water about 2 full turns (tap marked blue).  Switch on the power 
at the wall (LOW, WARM UP and STOP lamps will glow red).  Move (lower) EVAC 
POWER lever to on position (up).  Press the EVAC button on console (LOW and 
WARM UP lamps will glow red).  Wait for 20 minutes until HIGH lamp is lit green.   
 
Sample Preparation  
Samples are prepared by placing them on SEM stubs (1cm aluminium disks with a 
female thread on their base corresponding to the SEM sample mount) in the Polaron 
splutter coater to coat them with a fine film of platinum, so the microscope can see 
the surface. 
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Fig. 3.11 - Polaron sc7620 splutter coater 
 
Fig. 3.12 - Hitachi S-530 scanning electron microscope 
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Introducing Samples to Column 
Press AIR button.  Wait until hear an audible hiss.  Open the sliding drawer.  Screw 
the sample stub on.  Close the sliding drawer and hold.  Press EVAC button (pump 
will kick in).  Wait (around 2 minutes) until HIGH lamp is lit green. 
 
Image Formation 
Move (lower) DISPLAY lever to on position (up).  Wait until ACC VOLTAGE 
READY lamp is lit steady red (not flashing).  Switch on ACC VOLTAGE (normally 
5 or 10 kV).  Press the left-most SCANNING SPEED button (TV rate, 0).  FOCUS 
control: switch to AUTO and press COARSE button to produce image.  Flick WFM 
switch (under concealing panel) down.  Adjust FILAMENT knob clockwise (to about 
2 o'clock position) until trace at maximum height position on screen [if necessary use 
MANUAL CONTRAST BRIGHTNESS to make trace visible on screen).  Press the 
left-most SCANNING SPEED button to restore image.  Press ABC button twice 
under AUTO condition to optimise brightness and contrast. To suit eye, B and C can 
be controlled by switching to MANUAL and rotating lower B and C knobs.  Use 
AUTO (coarse / fine) or MANUAL control to adjust image focus.  Move around 
sample at low magnification to locate position of interest.  Adjust magnification to 
required level, focusing as required for image quality.   
 
Instrument Shutdown  
Reduce magnification to lowest.  Turn ACC VOLTAGE off.  Wait for about 1 
minute, then move (lower) DISPLAY lever to off position (down).  Press AIR button, 
await audible hiss.  Remove sample.  Close drawer, press EVAC button, wait until 
HIGH lit green.  Depress STOP button and wait until LOW and STOP lamps lit red.  
Move (lower) EVAC POWER lever to off position (down).  Wait for around 20 
minutes.  Switch off instrument at wall.  Turn off cooling water. 
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Analysis of Pore Size of PLA Sample 
The PLA pore size was determined by selecting SEM image representative of the 
PLA SEM images and measuring the dimensions of each pore (the horizontal and 
vertical), measuring the area of the pores using a ruler and calculating the percentage 
of pores in relation to the area of the image. 
 
3.4 Tissue Culture Study 
3.4.1 Methodology 
This experimental method was derived after reading through research papers and 
observing a gap in the research.  Many papers extolled the benefits of a particular 
material or examined explanted devices from human or animal subjects.  The primary 
aim of this study was to conduct a basic study to evaluate a range of materials on a 
quantitative level.  In addition to the standard materials, modified materials were 
included so that the modifications could be evaluated directly with the standard 
materials.  This study was designed to be as simple and as controlled as possible.  
Capillary tubes were used to act as ballast to prevent the samples from floating. 
 
Background 
This experiment was designed to evaluate a range of materials for their ability to 
support human cell growth.  This was a simple experiment that used MRC-5 cells to 
determine which material / surface treatment was optimal.  Initially, Human foetal 
fibroblasts were going to be used but the cells from the supplier were at the end of 
their passage limit and subsequently died very quickly.  The cells were seeded 
directly onto the test material with no additional materials used to encourage 
attachment (e.g. Matrigel).  Gelatine was tested as a means to improve cell 
attachment but it was discarded as it would influence the results. 
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Preparation 
The samples needed mounting for the tissue culture study so that the samples would 
sink when placed in the tissue culture media.  Glass capillary tubes were chosen as 
they would provide the necessary ballast to ensure the samples remained submerged.  
The samples were then sterilised at Anderson Caledonia using ethylene gas.  
Ethylene gas was chosen as it did not involve high temperatures that could melt some 
of the polymers with low melting points. 
 
Samples Preparation 
Materials 
10 cm soda glass capillary tubes 
Glass cutter 
Paperclip 
70% Ethanol 
Sterilisation Bags 
Samples 
Polypropylene 
Argon plasma treated polypropylene (Nanotech) 
Ammonia plasma treated polypropylene (Nanotech) 
Polypropylene coated in chitosan 
Argon plasma treated polypropylene coated in chitosan (Nanotech) 
Ammonia plasma treated polypropylene coated in chitosan (Nanotech) 
Tuftane polyurethane 
Argon plasma treated Tuftane polyurethane (Nanotech) 
Ammonia plasma treated Tuftane polyurethane (Nanotech) 
Argon plasma treated Tuftane polyurethane coated in chitosan (Nanotech) 
Argon Plasma treated Tuftane polyurethane (Europlasma) 
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Oxygen plasma Treated Tuftane polyurethane (Europlasma) 
Vascutek polyester 
Argon plasma treated Vascutek polyester (Nanotech) 
Ammonia plasma treated Vascutek polyester (Nanotech) 
Poly lactic acid 
Argon plasma treated poly lactic acid (Nanotech) 
Ammonia plasma treated poly lactic acid (Nanotech) 
Poly-ε-Caprolactone 6400 
Argon plasma treated poly-ε-caprolactone 6400 (Nanotech) 
Ammonia plasma treated poly-ε-caprolactone 6400 (Nanotech) 
Solanyl 
Argon plasma treated Solanyl (Nanotech) 
Ammonia plasma treated Solanyl (Nanotech) 
Solanyl extruded with 2% chitosan (w/w) 
Solanyl coated in chitosan 
Argon plasma treated Solanyl coated in chitosan (Nanotech) 
Ammonia plasma treated Solanyl coated in chitosan (Nanotech) 
 
Method 
Cut capillary tubes into 3cm lengths using a glass cutter.  Cut samples into 4cm 
lengths.  Insert into the capillary tubes using a paperclip to poke the ends in. The 
samples were prepared in excess (19 of each sample + one un-mounted for analysis in 
SEM).  Rinse samples 5 times with 70% ethanol and then placed in gas sterilisation 
bags.  Sterilise samples at Anderson Caledonia (ethylene gas sterilised). 
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Fig 3.13 - Demonstration of how the biomaterial sample was mounted to the capillary tube. 
  
3.4.2 Experimental Work 
For this experiment, the samples were seeded with a small drop of MRC-5 cells and 
the samples were then inoculated over 29 days. 
 
Materials 
Trypsin (10x Concentration) 100ml. Invitrogen 
Fetal Bovine Serum, certified (heat inactivated) Origin U.S. Invitrogen 
Performance, mycoplasma, virus bacteriophage and endotoxin tested  
Culture Medium - McCoy‟s 5a + 2mM Glutamine 
Gilson Pipettes - P20, p200, p1000 and p10 ml Pipettes 
Phosphate Buffered Saline Tablets 
25cm
3
 Iwaki
®
 Culture Flasks (Non-Treated, Hydrophobic surface) 
Centrifuge 
Tissue Culture Incubator (37ºC, 5%CO2) 
-80˚C freezer 
Media (modified minimal essential eagles medium) = 500mls minimal essential 
eagles medium + 50ml FBS + 11ml l-glutamine +5.5 ml NEAA 
L-lysine 
NEAA (nonessential amino acids) 
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DMSO (Dimethyl sulfoxide) 
Trypsin 
FBS (Fetal bovine serum) 
PBS (Phosphate buffered saline) 
Flasks 
Cryogenic storage tubes 
2um filters 
Centrifuge tubes 
Pipettes & tips 
Water bath 
LaminAir hood 
Biocide ZF (Spray Disinfectant for Incubators and Sterile Cabinets in Cell 
Culture Area) 
Ethanol 
10% Chloros 
Haemocytometer- improved Neubauer BS748, depth 0.01mm, 1/400mm
2
 
Samples 
Sterile tweezers 
Iwaki
®
 25ml tissue culture flasks (both treated and untreated) 
Liquid N2 
Liquid N2 Storage 
Centrifuge 
Water bath 
Molecular Probes “live or dead” viability/cytotoxicity kit (L-3224) (Invitrogen) 
o Contains Calcein AM and Ethidium Homodimer-1 
Human Foetal Lung Fibroblasts (http://www.ecacc.org.uk/) 
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Cell Line Name MRC-5 
ECACC No. 97112601 
Cell Line Description Established from normal lung tissue of a 14 week old male 
foetus. The cells undergo between 60-70 population 
doublings before senescence. The virus susceptibility of this 
line is similar to WI-38. This cell line is supplied on a 
standing order basis. 
Species Human 
Tissue Lung, foetal 
Morphology Fibroblast 
Sub Culture Routine Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding 
at 2-4 x 10,000 cells/cm using 0.25% Trypsin or 
Trypsin/EDTA; CO2; 37C. 
Culture Medium EMEM (EBSS) + 2mM Glutamine + 1% Non Essential 
Amino Acids (NEAA) + 10% Foetal Bovine Serum (FBS). 
Karyotype 2n = 46, diploid 
Depositor Dr P Jacobs, NIBSC, London 
Country UK 
References (Jacobs et al., 1970) 
 Table 3.14 Summary of MRC-5 cells  
Method 
Preparation 
To ensure the experiment would not have any glitches, the planning stage was vital to 
make the experiment as controlled as possible.  The most important factor was to 
ensure the cells were all in the same condition / passage number and consumables 
were available when required. 
 
Standard methods  
Preparation for any work in the LaminAir hood (Heraeus HS12) 
Turn on hood 30mins prior to work to stabilize air flow.  Clean the LaminAir hood 
with Biocide ZF.  Clean the LaminAir hood with Ethanol.  Then sterilise the 
LaminAir hood with UV.  Clean everything with Ethanol before placing in the 
LaminAir hood. 
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Procedure for Thawing Cells 
Warm up media and place in suitably labelled tissue culture flask.  Remove the 
chosen cells from the liquid nitrogen storage.  Place the cryo vial in the 37ºC water 
bath for ~ 1minute. Before the pellet is completely thawed, remove the vial, clean the 
vial (with biocide ZF) and pace in the LaminAir hood.  Immediately empty the 
contents of the vial into 1ml of the pre-warmed media.  Place the media and cells in a 
centrifuge tube and down at 2000rpm for 4mins at 30°C (Heraeus Megafuge 1.0R).  
Pour off the media and Re-suspend the cell pellet in 2mls of fresh media.  Empty the 
re-suspended cells in a tissue culture flask containing 8mls of pre-warmed media.  
Attach the flask cap loosely and place in the incubator.   
 
Passage procedure 
Warm up media, Trypsin and PBS (no Ca
2+
 or Mg
2+
) to 37°C for ~30mins before use 
in a Grant OLS200 water bath.  Examine cells carefully. If cells are ~70% confluent, 
then proceed with passage. If there is contamination, dispose of the cells.  If the cells 
are less than ~70% confluent but the media has turned orange/yellow, change media.  
If passage is required, dispose of old media.  Use PBS (no Ca
2+
 or Mg
2+
) to wash 
cells once (use pipette (~10mls) then dispose of PBS.  Add 2mls of Trypsin and place 
in incubator for 2mins at 37°C.  Once cells detach (Trypsin = orange), give the flask 
a tap against the side of a hard object to dislodge the cells from the bottom of the 
flask.  Check cells on the microscope (Axiovert 25).  They should be rounded and 
floating freely in the media.  If any cells remain attached to the bottom of the flask, 
give the flask an additional tap.  Add 2mls media (10% FBS) to neutralize the 
Trypsin.  Put in centrifuge tube and spin down at 2000rpm for 4mins at 30°C.  
Dispose of media + Trypsin.  Add 8mls media.  Re-suspend cell pellet in new flask.  
Check cells under inverted microscope.  Place cells in incubator (37ºC, 5% CO2).   
 
Cell count procedure  
Dispose of old media.  Use PBS (no Ca
2+
 or Mg
2+
) to wash cells once (use pipette 
(~10mls) then dispose of PBS.  Add 2mls of Trypsin and place in incubator for 2mins 
at 37°C.  Once cells detach (Trypsin = orange), give the flask a tap against the side of 
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a hard object to dislodge the cells from the bottom of the flask.  Check cells. They 
should be rounded and floating freely in the media. If any cells remain attached to the 
bottom of the flask, give the flask an additional tap.  Add 2mls media (10% FBS) to 
neutralize the Trypsin.  Take 10µl of cells.  Stain cells using methylene blue (10ul 
methylene blue to 10ul cell suspension).  Place methylene blue stained cells on 
Haemocytometer (improved Neubauer BS748, depth 0.01mm, 1/400mm
2
) and place 
cover slip on top of the drop of cells.  Place Haemocytometer on microscope (Zeiss 
Axiovert 25).  Count cells in 10 random squares. Cells are counted when in the 
middle of the square (not touching the lines) and when in contact with the bottom and 
left sides of the square. Cells touching the top and left sides are excluded from the 
cell count figure.  Obtain the average of the 10 cell counts.  Divide the average by 16 
and then multiply by 4. Multiply that figure by 10
6
 and you have the cells per ml. 
 
Procedure for Freezing Cells (cryogenic storage) 
Take cells after step 9 of passage procedure and wash the cells with media 
(containing FBS).  Centrifuge cells again as per step 9 of passage procedure.  Re-
suspend cells in freezing medium (10% DMSO, 20% FBS and 70% standard media). 
DMSO is filter sterilized using a 2um filter.  Dispense cells into cryo tubes.  When 
freezing, do it slowly (1hr @ 4°C, 1hr @ -20°C and 1hr @ -80°C then place in liquid 
nitrogen).   
 
Procedure for fluorescence staining of the samples 
Remove the LIVE/DEAD reagent stock solutions from the freezer and allow them to 
warm to room temperature.  Add 20µL of the supplied 2mM EthD-1 stock solution to 
10ml of sterile, tissue culture–grade D-PBS, vortexing to ensure thorough mixing. 
This gives an approximately 4µM EthD-1 solution.  Combine the reagents by 
transferring 5µL of the supplied 4 mM calcein AM stock solution (Component A) to 
the 10mL EthD-1 solution.  Vortex the resulting solution to ensure thorough mixing.  
The resulting approximately 2µM calcein AM and 4µM EthD-1 working solution is 
then added directly to cells.  Note that aqueous solutions of calcein AM are 
susceptible to hydrolysis.  Aqueous working solutions should therefore be used 
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within one day.  Cut the sample off the capillary tube mounting and place sample in a 
Petri dish. Add 100–150µl of the combined LIVE/DEAD assay reagents, using 
optimized concentrations, to the surface of the sample.  Incubate the cells for 30–45 
minutes at room temperature.  Following incubation, add about 10µL of the fresh 
LIVE/DEAD reagent solution or D-PBS to a clean microscope slide.  Using fine-
tipped forceps, carefully (but quickly) invert and mount the sample on the 
microscope slide. Place the slide on the on the Leica DMIRE2 confocal microscope. 
Set the microscope to 500nm for the Calcein stain and 550nm for the ethidium stain.  
View the labelled samples under the fluorescence microscope. 
 
Experimental Technique 
Before the experiment could commence, the cells from the ECACC needed to be 
grown to sufficient quantities to supply the entire experiment.  To do this, the cells 
were initially split into 4 flasks (1-4) and then frozen.  Each batch were then grown 
and split and the passages were recorded as n, n.x, n.x.y, n.x.y.z so the vials could be 
easily traced back to the original split.  This also made it easier to ensure the cells 
used for the experiment were all from the same passage stage.  It was essential to 
ensure the cells in the experiment were from the same passage number, as non-
immortalised cells in culture only have a finite number of passages before they die 
and the cells health varies with passage level.  This was one level of continuity built 
into the experiment. 
Before the start of each run, the cells to be used were resuscitated from cryogenic 
storage and given time to recover and reach ~ 70% confluences.  The cells were then 
Trypsinised, centrifuged and re-suspended in 1ml of media. 
 
The samples were inoculated with 20µl of cell suspension and left for ~10 minutes in 
an empty flask before media was added, to give the cells a chance to attach to the 
substrate without the media washing them off.  After the 10mins, 10mls of media was 
added and the C 5% CO2) with loosened 
caps. 
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Fig. 3.15 - Illustration of biomaterial inoculation. 
 
After inoculation, a cell count was performed.  Sample groups were started in three 
groups per month, two days apart.  Growth along the sample was measured using a 
photocopy of a ruler (Helix shatter proof) with millimetre markings on acetate after 7 
days, 14 days 21 days and 29 days.  The same acetate ruler was used throughout the 
experiment (the acetate copy was compared to the original ruler to ensure the 
gradations were accurate).  At the end of the 29 day study period, the samples were 
removed from the capillary tube mounting and placed in Petri dishes. The samples 
were then stained with Molecular Probes “live or dead” viability/cytotoxicity kit (L-
3224) and examined on the Leica DMIRE2 confocal microscope to confirm the level 
of growth. 
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Chapter 4 - Results 
4.1 Examination of Chitosan as a Bacteriostat 
The chitosan study was devised to test the reported antimicrobial effects of chitosan.  
The experiments were designed to present chitosan to MRSA and Staphylococcus 
epidermis and examine how effective chitosan is against the opportunistic pathogens.  
In addition, examining how the bacteriostatic effect varied with the quantity of 
chitosan presented to the bacteria would clarify how varying the chitosan quantity 
would alter growth.  Through the development of the experimental design, the 
experiment evolved.  Performing studies where the chitosan was presented to the 
bacteria in different forms, while not directly comparable with each other added an 
interesting dimension to the study. 
 
Method 1 - Chitosan dissolved in dilute acetic acid incorporated into nutrient agar 
Vs MRSA 9551 and Staphylococcus epidermis. 
 
Method 1 was the preliminary study designed to evaluate the efficacy of chitosan as a 
bacteriostat. 
 
Many of the chitosan (+ acetic acid) plates did not solidify enough to inoculate.  This 
included the acetic acid control, the 0.001g & 0.01g chitosan samples and some of 
the 0.1g & 1g chitosan samples.  This was due to the acetic acid hydrolysing the agar 
and destroying the structure of the polysaccharide. 
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Cell counts MRSA 9551 S. epidermis 
1 54 7 
2 41 12 
3 51 7 
4 43 6 
5 48 8 
6 44 21 
7 36 15 
8 42 10 
9 46 21 
10 37 9 
Average 44.2 11.6 
Table 4.1 - Cell count data for MRSA and S. epidermis inoculum - haemocytometer count (volume of 
square = 1/400ml) 
 
Therefore to reach bacteria per ml; 
((Average cells per box) x 4) x (10
-6
) = Cells per ml 
(44.2 x 4) x 10
-6
 = 1.77 x 10
9
  bacteria per ml for MRSA 
(11.6 x 4) x 10
-6
 = 4.64 x 10
8
  bacteria per ml for S. epidermis 
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 MRSA 9551 S. epidermis 
Control 1 (NA) 1 small cream colony (less than 
1mm) 
5 small yellow colonies (less 
than 1mm) 
Control 2 (NA) 1 small yellow colony (less than 
1mm) not cream (like MRSA) 
therefore contamination 
1 small orange colony (under 
agar) not cream (like MRSA) 
therefore contamination 
NA + Chitosan Film 29 small colonies less than 
0.5mm in diameter, all in one 
location around initial streak. No 
growth anywhere near the film 
No colonies 
NA + 1g Chitosan in 10 
ml acetic acid (1) 
No growth No growth 
NA + 1g Chitosan in 10 
ml acetic acid (2) 
No growth No growth 
NA + 1g Chitosan in 10 
ml acetic acid (3) 
No growth No growth 
NA + 0.1g Chitosan in 
10 ml acetic acid  
No growth No growth 
Table 4.2 - Results after 48 hrs 
 
In this experiment, growth was low and the control containing acetic acid did not 
solidify due to hydrolysis of the agar therefore this experiment was revised. 
 
Method 1b - Modified method – Chitosan dissolved in dilute acetic acid 
incorporated into nutrient agar Vs MRSA 9551 and Staphylococcus epidermis 
 
Method 1b is a modified version of method 1.  
 
The NA control was kept and instead of the NA + acetic acid control, NA + acetic 
acid neutralised to pH 7 (using NaOH and a corning pH meter 215) was used.  The 
NA + 1g chitosan in 10 ml acetic acid and NA + 0.1g chitosan in 10 ml acetic acid 
agar plates were re-used after re-sterilisation (as there was no previous growth).  
 
In addition, instead of diluting the bacteria, each plate was inoculated from the saline 
inoculum with a sterile swab.  
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The chitosan film was also included in this experiment.  The NA plates with the 
chitosan film were inoculated before adding the film, so the growth could be 
examined to see if the bacteria would grow up to, under or over the film.  
After inoculation, the plates were incubated for 48hrs at 37 C 
 
 MRSA 9551 S. epidermis 
NA control Good growth. A lawn grew from 
where the plate was inoculated. 
No contamination. 
Good growth. A lawn grew from 
where the plate was inoculated. 
No contamination. 
NA + neutralised acetic 
acid control 
Good growth. A lawn grew from 
where the plate was inoculated. 
No contamination. 
Good growth. A lawn grew from 
where the plate was inoculated. 
No contamination. 
Chitosan film on NA Bacterial growth surrounding 
film. No growth on film. 
Bacterial growth surrounding 
film. No growth on film. 
1g Chitosan + 1ml acetic 
acid in NA 
No growth, bacteria still present. 
The plate appears no different 
from when inoculated. 
(Bacteriostatic effect) 
No growth, bacteria still present. 
The plate appears no different 
from when inoculated. 
(Bacteriostatic effect) 
0.1g Chitosan + 1ml 
acetic acid in NA 
No growth, bacteria still present. 
(Bacteriostatic effect) 
No growth, bacteria still present. 
(Bacteriostatic effect) 
Table 4.3 - Results after 48 hrs 
 
This experiment produced interesting data for how the bacteria reacted in the 
presence of chitosan film, but the data for the nutrient agar containing chitosan was 
less clear.  The acetic acid control still did not provide a suitable control for the 
chitosan samples (as the chitosan could not be neutralised without the chitosan 
precipitating and not mixing with the agar).  
 
With this in mind, Nutrient broth appeared to be a better choice than nutrient agar as 
this would avoid the problem of agar hydrolysis. 
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Method 2 - Chitosan dissolved in acetic acid added to nutrient broth Vs MRSA 9551 
and Staphylococcus epidermis  
Three quantities of chitosan powder were weighed out; 1g, 0.1g and 0.01g (+ /- 
0.001g). These samples were added to 10 ml acetic acid (2M), forming a range of 
solutions designed to avoid the problem of agar hydrolysis by substituting nutrient 
agar for nutrient broth.  This method uses spectrophotometry to measure the turbidity 
(cloudiness resulting from the bacterial growth) to produce quantitative data.  The 
samples were inoculated using a standard inoculum (an inoculation loop of bacteria 
mixed in a saline solution, and then counted). 
 
Cell counts MRSA 9551 S. epidermis 
1 34 20 
2 12 25 
3 36 30 
4 38 18 
5 38 33 
6 54 22 
7 44 34 
8 40 41 
9 45 30 
10 57 32 
Mean 39.8 28.5 
Table 4.4 - Cell count data for MRSA and S. epidermis inoculum. 
 
Haemocytometer Vol = 1/400 ml per small square (visible through microscope) 
Therefore for; 
 MRSA = (39.8 * 4) * (10
6
) = 1.59 x 10
9
 bacteria per ml 
 S. epidermis = (28.5 * 4) * (10
6
) = 1.14 x 10
9
  bacteria per ml 
 
The broths were then inoculated with 0.5mls of the bacterial dilutions (either MRSA 
9551 or S. epidermis). 
77 
Cell density was measured spectrophotometrically for Staphylococcal species using a 
wavelength of 550nm.  Samples were measured every 2 hrs to examine for changes 
in growth.  After 2hrs there was growth in the NB control, but there was no growth in 
the acetic acid control.   The pH was inhibiting bacterial growth.  The experimental 
design would have to change so that the pH was no longer an issue.  
 
Method 2b - Modified method - Chitosan added to nutrient broth Vs MRSA 9551 
and Staphylococcus epidermis 
 
This experiment was redesigned so the chitosan would not be dissolved into solution.  
This would determine if chitosan in suspension would elicit the desired bacteriostatic 
effect.  Three quantities of chitosan powder were weighed out; 1g, 0.1g and 0.01g (+ 
/- 0.001g).  These samples were added to 10 ml distilled water, forming a range of 
suspensions (the powder did not remain in suspension long before settling out and 
therefore needed constant agitation).  
 
1ml of the suspension was added to each of the chitosan nutrient broths (therefore the 
1g becomes 0.1g, although it is still referred to as 1g) and 1ml of distilled water was 
added to the control. 
 
The samples were inoculated directly from an inoculation loop to increase the 
quantity of bacteria present in each broth.  After inoculation, the samples were placed 
on a shelf in a 37ºC incubator.  
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Sample Contents AD550nm (11.30 -
11.45am) (+/- 0.007) 
Control (ref) NB 0.001 
Control 0.01g NB + 1ml (0.01g chitosan /10mls distilled water) 0.007 
Control 0.1g NB + 1ml (0.1g chitosan /10mls distilled water) -0.005 
Control 1g NB + 1ml (1g chitosan /10mls distilled water) 0.065 
S. epidermis 
Control  
NB + 0.5mls S. epidermis broth -0.005 
MRSA Control  NB + 0.5mls MRSA 9551 broth -0.005 
S. epidermis 
0.01g 
NB + 1ml (0.01g chitosan /10mls distilled water) + 
0.5mls S. epidermis broth 
-0.004 
S. epidermis 0.1g  NB + 1ml (0.1g chitosan /10mls distilled water) + 
0.5mls S. epidermis broth 
0.007 
S. epidermis 1g  NB + 1ml (1g chitosan /10mls distilled water) + 
0.5mls S. epidermis broth 
0.077 
MRSA 0.01g  NB + 1ml (0.01g chitosan /10mls distilled water) + 
0.5mls MRSA 9551 broth 
-0.006 
MRSA 0.1g  NB + 1ml (0.1g chitosan /10mls distilled water) + 
0.5mls MRSA 9551 broth 
-0.004 
MRSA 1g  NB + 1ml (1g chitosan /10mls distilled water) + 
0.5mls MRSA 9551 broth 
0.089 
Table 4.5 - Absorbance reading at Time 0 
 
Sample AD550nm 
Control (ref) 0.000 
Control 0.01g -0.004 
Control 0.1g 0.002 
Control 1g 0.007 
S. epidermis Control  -0.005 
MRSA Control  -0.007 
S. epidermis 0.01g -0.004 
S. epidermis 0.1g  0.011 
S. epidermis 1g  -0.004 
MRSA 0.01g  -0.005 
MRSA 0.1g  -0.002 
MRSA 1g  0.025 
Table 4.6 - Absorbance reading at 1hr  
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Sample AD550nm 
Control (ref) 0.006 reset to 0.000 
Control 0.01g -0.004 
Control 0.1g -0.003 
Control 1g 0.001 
S. epidermis Control  -0.002 
MRSA Control  -0.010 
S. epidermis 0.01g -0.004 
S. epidermis 0.1g  0.004 
S. epidermis 1g  0.130 
MRSA 0.01g  -0.015 
MRSA 0.1g  -0.008 
MRSA 1g  0.102 
Table 4.7 - Absorbance reading at 2hrs 
 
3 hrs  
This experiment was abandoned as there was no growth in the controls.   
 
Method 2c - Modified method - Chitosan added to nutrient broth Vs MRSA 9551 
and Staphylococcus epidermis  
 
This is a modified version of method 2b.  In this method, the nutrient broths were 
kept on a platform shaker to keep the chitosan powder in suspension. 
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Sample Name Description 
Reference Control (NB) 
S. epidermis NB + 0.5mls S. epidermis broth 
S. epidermis 0.01g NB + 1ml(0.01g chitosan /10mls distilled water) + 0.5mls S. 
epidermis broth 
S. epidermis 0.1g  NB + 1ml(0.1g chitosan /10mls distilled water) + 0.5mls S. 
epidermis broth 
S. epidermis 1g  NB + 1ml(1g chitosan /10mls distilled water) + 0.5mls S. epidermis 
broth 
MRSA NB + 0.5mls MRSA 9551 broth 
MRSA 0.01g  NB + 1ml(0.01g chitosan /10mls distilled water) + 0.5mls MRSA 
9551 broth 
MRSA 0.1g  NB + 1ml(0.1g chitosan /10mls distilled water) + 0.5mls MRSA 
9551 broth 
MRSA 1g  NB + 1ml(1g chitosan /10mls distilled water) + 0.5mls MRSA 
9551 broth 
Table 4.8 – Sample descriptions. 
 
Time 0 
Samples inoculated and absorbance measured (AD550nm). 
The samples were left for 15mins to allow the chitosan suspension to settle before 
taking spectrophotometer readings. 
Reference = NB. 
 
Sample AD550nm 
Reference -0.001 (+/- 0.005) 
S. epidermis 0.000 (+/- 0.005) 
S. epidermis 0.01g -0.010 (+/- 0.004) 
S. epidermis 0.1g  0.000 (+/- 0.004) 
S. epidermis 1g  0.135 (+/- 0.004) 
MRSA -0.010 (+/- 0.001) 
MRSA 0.01g  -0.016 (+/- 0.002) 
MRSA 0.1g  -0.004 (+/- 0.003) 
MRSA 1g  0.113 
Table 4.9 - Absorbance reading at Time 0 
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Sample AD550nm 
Reference 0.000 (+/- 0.004) 
S. epidermis 0.000 (+/- 0.004) 
S. epidermis 0.01g -0.001 (+/- 0.003) 
S. epidermis 0.1g  0.000 (+/- 0.002) 
S. epidermis 1g  0.113  
MRSA 0.006 (+/- 0.002) 
MRSA 0.01g  -0.006 (+/- 0.004) 
MRSA 0.1g  0.001 (+/- 0.003) 
MRSA 1g  0.125 
Table 4.10 - Absorbance reading at 1hr 
 
Sample AD550nm 
Reference 0.000 (+/- 0.001) 
S. epidermis 0.005 (+/- 0.002) 
S. epidermis 0.01g 0.003 (+/- 0.001) 
S. epidermis 0.1g  0.006 (+/- 0.002) 
S. epidermis 1g  0.070 (+/- 0.001) 
MRSA 0.016 (+/- 0.004) 
MRSA 0.01g  0.005 (+/- 0.001) 
MRSA 0.1g  0.007 (+/- 0.001) 
MRSA 1g  0.080 (+/- 0.003) 
Table 4.11 - Absorbance reading at 2hrs 
 
Sample AD550nm 
Reference 0.000 (+/- 0.001) 
S. epidermis 0.020 (+/- 0.002) 
S. epidermis 0.01g 0.008 (+/- 0.001) 
S. epidermis 0.1g  0.008 (+/- 0.001) 
S. epidermis 1g  0.017 (+/- 0.002) 
MRSA 0.160 (+/- 0.002) 
MRSA 0.01g  0.148 (+/- 0.002) 
MRSA 0.1g  0.147  
MRSA 1g  0.174 (+/- 0.002) 
Table 4.12 - Absorbance reading at 3hrs 
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After 25 hrs the samples were taken out of the 37 C incubator and shaken to re-
suspend the bacteria and chitosan.  In the 1g chitosan and S. epidermis sample, It was 
noticed the chitosan powder (which settles quite quickly (~5-10 minutes) was looking 
bigger (particle size).  When it settled, it was less dense and of greater volume.  It 
appears to have agglutinated with the S. epidermis. With this observation, it was 
decided to examine the other samples closely.  It appeared that it had the same effect 
on the other S. epidermis samples, but not with the MRSA 9551 samples.  This was 
an unexpected outcome as S. epidermis and MRSA 9551 are closely related.  It was 
decided to continue with taking the spectrophotometer readings and see what 
differences that revealed. 
 
Sample AD550nm 
Reference 0.000 (+/- 0.001) 
S. epidermis 0.450 (+/- 0.001) 
S. epidermis 0.01g 0.502 (+/- 0.001) 
S. epidermis 0.1g  0.429 (+/- 0.001) 
S. epidermis 1g  0.113 (+/- 0.002) 
MRSA 0.558  
MRSA 0.01g  0.510 (+/- 0.001) 
MRSA 0.1g  0.466 (+/- 0.002) 
MRSA 1g  0.549 (+/- 0.001) 
Table 4.13 - Absorbance reading at 25hrs 
83 
chitosan Vs MRSA 9551 & S.epidermis excluding 1g chitosan sample
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Fig. 4.14 - Absorbance readings for MRSA and S. epidermis
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Fig. 4.14 has the values for NB + 1ml (1g chitosan/10mls distilled water), NB + 1ml 
(1g chitosan/10mls distilled water) + S. epidermis and the NB + 1ml (1g 
chitosan/10mls distilled water) + MRSA removed.  This was because the high level 
of chitosan was distorting the absorbance readings.  The original graph is in appendix 
A.2, Method 2c.  This graph shows two results. The chitosan appears to have a 
bacteriostatic effect on MRSA as shown by the reduced growth of the samples with 
0.01g of chitosan and 0.1g of chitosan.  This bacteriostatic effect also appears to be 
related to the quantity of chitosan present.  The S. epidermis does not appear to 
demonstrate reduced growth in the presence of chitosan. 
 
Method 3 - Testing of Chitosan treatment of Cotton cloth 
 
For this study, two types of cotton cloth were used, chitosan gel coated and untreated.  
Hypothesis; inoculate NA plate so that a bacterial lawn will develop and place cotton 
cloth on top (treated or untreated) and observe for signs of inhibition around edge of 
material.  
 
After 24 hours the cotton cloth plates were examined but there was insufficient 
bacterial growth on the agar plates.  
 
Method 3b - Modified method - Testing of Chitosan treatment of Cotton cloth 
After the poor growth in method 3, the nutrient agar plates were inoculated using a 
20µl pipette and the inoculum was spread around the agar using an inoculation loop 
in an attempt to produce better bacterial lawn growth. 
 
There were zones of inhibition around the chitosan treated samples, but the bacterial 
growth was poor, so the experiment was repeated with fresh bacteria and fresh 
samples. 
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Repeat of method 3b 
 Observation 
MRSA 9551 Cotton cloth control little growth, but up to edge of material 
MRSA 9551 Chitosan treated cotton 
cloth 
not very good growth, but still observable zone of 
inhibition 
S. epidermis  Cotton cloth control Reasonable growth up to the edge of the material 
S. epidermis  Chitosan treated cotton 
cloth 
Good growth. Observable zone of inhibition on three 
sides of the treated sample 
Table 4.15 – chitosan treated cotton cloth results 
 
There were zones of inhibition around the chitosan treated samples, but the bacterial 
growth was poor, so it was decided to repeat the experiment with fresh bacteria. 
 
Method 3c - Modified method - Testing of Chitosan treatment of Cotton cloth 
Method 3c is a modified version of method 3 as it contains a slightly expanded range 
of test samples.  Some of the treated cotton cloth was kept un-sterilised to see if the 
high-pressure, high temperature steam has any effect on the bacteriostatic effect of 
the chitosan. 
 
The chitosan did not adhere to the polypropylene as well as it did on the cotton cloth 
(polypropylene mesh is multifilament and knitted into an open structure and is not 
very wetable.  The cotton cloth is a natural fibre woven structure and it is 
hydrophilic).  
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Sample Observation 
MRSA cotton cloth control 
(sterilised) 
Good lawn growth up to and under cotton cloth 
sample 
MRSA Chitosan treated cotton cloth 
(sterilised) 
Good lawn growth. Zone of inhibition between 
0.5mm and 3mm 
MRSA Chitosan treated cotton cloth 
(not sterilised) 
Good lawn growth. Zone of inhibition between 
0.5mm and 7mm.  
MRSA Chitosan treated 
polypropylene (sterilised) 
Good lawn growth. Possible zone of inhibition less 
than 0.5mm. 
  
Sample Observation 
S. epidermis cotton cloth control 
(sterilised) 
Strong lawn growth up to and under cotton cloth 
sample 
S. epidermis Chitosan treated cotton 
cloth (sterilised) 
Good lawn growth. Zone of inhibition between 
0.5mm and 3mm.  
S. epidermis Chitosan treated cotton 
cloth (not sterilised) 
Good lawn growth. Zone of inhibition between 
0.2mm and 1.5mm. 
S. epidermis Chitosan treated 
polypropylene (sterilised) 
Good lawn growth. No zone of inhibition. 
Table 4.16 – Chitosan coated cotton cloth and polypropylene results 
 
The poor performance of the chitosan coated polypropylene could be due to the 
chitosan film failing to adhere to the hydrophobic polypropylene. 
 
Method 3c (Modified method - Testing of chitosan treatment of cotton cloth) yielded 
some interesting data relating to the coating of cotton cloth with chitosan solution, 
with zones of inhibition observed.  The polypropylene coated with chitosan had little 
to no observable effect on the bacteria.  This study was derived partially to examine 
the potential for chitosan coatings for medical applications.  One application could be 
as an anti infective coating for medical devices, but this could find a use as a spray-
able coating for textiles within a hospital environment by reducing the ability of 
opportunistic pathogens to thrive on the clothes worn by hospital personnel and the 
soft furnishings found within a hospital environment, reducing potential transmission 
vectors.  These applications are worthy of further study to determine their efficacy for 
the hospital environment. 
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Method 4 - Chitosan suspended in nutrient broth Vs MRSA 
This method continues on from method 2c, but instead of using spectrophotometry to 
measure the bacterial growth, plate count agars were used along with serial dilutions 
of the broths at set time points to produce clearer data on the effect of chitosan in 
suspension in different quantities. 
 
In this study, the chitosan samples are referred to as 0.01g, 0.008g, 0.006g, 0.004g, 
0.002g and 0g.  These refer to the w/v of chitosan in NB (where 0g is the control). 
 
A plate count was done to find out how concentrated the inoculum was using a 
haemocytometer. 
 
Cell (area on haemocytometer) count (number of cells) 
1 5 
2 7 
3 6 
4 7 
5 9 
6 9 
7 13 
8 8 
9 8 
10 4 
Mean 7.6 
Table 4.17 - Cell count data for MRSA inoculum. 
 
To convert this to cells per ml; 
7.6 x (4x10
-6
) = 3.04x10
7 
cells per ml in the initial inoculum 
 
After 48 hours, the nutrient broths were observed.  Upon observation, it was clear 
that the broths displayed some degree of variation in their visual appearance.  As a 
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result, broths that appeared to be either more turbid or less turbid than the other 
broths of a certain chitosan concentration were not used for plate count purposes. 
 
Sample Sample No. Observation 
0.01g  Chitosan 1 more turbid than the other two 
0.008g Chitosan 2 less turbid than the other two 
0.006g Chitosan - no variance 
0.004g Chitosan 3 little less turbid than the other two 
0.002 g Chitosan 2, 3 2 was more turbid, 3 was less turbid, 1 was 
in the middle 
0g Chitosan (control) - no variance 
Table 4.18 - Samples discounted on the basis of a difference in the broth appearance. 
 
 
Sample Sample No. 
0.01g Chitosan 3 
0.008g Chitosan 3 
0.006g Chitosan 2 
0.004g Chitosan 2 
0.002 g Chitosan 1 
0g Chitosan (control) 1 
Table 4.19 - Samples used for the initial dilution 
 
 Dilution 
Sample 10-6 10-7 10-8 
Control (0g) tmtc 110 9 
0.002g 0 0 4 
0.004g tmtc 181 20 
0.006g 461 64 6 
0.008g 180 86 - 
0.01g tmtc 111 0 
Table 4.20 - Results from 48 hours.  Tmtc – too many to count 
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The results from 48 hrs shows an unusual result for 0.002g and it is likely to be 
caused by human error. 
 
 Dilution 
Sample 10-6 10-7 10-8 
Control (0g) ng 1049 ng 
0.002g 3 ng ng 
0.004g ng ng ng 
0.006g ng ng ng 
0.008g ng ng ng 
0.01g ng ng ng 
Table 4.21 - Results from 72 hours.  Ng – no growth 
 
This result was unexpected. The control, only one PCA grew and showed an 
abundance of bacteria.  The 0.002g, only one plate grew and showed a marked 
decrease in culture density.  There are four possible explanations for this. 1. Problem 
with the culture media, 2. Human error or 3. (discounting the control) that the viable 
bacterial population had decreased to such a level, that the dilutions did not contain 
enough bacteria or 4. Phenomena as yet not understood. 
 
Further to this unexpected result, the broth cultures used the day before were kept and 
stored in the 20ºC incubator in case of such problems. When they were examined, 
they had changed appearance.  Some of the broths had almost lost their turbidity, 
whilst others had a clear section at the top of the broth as if the media had separated.  
Realising the relevance of this, the results were noted so they could be correlated to 
the findings. 
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Sample Repeat Observation 
Control (0g) 1 Medium turbidity. Can see through 
Control (0g) 2 Medium turbidity. Can see through 
Control (0g) 3 Medium turbidity. Can see through 
0.002g 1 The lower 6/7th of the broth = very turbid, can‟t see 
through. Top 1/7th, very clear. Upon disturbance, turbid 
layer settles back, leaving the clear top 1/7th 
0.002g 2 The lower 6/7th of the broth = very turbid, can‟t see 
through. Top 1/7th, very clear. Upon disturbance, turbid 
layer settles back, leaving the clear top 1/7th 
0.002g 3 Medium turbidity. Can see through 
0.004g 1 Medium turbidity. Can see through 
0.004g 2 Medium turbidity. Can see through 
0.004g 3 The lower 6/7th of the broth = very turbid, can‟t see 
through. Top 1/7th, very clear. Upon disturbance, turbid 
layer settles back, leaving the clear top 1/7th  
0.006g 1 Medium turbidity. Can see through 
0.006g 2 A little more turbid. Can see through 
0.006g 3 Medium turbidity. Can see through 
0.008g 1 0.008 1 and 0.008 3 look identical. Both are very turbid. 
Top 1/7th is not clear, but appears to be starting to clear. 
0.008g 2 Medium turbidity. Can see through 
0.008g 3 0.008 1 and 0.008 3 look identical. Both are very turbid. 
Top 1/7th is not clear, but appears to be starting to clear. 
0.01g 1 very Turbid – opaque 
0.01g 2 Medium turbidity. Can see through 
0.01g 3 Quite turbid. Can still see through 
Table 4.22 - Observations of broth appearance 
 
In discussion with a colleague it was explained that MRSA changes from Gram +ve 
to Gram –ve when a colony reaches a certain age.  Further studies will be performed 
with fresh cultures of MRSA. 
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Method 4b - Modified method - Chitosan suspended in nutrient broth Vs MRSA 
 
Method 4 was modified to include a more appropriate selection of dilutions for 
inoculating the plate count agar. 
 
The graphs on the next few pages show growth rates over time of MRSA challenged 
by chitosan in varying quantities. 
 
The raw data has been excluded from the results section.  The full results can be 
found in appendix A.3, method 4b. 
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06/10/03 Chitosan Vs MRSA study
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Fig. 4.23  - Graph of average growth of MRSA Vs Chitosan.
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Looking at fig. 4.23 there is one sample that shows improved growth over the 
control, and the other 4 indicating lower growth than the control.  The 0.1g sample is 
clearly showing improved growth and the reasons for this are unknown.  The initial 
inoculum for this experiment was approximately 3.85 x 10
7
 cells (1.93 x 10
8
 cells per 
ml), and the maximum viable number of cells in the control during the experiment 
was approximately 2.69 x 10
11
 cells per ml. 
 
Looking at the samples between 0.02g and 0.08g, we see two interesting features.  
Firstly, none of these samples contain bacterial growth greater than the control. 
Secondly, the growth rate is considerably slowed.  The slow growth could be due to 
the bacteriostatic effect of chitosan inhibiting the slowing the growth of the bacteria.  
With a slowed growth of the bacteria, one may assume that the bacteria would still 
reach the abundance found in the control, but what we see is that the bacteria decline 
at lower abundance than the control.  This might suggest that chitosan increases the 
auto toxic effect of the bacteria, preventing them reaching the numbers of the control 
and causing them to die at lower bacterial concentrations.  
 
With the 0.1g sample out growing the control, it could be that there was an error in 
the experiment or that chitosan is most effective at a certain concentration and may 
even be metabolised by the bacteria when out with that concentration. 
 
No graph could be produced for the chitosan and MRSA data from 20/10/03.  This 
was due to the sample dilutions not falling within the countable range. 
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05/11/03 Chitosan Vs MRSA study
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Fig. 4.24  - Graph of average growth of MRSA Vs Chitosan.
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Looking at fig 4.24 we can see that all of the chitosan samples show lower growth 
than the control.  The initial inoculum for the 05/11/03 experiment was 
approximately 9.76x 10
6
 cells (4.88x 10
7
 cells per ml), and the maximum viable 
number of cells in the control during the experiment was approximately 3.09 x 10
9
 
cells per ml. 
 
Looking at this graph, we see that none of the samples containing chitosan develop 
the same number of bacteria as the control, although the 0.08g sample comes near 
and the 0.1g sample shows the lowest growth.  The only obvious difference between 
this experiment is the concentration of the inoculum, which is ~1/4 the concentration 
used in the 06/10/08 study.  It would therefore appear that the efficacy of chitosan is 
related in some manner to the quantity of bacteria used for the initial inoculation. 
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19/01/05 Chitosan Vs MRSA study
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Fig. 4.25 - Graph of average growth of MRSA Vs Chitosan.
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Fig 4.25 does not show the same trend as the previous two graphs (fig 4.23 and 4.24).  
The initial inoculum for this experiment was approximately 1.88 x 10
7
 cells (9.40 x 
10
7
 cells per ml), and the maximum viable number of cells in the control during the 
experiment was approximately 5.33 x 10
9
 cells per ml. 
 
This data does not appear to correlate with the two previous graphs.  It could be 
human error but it is more likely that there is some phenomenon occurring that is as 
yet unknown.   The only known variable is that this experiment contained half the 
inoculum of the 06/10/03 experiment and double the inoculum of the 05/11/03 
experiment.  The question as to whether this is a factor in the variation seen in the 
results can only be addressed by further study. 
 
4.2 Production of Biomaterial Samples  
The polyurethane and polyester were fabricated externally (commercially available 
materials).  These samples were cut into sample sizes and plasma treated.  The 
polypropylene, poly-ε-caprolactone and Solanyl were extruded at Heriot-Watt 
University as described in the methodology section.  The PLA was to be extruded but 
no useable tape could be produced, therefore it was cast as a film instead. 
 
The plasma treatment was to be performed on the Europlasma equipment using 
argon, oxygen and ammonia, but due to a technical fault with the equipment, 
alternative equipment was used (the Nanotech equipment).  Only argon and ammonia 
gas were available for the Nanotech plasma equipment.  As some samples had been 
treated on the Europlasma equipment, they were included in the tissue culture study.  
 
4.3 Sample Characterisation 
4.3.1 Differential scanning calorimetry (DSC) Analysis 
The DSC images display the energy required to increase the temperature of the 
sample over a range of temperatures versus time. The dips and spikes in the energy 
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profile correlate to the polymer sample proceeding through different phases. The 
lowest dip is the melting point of the polymer. 
 
 
Fig. 4.26 - Polypropylene DSC. Melting point 151.4ºC 
 
 
Fig. 4.27 - Polyurethane DSC. Melting point 149.5ºC 
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Fig. 4.28 - Polyester DSC. Melting point 257.5ºC 
 
 
Fig. 4.29 - Polycaprolactone DSC. Melting point 62.5ºC 
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Fig. 4.30 - Solanyl Flexibilitis DSC. Melting point 112.5ºC 
 
 
Fig. 4.31 - Poly-L-Lactic Acid DSC. Melting point 168.0ºC 
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4.3.2 SEM Analysis 
The samples were analysed by scanning electron microscope to examine the surface 
for change after plasma treatment and to illustrate differences in surface morphology.  
Some of the materials have a very plain surface but they are included to illustrate the 
difference in the surfaces of the biomaterials. 
 
Artefacts are visible in some of the SEM images (dust ect). 
Polypropylene 
 
Fig. 4.32 - Polypropylene control.  Very plain surface with few surface grooves produced during 
extrusion 
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Fig. 4.33 - Argon Plasma Treated Polypropylene (Nanotech).  At this magnification, there is no visual 
difference between this polypropylene and the control polypropylene. 
 
Fig. 4.34 - Ammonia Plasma Treated Polypropylene (Nanotech).  At this magnification, there is no visual 
difference between this polypropylene and the control polypropylene. 
 
  
Fig 4.35 - Spherical cap shapes of water on untreated 
fibre surface.  
Source (Wei et al., 2004) 
Fig 4. 36 - Growth and coalescence of water 
droplets on plasma treated PP fibre surface.  
Source (Wei et al., 2004) 
 
Fig 4.35 is an environmental SEM image of untreated polypropylene and Fig 4.36 is 
an environmental SEM image of oxygen plasma treated polypropylene.  These 
images illustrate that although there is no visual difference in the surface, the 
hydrophilicity of the sample in fig. 4.36 is greater than the sample in fig. 4.35. 
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Tuftane Polyurethane  
 
Fig. 4.37 - Tuftane Polyurethane.  This material has a very smooth surface. 
 
Fig. 4.38 - Argon Plasma Treated Tuftane Polyurethane (Nanotech).  At this magnification, there is no 
visual difference between this polyurethane and the control polyurethane. 
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Fig. 4.39 - Ammonia Plasma Treated Tuftane (Nanotech).   At this magnification, there is no visual 
difference between this polyurethane and the control polyurethane. 
  
Fig. 4.40 - Argon Plasma Treated Tuftane Polyurethane (Europlasma).   At this magnification, there is no 
visual difference between this polyurethane and the control polyurethane. 
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Fig. 4.41 - Oxygen Plasma Treated Tuftane Polyurethane (Europlasma).   At this magnification, there is 
no visual difference between this polyurethane and the control polyurethane. 
Vascutek polyester 
 
  
Fig. 4.42 - Vascutek Polyester control.  The structure of this material is very different to the other 
materials therefore no direct comparisons may be made between this material and the others.  
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Fig. 4.43 - Argon Plasma Treated Vascutek polyester (Nanotech).   At this magnification, there is no 
visual difference between this polyester and the control polyester. 
 
  
Fig. 4.44 - Ammonia Plasma Treated Vascutek polyester (Nanotech).   At this magnification, there is no 
visual difference between this polyester and the control polyester. 
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Poly-ε-Caprolactone 6400 
 
 
Fig. 4.45 - Poly-ε-Caprolactone 6400 control. This material displays a grooved surface. 
 
Fig. 4.46 - Argon Plasma Treated Poly-ε-Caprolactone 6400 (Nanotech).   At this magnification, there is 
no visual difference between this Poly-ε-Caprolactone and the control Poly-ε-Caprolactone. 
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Fig. 4.47 - Ammonia Plasma Treated Poly-ε-Caprolactone 6400 (Nanotech).   At this magnification, there 
is no visual difference between this Poly-ε-Caprolactone and the control Poly-ε-Caprolactone. 
 
Solanyl 
 
Fig. 4.48 - Solanyl Control.  This material has a very smooth surface. 
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Fig. 4.49 - Argon Plasma Treated Solanyl (Nanotech).   At this magnification, there is no visual 
difference between this Solanyl and the control Solanyl. 
 
 
 
Fig. 4.50 - Ammonia Plasma Treated Solanyl (Nanotech).   At this magnification, there is no visual 
difference between this Solanyl and the control Solanyl. 
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Fig. 4.51 - Solanyl extruded with 2% chitosan (w/w).  The fine bumps in this image were interpreted as 
chitosan powder 
 
 
Fig. 4.52 - Solanyl extruded with 2% chitosan (w/w).  The fine bumps can be seen more clearly in this 
image. 
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Fig. 4.52 shows the chitosan powder incorporated into the Solanyl tape.   
Poly-l-lactic acid 
  
Fig. 4.53 - Poly-l-lactic acid Control.  The highly porous structure can be seen in this image.  It is 
assumed that this structure is due to the solvent casting method of production (Chun et al., 2000). 
  
Fig. 4.54 - Argon Plasma Treated Poly-l-lactic acid (Nanotech).   At this magnification, there is no visual 
difference between this Poly-l-lactic acid and the control Poly-l-lactic acid. 
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Fig. 4.55 - Ammonia Plasma Treated Poly-l-lactic acid (Nanotech).   At this magnification, there is no 
visual difference between this Poly-l-lactic acid and the control Poly-l-lactic acid. 
 
Analysis of Pore Size of PLA Sample 
With the PLA displaying a highly porous structure, measurement of the pore size was 
performed.  The following images were used in the measurements as they were 
deemed representative of the PLA pore size.  The pore sizes were calculated 
assuming the pores were circular.  The area of the pores was calculated using the 
equation (4.1).   
Area of a circle = π x Diameter                                                             Equation (4.1) 
The measurements were converted to scale using the scale bars in the SEM images.  
For pores where only half was visible in the image, the area was halved. 
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Fig. 4.56 This image is the first of the PLA images to be measured and therefore will be referred to as 
PLA 1. 
 
Fig. 4.57 This image is the second of the PLA images to be measured and therefore will be referred to as 
PLA 2. 
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Fig. 4.58 This image is the third of the PLA images to be measured and therefore will be referred to as 
PLA 3. 
 
Pore Size Measurements of Figures 4.55 – 4.57 
The PLA images were printed out and the dimensions of the pores were measured 
using a ruler.  The scale bar in the images was used to convert the measurements 
from cm to µm.  The complete measurement data can be found in appendix B. 
  PLA 1 PLA 2 PLA 3 
Average pore area (µm
2
) 7.04 7.44 12.22 
Total area of pores in image (µm
2
) 563.03 402.03 464.37 
Percentage porosity 55.80% 39.84% 46.02% 
        
Average area of pores for the three images (µm
2
) 8.90 
Average percentage of pores for the three images   47.22% 
Table 4.59 Summary of PLA pore size measurements. 
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The result of these measurements was that the PLA had pores between 0.13µm
2
 to 
39.58 µm
2
, with the average pore size at 3.31 µm
2
 and a percentage area of pores of 
17.4%. 
 
4.4 Tissue Culture Study 
The following images help illustrate the difficulty with measuring the growth 
accurately.  The use of cellular stains was avoided to prevent potential detrimental 
effects on cell growth. 
 
The next 2 pages show photographs of the tissue culture samples through a 
microscope. These photographs are for illustration only. 
 
 
Fig. 4.60 
Polypropylene 
 
  
Fig. 4.61 
Polyurethane 
Fig. 4.62 
Polyurethane 
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Fig. 4.63 
Polyester 
Fig. 4.64 
Polyester 
 
 
Fig. 4.65 
Poly-ε-caprolactone 
 
 
 
Fig. 4.66 
Solanyl 
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Fig. 4.67 
Poly-L-Lactic acid 
Fig. 4.68 
Poly-L-Lactic acid 
 
Figures 4.60 through to 4.68 illustrate what was seen down the microscope when 
measuring the MRC-5 cell growth along the samples.  These images are a mixture of 
demonstrating the material as seen through the microscope combined with attempts 
to photograph the cells growing on the material clearly.  These images were taken 
using a 35mm SLR with a microscope mount. 
 
When the samples were examined weekly, measurements of growth along the 
samples were recorded.  In addition, cells could sometimes be seen growing on the 
glass sample support or the tissue culture flask.  This was recorded and the data can 
be seen in appendix C.2.  The colour of the media was recorded to provide supporting 
evidence for the growth measurements.  This can also be seen in appendix C.2. 
 
All of the materials tested comprised a control, an argon treated material and an 
ammonia treated material.  For some materials, other treatments were included.  Both 
Solanyl and polypropylene were treated with a chitosan solution both with and 
without plasma treatment.  In addition, some one off treatments were tested.  
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These treatments were; argon treated polyurethane (on the Europlasma machine), 
oxygen plasma treated polyurethane (on the Europlasma machine), chitosan powder 
sprinkled on to a sample of polyurethane prior to argon plasma treatment (Nanotech) 
and Solanyl extruded with 2% chitosan powder (w/w). 
 
The oxygen and argon samples were created using the Europlasma equipment.  The 
equipment failed shortly after these treatments and therefore alternative equipment 
was used for the other samples.  The argon treatment provided a comparison between 
the two different plasma treatment machines, while the oxygen plasma treatment can 
only be directly related to the Europlasma treated argon sample and the control.  The 
chitosan powder sprinkled on to a sample of polyurethane prior to argon plasma 
treatment sample was made to determine whether plasma could be used to attach 
powders to surfaces and to compare this method with the addition of chitosan film.  It 
was then used in the study to determine if the chitosan powder would persist on the 
material and to see what effect it might have on cell growth. 
 
The following pages show graphs that chart the growth of the cells along the samples 
over a period of 29 days.  Each sample was replicated 9 times, although not every 
sample produced a clear result. See the appendix C.1 for further details.  
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Polypropylene Data
0
5
10
15
20
25
30
0 8 15 22 29
Day
A
v
e
ra
g
e
 G
ro
w
th
 (
m
m
)
Polypropylene
Polypropylene Argon treated (Nanotech)
Polypropylene Ammonia  treated (Nanotech)
Polypropylene Chitosan treated
Polypropylene Argon and Chitosan treated  (Nanotech)
Polypropylene Ammonia and Chitosan treated (Nanotech)
 
Fig. 4.69 - Graph of average growth of fibroblasts on the polypropylene samples. 
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Fig 4.69 shows the growth of MRC-5 cells along the polypropylene samples.  
Looking at the first 15 days of growth, it is clear that the untreated polypropylene 
performs the worst for supporting initial growth of the cells.  The majority of the 
other treatments seem to perform better, supporting 2-2.5mm of growth on the 
samples (polypropylene argon treated, polypropylene chitosan treated, polypropylene 
argon chitosan treated and polypropylene ammonia chitosan treated).  The best 
material over the initial 15 days was the polypropylene ammonia treated.  This data 
indicates that any of the treated materials performs better than native polypropylene 
for supporting growth over 15 days.  
 
Over the next 15 days, the data shows a change in the growth rate of he MRC-5 cells 
on the samples.  The polypropylene samples with gas plasma treatment and chitosan 
coating maintain a steady growth rate but perform poorly when compared to the other 
samples.  The unmodified polypropylene displays a sharp increase in growth up to 
day 22 and then displays no further growth over the remaining 7 days.   The 
polypropylene samples with single treatments (chitosan, argon and ammonia) display 
sustained growth, out performing the native polypropylene, although the chitosan 
coating growth rate appears to be tailing off over the last 7 days.  The slowing of the 
chitosan coated polypropylene sample could in part be due to the hydrophobic 
polypropylene on which the coating was applied.  The chitosan coating may be 
partial, with sections of no coating. The plasma treated samples show sustained 
growth, due in part to a consistent surface modification which enhances the 
polypropylene hydrophilicity. 
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Polyurethane Data
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Fig. 4.70 - Graph of average growth of fibroblasts on the polyurethane samples. 
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Fig. 4.70 shows the growth of MRC-5 cells along the Polyurethane samples.  This 
selection of treatments includes plasma treatment from two different plasma 
treatment machines; therefore they shall be differentiated by manufacturer of the 
control equipment (Nanotech and Europlasma).  Looking at the first 15 days of 
growth, it is clear that the untreated polyurethane is out-performed by the modified 
polyurethane samples.  The oxygen plasma treated polyurethane (Europlasma) and 
the polyurethane sprinkled with chitosan powder prior to argon treatment were both 
displaying greater growth rates than the untreated polyurethane over the first 15 days.  
 
The two Nanotech treated samples and the Europlasma argon sample perform very 
well, although the difference in growth rate between the two argon treatments is 
interesting, with the Nanotech sample encouraging twice the growth of the 
Europlasma samples.  This could be partially due to differences in the plasma 
chamber.  The Nanotech chamber was far smaller than the Europlasma chamber and 
as a direct result, although the gas was in excess, and the other parameters were 
matched as closely as possible, the distance between the plates (between which the 
RF frequency was discharged) was far smaller, therefore producing a more focused 
plasma discharge.   This hypothesis will need to be confirmed in a later study. 
 
In the latter 14 days of the study it can be seen that the control sample and the oxygen 
plasma treated sample perform similarly, while the argon and chitosan sample and 
the Europlasma argon treated sample are outperformed by the control.   This was an 
unexpected outcome.  
 
In contrast, the two  samples treated on the Nanotech equipment, the argon and 
ammonia samples dramatically outperform the control, with the ammonia again 
performing the best with an average growth ~15mm greater than the control.  The 
two Nanotech samples also perform considerably better than the polypropylene 
samples with the corresponding treatments.  The results also show that the 
polyurethane control outperforms the polypropylene control. 
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Vascutek Polyester Data
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Fig. 4.71 - Graph of average growth of fibroblasts on the polyester samples. 
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Fig. 4.71 shows the growth of MRC-5 cells along the Vascutek samples. This graph 
shows the control material out performing both of the plasma treated samples.  This 
material is used as a vascular prosthesis and when adding cells to the samples, the 
cells could be seen to wick into the sample very quickly, demonstrating the 
hydrophilicity.  By plasma treating the samples, it is possible that the hydrophilicity 
was reduced resulting in lower growth on the samples.  Although the plasma treated 
samples do not perform as well as the control, it can still be seen that the ammonia 
plasma treated sample performs better than the argon plasma treated sample, although 
for the first 15 days, the growth rate is similar. 
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Poly-L-Lactic Acid Data
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Fig. 4.72 - Graph of average growth of fibroblasts on the polylactic acid samples. 
Fig. 4.72 shows the growth of MRC-5 cells along the poly-l-lactic acid samples.  The 
data also shows the control performing better than the plasma treated samples and 
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therefore, like the polyester, these plasma treatments are not stimulating tissue 
growth. 
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Fig. 4.73 - Graph of average growth of fibroblasts on the poly-ε-caprolactone samples. 
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Fig. 4.73 shows the growth of MRC-5 cells along the polycaprolactone samples.  
With this collection of samples, they all perform similarly over the first 15 days.  It is 
only in the last 15 days where there is an obvious difference in growth.  The order of 
ammonia plasma, argon plasma then control can be seen and while the ammonia 
performs best, the argon plasma treatment is only marginally better than the control.  
It can also be seen that the argon plasma does not appear to encourage further growth 
after 15 days, suggesting that the cells are having difficulty growing on this substrate, 
and are performing poorly on the control which indicates a decline.  
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Solanyl Flexibilitis Data
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Fig. 4.74 - Graph of average growth of fibroblasts on the Solanyl samples. 
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Fig. 4.74 shows the growth of MRC-5 cells along the Solanyl samples.  This sample 
collection contains a few variations, so the standard three materials shall be looked at 
first.  
 
Over the first 15 days, the control and the ammonia plasma samples show steady 
growth (the ammonia picks up after day 8) but it takes until day 15 for the argon 
plasma samples to show growth.  Over the next 15 days, the control and ammonia 
plasma samples show continued and steady growth but the argon plasma samples 
show a burst of growth then a decline.  These three samples perform similarly to the 
PLA samples, with growth around the 5mm point and like the PLA, the two basic 
plasma treatments do not perform as well as the control.  The main difference 
between the Solanyl control and the PLA is that the PLA control performed better.  
 
The additional treatments with the exception of Solanyl with chitosan coating (no 
plasma) promote better tissue growth than the control.  The Solanyl with argon 
plasma and chitosan coating and the Solanyl with ammonia plasma and chitosan 
coating perform similarly except for the last seven days, where the ammonia and 
chitosan samples show a sharp increase in cell growth.  The Solanyl with 2% 
chitosan does not show noticeable growth for the first 15 days, and then it shows a 
sharp increase in growth for the last 15 days.  This is an interesting finding and could 
be related to the fact that the chitosan is embedded in the polymer.  The sharp 
increase in growth may occur as the surface of the polymer erodes slightly, exposing 
the chitosan to the cells. 
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Control Sample Data
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Fig. 4.75 - Graph of average growth of fibroblasts on the control samples. 
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Fig 4.75 shows the average growth of the control materials over 29 days.  Over the 
first 15 days, there are three distinct groups.  The first group showing very little 
growth includes polypropylene, polyurethane and polycaprolactone.  The second 
group with growth average growth around 4mm includes Vascutek polyester and 
Solanyl.  The last sample is the only sample with growth above 5mm in the first 15 
days is the PLA. At day 22, all but the polycaprolactone, group around the 5mm of 
growth, but over the last 7 days, the growth changes for most of the samples.  The 
polycaprolactone shows no growth.  The Solanyl continues to encourage steady 
growth.  The polypropylene shows no further growth after day 22. The polyurethane 
and polylactic acid produce better growth and the Vascutek polyester samples 
encourage a steady increase in growth rate indicating that it is the best standard 
material for supporting tissue growth.  This is not a surprising finding as this material 
is commercially available but also because it is the only material with a knitted 
structure. 
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Argon Treated Samples Data
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Fig. 4.76 - Graph of average growth of fibroblasts on the argon plasma treated samples. 
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Fig 4.76 shows the argon treated samples.  In relation to fig 4.75, it shows that the 
argon treatment of polyurethane and polypropylene were a success, as they supported 
greater growth than the best control material.  It also shows how the argon treatment 
reduced growth compared to the controls, with the exception of polycaprolactone, 
where the average growth is approximately the same. 
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Ammonia treated Samples Data
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Fig. 4.77 - Graph of average growth of fibroblasts on the ammonia plasma treated samples. 
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Fig 4.77 primarily shows that the ammonia plasma was the best treatment for the 
polypropylene and polyurethane.  The average growth supported on the 
polypropylene is almost as much as the average growth on the control Vascutek 
polyester.  This is double the average growth measured on the polypropylene control. 
 
The ammonia treated polyurethane supports the highest average cell growth of all the 
samples tested, improving the average growth by around 15mm over the 
polyurethane control, and almost 10mm over the Vascutek polyester control.  
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Sample 
Average 
growth After 
29 Days (mm) 
Standard 
Deviation 
Polyurethane Ammonia treated 25.3 8.8 
Polyurethane Argon treated 18.0 14.5 
Vascutek Polyester 15.9 12.7 
Polypropylene Ammonia  treated 14.9 14.4 
Solanyl Flexibilitis Ammonia and Chitosan treated 12.3 14.9 
Polypropylene Argon treated 12.0 14.4 
Polyurethane Oxygen treated in (Europlasma) 11.3 14.5 
Polyurethane 10.3 12.9 
Solanyl Flexibilitis extruded with 2% Chitosan powder 10.0 15.5 
Poly-l-lactic acid 10.0 15.0 
Polypropylene Chitosan treated 9.6 13.0 
Polyurethane with Chitosan powder prior to argon treatment 8.4 13.0 
Poly-ε-caprolactone Ammonia treated 8.3 13.6 
Solanyl Flexibilitis Argon and Chitosan treated 7.6 11.9 
Polyurethane Argon treated in (Europlasma) 7.3 13.0 
Polypropylene 6.7 13.2 
Solanyl Flexibilitis 6.4 12.0 
Polypropylene Ammonia and Chitosan treated 6.2 11.0 
Vascutek Polyester Ammonia treated 5.9 9.8 
Solanyl Flexibilitis Ammonia treated 5.0 12.2 
Poly-l-lactic acid Argon treated 5.0 12.2 
Poly-l-lactic acid Ammonia treated 5.0 12.2 
Polypropylene Argon and Chitosan treated 3.6 9.9 
Solanyl Flexibilitis Chitosan treated 3.3 6.3 
Solanyl Flexibilitis Argon treated 3.2 7.8 
Vascutek Polyester Argon treated 2.0 3.2 
Poly-ε-caprolactone Argon treated 1.1 3.0 
Poly-ε-caprolactone 0.7 2.0 
Table 4.78 - Average cell growth of samples after 29 days arranged in descending order 
 
As can be seen by the tissue culture data, ammonia treated polypropylene is the 
fourth best material, with untreated Vascutek polyester performing marginally better. 
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The top two performers are the plasma treated polyurethanes.  The ammonia treated 
polyurethane comes out top, with an average growth figure 7mm greater than the 
argon treated polyurethane. 
When looking the data, one can see a trend where the ammonia plasma treatment out 
performs argon treatment, with the exception of the PLA where they both perform the 
same.  This was as hypothesised, as the ammonia will present nitrogen and hydrogen 
on the surface, much like proteins.  
 
Samples were examined on day 30 using a Leica confocal microscope. Cells were 
stained using an Invitrogen live/ dead cytotoxicity test (containing ethidium 
homodimer and calcein AM cellular stains).  These images were to be used primarily 
as conformation of optical microscope measurements and to gain an insight into the 
quality of cell growth.  The fluorescence images were not consistent across the 
selection of samples and some of them indicated that the cells had been ripped off 
during the preparation of the samples for fluorescence microscopy.   
 
 
Fig 4.79 Polypropylene 2 sample from 24/09/2005 illustrating an abrupt termination of cells due to the 
cells ripping off the sample during sample preparation. 
 
 The data from the fluorescence imaging can be found in appendix C.2.   
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Chapter 5 – Discussion 
This project aimed to; 
 review the advantages and disadvantages of materials used in soft tissue 
repair and to review potentially alternative materials.  
 investigate the reported benefits of using chitosan in relation to medical 
device applications. 
 investigate in depth a limited selection of alternative materials.  
 investigate the value of gas plasma treatment on the ability of these materials 
to support tissue growth in vitro.  
 
This research set out to investigate the current state of biomaterials used for soft 
tissue repair.  Current mesh prostheses made of polypropylene (PP), polyethylene 
terephthalate (PET) or polytetrafluoroethylene (PTFE) have proven themselves 
invaluable for the repair of soft tissue defects but they can often lead to complications 
such as restriction of the abdominal wall mobility, intra-abdominal adhesions with 
erosion of adjacent organs (or consecutive fistula formation) and inflammatory 
foreign body reaction where the prosthesis is embedded into a fibrous scar plate 
causing shrinkage of the mesh area (~40%).  They can also provide a surface which 
bacteria can colonise causing persistent infections that can sometimes only be cleared 
by the removal of the prosthesis.  Polypropylene meshes, which have been in use 
since 1962, are still the most common material for hernia repair (Morris-Stiff and 
Hughes, 1998) due to their perceived long term maintenance of tensile strength and 
low tissue reactivity although in a study conducted in 1998 a failure rate of 10% was 
recorded (4 out of 40 patients in a single unit) and therefore it was concluded that the 
complications associated with polypropylene meshes are under reported.  While these 
complications are rarely life threatening, they highlight the need for further research 
into these devices.  Degradable biomaterials used (e.g. polyglycolic acid) can also 
cause complications such as the recurrence of the hernia due to failure of the device 
and inflammatory reactions caused by rapid degradation of the material. 
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It is hypothesised that complications associated with medical devices are associated 
with an inability to assimilate with the host tissue, therefore by improving host tissue 
regeneration, complications will be reduced.  
 
To address the issue of prosthesis related infections, there needs to be a material that 
could inhibit bacterial growth that was suitable for use within the human body. 
Chitosan (& chitin) have been reported to inhibit bacterial growth and fungal growth 
whilst enhancing human tissue growth (and many other attributes).  It was therefore 
hypothesised that by using chitosan as a coating or incorporating chitosan into a 
biomaterial, tissue regeneration would be enhanced and prosthesis related infections 
would be reduced.  
 
From these two hypothesises two lines of research became evident.  
 To examine the efficacy of chitosan as a bacteriostat.  
 To examine a range of biomaterials for their ability to encourage fibroblast 
growth and see if fibroblast growth could be improved by modifying the 
surface of the biomaterial. 
 
5.1 Examination of Chitosan as a Bacteriostat 
As a result of the reports of chitosan as a bacteriostat in the literature, this study was 
devised to determine the efficacy of chitosan against a common and prolific 
opportunistic pathogen. Staphylococcus epidermis was also included in the early 
study but MRSA was the most relevant candidate for testing the efficacy of chitosan.  
MRSA is gram positive and resistant to certain antibiotics.  It is also one of the most 
problematic infections to clear when acquired in a hospital environment and can be 
life threatening and therefore it is the most interesting bacterium to test the 
bacteriostatic claims reported for chitosan. 
 
The means of testing the bacteriostatic effect of chitosan followed two distinct paths.  
One was to examine the ability of chitosan to inhibit growth on a surface and the 
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other was designed to determine a quantifiable effect on MRSA (and to a lesser 
extent S. epidermis) in broth culture by varying the quantity of chitosan in the broth.  
The methods employed were of an evolutionary nature in that deficiencies in one 
method were addressed in the next. 
 
Method 1 - Chitosan dissolved in dilute acetic acid incorporated into nutrient agar 
Vs MRSA 9551 and Staphylococcus epidermis. 
Method 1 was the beginning of the method development where initial investigations 
into both aspects of this study started producing preliminary data but the methods 
diverged as the requirements of each method were developed.  From there, method 3 
examined the inhibition of growth around chitosan film or materials coated in 
chitosan film while methods 2 and 4 examined the growth of MRSA in solutions 
containing chitosan. 
 
Method 2 - Chitosan dissolved in acetic acid added to nutrient broth Vs MRSA 9551 
and Staphylococcus epidermis  
The data for Method 2 suggested a bacteriostatic relationship between chitosan and 
MRSA.  This experiment illustrates the bacteriostatic effect of chitosan against 
MRSA (although the data is less clear for S.epidermis).  This experiment shows the 
first four hours of bacterial growth in the presence of chitosan in detail, although after 
the first 4 hours, there is a 22 hour gap between measurements.  The data clearly 
shows the lag phase and logarithmic growth phase but not the stationary phase or 
death phase.  This experiment may have benefited from hourly measurements over 
the 26 hour period, but with the resources available, this was not possible.  
 
Method 3 - Testing of Chitosan treatment of Cotton cloth 
Method 3 was designed to expand on the early investigation in method 1 of chitosan 
film.  The cotton cloth coated with the chitosan solution demonstrated an observable 
zone of inhibition.  The polypropylene coated with chitosan solution was not so 
effective.  The result for polypropylene coated in chitosan against MRSA produced a 
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partial zone of inhibition.  When tested with S. epidermis, no zone of inhibition was 
observed. 
 
Method 3 examined the effect of a chitosan coated material on an inoculated agar 
plate. Although the chitosan coating was not pH neutralised, the results indicate a 
zone of inhibition around most of the treated samples.  These methods indicate that 
chitosan coating may be a viable means of producing materials which inhibit 
bacterial growth with the added advantage that it is easy to apply.  This application 
could be used in both medical devices and on textiles used within the hospital 
environment although further research to optimise this coating is recommended. 
 
Method 4 - Chitosan suspended in nutrient broth Vs MRSA 
Method 4b was the final evolution of methods 2 and 4.  This method yielded a large 
quantity of data on the efficacy of chitosan in suspension Vs MRSA.  These results 
suggest that the bacteriostatic effect varies with the quantity of chitosan presented to 
the bacteria but it does not appear, from this data, to be a direct relationship. 
 
The studies in method 4b suggest that there is a large variation in the efficacy of 
chitosan powder as a bacteriostat against MRSA.   There are two potential 
explanations for the results in the 06/10/03 and 19/01/05 studies.  First, the efficacy 
of chitosan may be related to the concentration of bacteria.  Second, the initial 
measurements were taken after 24 hours, and it is possible that the control may have 
already finished the exponential phase and stationary phase and started on the death 
phase before the first measurements were taken.  In future, it would be interesting to 
measure the samples every 4 hours in the first 24 hours to see if the extra resolution 
proves this hypothesis to be the case.  
 
Examination of Chitosan as a Bacteriostat Summary 
The chitosan study set out to examine the efficacy of chitosan as a bacteriostat.  To 
that end, it has been observed that chitosan does have a bacteriostatic effect.  In film 
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form the chitosan produced a clear zone of inhibition against MRSA and in 
suspension it caused inhibition of growth for the majority of samples tested.  In terms 
of producing quantitative data, the methods developed towards the end of the study 
could still not elucidate a relationship between the quantity of chitosan suspension 
and the effect on MRSA.  
 
This study indicates that when chitosan is applied to a material as a film, it has a 
bacteriostatic effect against MRSA and when it is used as a suspension it can produce 
a bacteriostatic effect although it is a variable one.  As the main application of 
chitosan in this project is as a coating, this data suggests it will impart bacteriostatic 
properties to the material it is applied to. 
 
It has been reported that among other properties that chitosan is an effective 
bacteriostat, but this study indicated the need for further studies to clarify the 
susceptibility of a wide range of pathogens to chitosan. Chitosan is a difficult 
material to study in these experiments as it is not readily soluble except in acidic 
solutions and is therefore difficult to study a neutral environment.  Chitosan has an 
effect on bacteria as reported in the literature, but the results of this study found that 
the results varied greatly depending on how the chitosan was presented and the 
concentration of the inoculum.  
 
There are many sources of chitosan including crustacea and fungi and many different 
degrees of deacetylation (chitosan is stated as being greater than 70% deacetylated).  
There are also many modifications of chitosan, including water soluble chitosan but 
this study used the same chitosan throughout this study and the tissue culture study 
(high molecular weight, high purity squid chitosan). Chitosan derived from different 
organisms and different deacetylation techniques may demonstrate different levels of 
bacterial growth inhibition.  With all of the reported benefits of using chitosan, 
research will continue and further applications will be developed.  Until experimental 
analysis reveals a better chitosan for inhibiting bacterial growth, the high purity squid 
chitosan will be useful as a bacteriostatic coating for medical prostheses to inhibit 
post-operative infections.  
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5.2 Production of Biomaterial Samples  
The biomaterial samples used in this research were produced using a variety of 
production methods.  This variety of production methods introduced differences in 
morphology of the biomaterials. This factor limits the conclusions that can be drawn 
between biopolymers used in this research although with these differences noted, 
careful comparisons may be made.  The two samples with the greatest difference in 
surface morphology were the PLA and the polyester.  The polyester and PLA were 
included because they were so different from the extruded samples and because they 
were expected to outperform the extruded samples due to increased cell adhesion.   
 
5.3 Sample Characterisation 
5.3.1 Differential scanning calorimetry (DSC) Analysis 
The DSC analysis provided the melting points of the polymers.  Due to the low 
melting point of the poly-ε-caprolactone, the samples could not be sterilised using an 
autoclave (121ºC for 15 minutes) so ethylene gas sterilisation was used instead. 
5.2.2 SEM Analysis 
The SEM analysis of the samples showed a degree of variation in the surfaces of the 
different polymers.  Some of the polymers had a very smooth surface (Solanyl and 
polyurethane), some had minor grooving from the extrusion process (polypropylene 
and poly-ε-caprolactone) and two materials had very different surfaces (polyester and 
polylactic acid). These differences affect the growth of cells on the materials 
therefore conclusions from the tissue culture study should only be made with these 
differences in mind.  Plasma treatment made no observable change to the surfaces of 
the biomaterials, but as seen in fig. 4.35 and 4.36, plasma treatment has a great effect 
on the hydrophilicity/ hydrophobicity of a polymer.   
 
Looking at the Solanyl containing 2% chitosan (w/w), particles of chitosan powder 
can be seen on the surface of the sample.  It appears from fig. 4.52 that the chitosan 
powder was not evenly distributed through the Solanyl.  This should not be of great 
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importance for this study, but should be addressed if this material is to be developed 
further.   
 
The PLA images illustrate the porous nature of the film cast using DCM evaporation. 
The pore sizes were measured and compared to the area of the images used in the 
pore size measurements.   
 
Average area of pores for the three images (µm
2
) 8.90 
Average percentage of pores for the three images   47.22% 
Table 5.1 summary of the pore size measurements. 
 
The PLA shows a highly porous structure although the average pore size and 
percentage porosity are both lower than the optimal sizes/ percentages quoted by Oh 
(186–200 µm pore size (Oh et al., 2007)) and Minns (10-50 µm pore size overall 
porosity of 85-90% (Minns, 1999)). 
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5.4 Tissue culture study 
This project aimed to determine which biomaterial or surface treatment yielded the 
greatest fibroblast growth and to test a selection of surface treatments to see if they 
can be used to improve current biomaterials.  The theory behind this was that by 
testing biomaterials for their ability to support fibroblast growth, a logical foundation 
is created for the design and optimisation of soft tissue repair prostheses.  This was 
achieved by inoculating the biomaterial samples at one end with a 20µl drop of 
MRC-5 cells and measuring their growth along the 30mm strip of material.  As the 
samples could not all be tested at once, the samples were tested in mixed groups of 
three treatments of three materials in triplicate and each sample was tested 9 times.  
Therefore 243 samples were tested in total (27 different samples tested 9 times each), 
each tested over a 29 day period. 
 
Prior to testing the biomaterials with MRC-5 cells, the materials were washed in 70% 
ethanol, ethylene gas sterilised and examined using SEM to observe any differences 
between the materials and to observe any differences in the surfaces as a result of 
modification.  When examining the data in chapter 4.1, the surface topography can be 
seen.  By examining these SEM images, it can be seen that the surface topography is 
different for each material.  The difference is modest between polypropylene, Tuftane 
and Solanyl and polycaprolactone.  With the PLA and polyester samples the surface 
topography is quite different.  This would have an effect on how well the MRC-5 
cells grew on the substrate therefore comparisons should be made only with these 
differences in mind.  No difference was observed in the SEM images between the 
plasma treated samples and the standard materials, although the Solanyl containing 
2% chitosan had slight bumps on the surface due to the incorporation of the chitosan 
powder. 
 
The tissue culture study performed well as a comparison between the six different 
materials and produced useful data on how the plasma treatment affected tissue 
growth on the different materials.  In addition to evaluating plasma treatment, 
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selections of chitosan based treatments were tested but these were primarily 
explorative in their nature (to examine the viability of such treatments).  
 
Polypropylene, the most commonly used biomaterial in surgery, made a useful 
reference point for studying biomaterials.  It was also the starting point for examining 
modifications that can enhance biocompatibility.  Three treatments were shown to 
improve fibroblast growth on polypropylene (argon plasma, ammonia plasma and 
chitosan coating with no prior plasma treatment).  Argon and chitosan treated 
polypropylene and ammonia and chitosan treated polypropylene both demonstrate 
inferior tissue growth compared to the control after 29 days, although growth is faster 
over the first 15 days, therefore any benefit derived from these treatments is 
transitory.  
 
The polyurethane data indicates that three treatments produced enhanced growth over 
the unmodified material, the ammonia treatment, the argon treatment and the oxygen 
treatment, although all of the treatments show enhanced growth over the first 15 
days.  This reflects what is seen for the polypropylene data.  The two samples of 
polyurethane treated with argon plasma on different plasma treatment equipment 
produce radically different results.  The polyurethane treated with argon on the 
Europlasma equipment and the polyurethane treated with argon on the Nanotech 
equipment were used to illustrate that although the equipment was different, the 
effect was the same but as can be seen by the data, they produced quite different 
results.  This was quite unexpected and will need to be investigated further. Shortly 
after treating the polyurethane with argon and oxygen on the Europlasma equipment, 
the plasma equipment became faulty, so other samples treated on the Europlasma 
equipment were discarded and the plasma treatment was performed in the older 
Nanotech equipment. Although the Europlasma argon and ammonia treatments 
performed poorly compared to the equivalent Nanotech samples, the oxygen plasma 
treated sample showed improved growth over the standard material.  This suggests 
that if the sample was treated with oxygen plasma on the Nanotech equipment, the 
oxygen plasma may have performed very well.  Oxygen plasma could not be 
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produced on the Nanotech equipment as there was no oxygen gas available at the 
time of plasma treatment. 
 
The Vascutek polyester data clearly shows that argon and ammonia plasma treatment 
does not improve fibroblast growth.  What is interesting about the data is that the 
ammonia plasma still outperforms the argon plasma. 
 
The PLA was predicted to perform well, considering it had a porous surface.  It 
performed better than untreated polypropylene, untreated poly-ε-caprolactone and 
untreated Solanyl.  The untreated PLA does not promote as much growth as the 
untreated Vascutek polyester, although it does outperform the untreated 
polypropylene.  None of the plasma treatments improved growth on the PLA.  
 
The untreated poly-ε-caprolactone performed poorly.  Argon treatment had little 
effect compared to the control.  Ammonia treatment promoted approximately thirteen 
times the growth of the poly-ε-caprolactone control.  This is the greatest 
improvement over the control recorded.  In addition, ammonia treatment of poly-ε-
caprolactone promoted growth slightly greater than the polypropylene control. 
 
The data for Solanyl indicated that the argon, ammonia and chitosan treatment 
(without plasma pre-treatment) produce products that are inferior to the control 
material.  In contrast to the polypropylene samples, the argon and ammonia pre-
treated Solanyl coated in chitosan both perform better than the control material, with 
the ammonia and chitosan treated Solanyl promoting twice the growth of the control.  
The Solanyl containing 2% chitosan performed well; therefore this method of 
incorporating chitosan in degradable biomaterials requires further study to determine 
the best ratio of chitosan to polymer and to examine which other degradable 
biopolymers can benefit from the addition of chitosan.  
 
The data for the control samples reveals that three of the tested materials support 
greater fibroblast growth than polypropylene (Vascutek polyester, polyurethane and 
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poly lactic acid) but it is clear that plasma treatment can be used to produce a better 
surface for fibroblast growth.  With the plasma treatment, the samples were 
considered a success if they supported cell growth greater than the untreated material.  
They were a greater success if they encouraged cell growth beyond the untreated 
material and produced growth greater than polypropylene (the benchmark). 
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Average Growth Of Permanent Materials In Relation To Polypropylene
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Graph 5.2 - Summary of fibroblast growth on permanent materials.  Polypropylene is shown in black as it is the control.  The untreated materials are shown in green.  
The yellow bars are samples where the treatment improved fibroblast growth over the untreated material.  Blue bars are samples where the surface treatments reduced 
fibroblast growth compared to the untreated samples.
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Graph 5.3 - Summary of fibroblast growth on resorbable materials.  Polypropylene is shown in black as it is the control.  The untreated materials are shown in green.  
The yellow bars are samples where the treatment improved fibroblast growth over the untreated material.  Blue bars are samples where the surface treatments reduced 
fibroblast growth compared to the untreated samples. 
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The argon and ammonia treated polyurethane were clearly the most successful 
treatments, but growth on ammonia plasma treated polypropylene was more than 
twice the growth of standard polypropylene.  Ammonia and chitosan treated Solanyl 
produced the best growth on a degradable material, although there is only 2.3mm 
difference in average growth between this and Solanyl containing 2% chitosan which 
would make both materials viable options for degradable prostheses.  The Ammonia 
and chitosan treated Solanyl would also impart a bacteriostatic effect due to the 
chitosan film therefore inhibiting prosthesis related infections.  The Solanyl 
containing 2% chitosan may also impart this protection, although further study would 
be required to prove this.  The oxygen plasma treated polyurethane (Europlasma) 
does not perform as well as the argon plasma treated polyurethane (Nanotech) or the 
ammonia plasma treated polyurethane (Nanotech, but when the poor performance of 
the Europlasma treated argon sample is taken into account (an average growth of 10.7 
difference between the Europlasma and Nanotech argon treated samples) it can be 
suggested that oxygen plasma could perform better if produced on the Nanotech 
equipment.  
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Conclusions  
It is clear from the data that chitosan is affecting the growth of MRSA, with chitosan 
film producing observable zones of inhibition against MRSA, although there is not a 
direct relationship between the quantity of chitosan powder in solution and the effect 
on growth.  This project achieved its aim to examine the bacteriostatic effect but 
further work will be required to find a direct relationship.  Medical applications may 
include implanted devices and textiles used in the hospital environment (e.g. soft 
furnishings, nurses‟ uniforms and doctors‟ coats). 
 
The tissue culture study completed the objective of comparing a range of biomaterials 
and surface treatments in a consistent and unbiased manner, producing interesting 
results.  It is also clear from the data that gas plasma treatment can improve fibroblast 
growth on some of the biomaterials. 
 
Ammonia and chitosan treated Solanyl and Solanyl containing 2% chitosan proved to 
be the best degradable biomaterials tested.  These materials should be tested in vivo 
for their ability to repair soft tissue defects.   The ammonia and chitosan treated 
Solanyl may also be tested as repair prostheses for non-sterile tissue repair, perhaps 
as a suture material as it should inhibit infections associated with such wound 
closures.  If the Solanyl containing 2% chitosan proves to be effective as a 
bacteriostat, it too may be suitable for this application. 
 
The polyurethane sample treated with ammonia plasma appears to be an interesting 
candidate for further study as the only material with 100% survival of cells in culture 
and the best growth measurements over the 29 days.  This material requires further 
study to determine its efficacy in vivo and to develop the best design to support the 
load of abdominal and pelvic floor contents.  The next stage for this material is to 
design mesh prosthesis for animal trials, so the efficacy can be determined in vivo. 
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Other materials performed well, with ammonia treated polypropylene yielding a great 
improvement in cell growth over untreated polypropylene.  As polypropylene is 
already a widely used material for soft tissue repair, it would be feasible to produce a 
new polypropylene prosthesis with ammonia treatment.  This would provide a 
prosthesis with the handling and mechanical characteristics that surgeons are familiar 
with but with the benefit of improved incorporation within the patient. 
 
As hypothesised, the ammonia plasma consistently performs better than the argon 
plasma (with the exception of polylactic acid, where it performs the same as argon).  
Further work will be needed to determine if the ammonia does deposit NH groups as 
hypothesised. 
 
Further study is required into the use of gas plasma, considering the difference in 
results from polyurethane samples treated with the same gas using different 
equipment.  With further testing and optimisation, the Europlasma equipment could 
produce results equivalent to the Nanotech equipment by altering the gap between the 
charged plates.  The Europlasma has advantages over the Nanotech equipment in that 
it is computer controlled and should therefore be able to produce more consistent 
results.  
 
Recommendations for further study of gas plasma include; 
 Examining a greater range of gases for their ability to enhance cell 
proliferation on biomaterials. 
 Examine the efficacy of gas plasma treatments for a broader range of 
biomaterials gases for their ability to enhance cell proliferation on 
biomaterials. 
 Examining different parameters within the plasma chamber to optimise gas 
plasma treatments for enhancing cell proliferation on biomaterials. 
 Examine the efficacy of atmospheric plasma treatment as an alternative to low 
pressure plasma treatment for coating biomaterials 
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Recommendations for further developing the methods used to examine chitosan as a 
bacteriostat include; 
 Measuring the growth of the bacteria in the presence of chitosan (in 
suspension) at one to two hour periods during the first 24 to 48 hours.  
 Testing the bacteriostatic effect of chitosan against a greater range of 
pathogens.  
 An investigation into the molecular basis behind the bacteriostatic effect so it 
can be optimised and then verified.  
 Testing the efficacy of chitosan derived from different sources, with different 
molecular weights to determine which chitosan has the greatest effect on 
bacterial growth.  
 
Recommendations for developing optimal soft tissue repair prosthesis include an in 
vivo study, where the response of the immune system can be taken into account.  This 
would include testing the selected biomaterials in a range of morphologies as well as 
a range of treatments as the morphology of the implant will have a great effect on the 
response of host tissue to the medical device.  Novel production techniques may 
allow the production of materials with biomimetic structures that may enhance 
biocompatibility. 
 
In conclusion, it is the recommendation of this study that the optimal material tested 
in this project was ammonia plasma treated polyurethane.  The next stage of 
development would be to develop prototype prosthesis and perform in vivo testing to 
gather data on tissue regeneration and immune response. 
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Appendix 
Items in the appendix consist of supporting material of considerable length or 
additional data that would interrupt the flow of the thesis. 
A. Examination of Chitosan as a Bacteriostat  
A.1 Details of media used for the examination of chitosan as a bacteriostat 
157 
Nutrient agar (NA) 
 pH 7.4 approx 
 Oxoid code cm3 
 lot 01036886 
 2.8g per 100mls distilled water 
 formula [per litre] 
  lab-lemco powder [Oxoid L29] 1g 
  Yeast extract [Oxoid L20] 2g 
  Peptone [Oxoid L37] 5g 
  Sodium chloride  5g 
  Agar No 3 [Oxoid L13] 15g 
  
Nutrient broth (NB) 
 pH 7.5 +/- 0.2 
 Oxoid code cm67 
 lot 10559702 
 2.5g per 100mls distilled water 
 formula [per litre] 
  lab-lemco powder [Oxoid L29] 10g 
  Peptone [Oxoid L37] 10g 
  Sodium chloride  5g 
  
Plate Count Agar (PCA) 
 A medium for the enumeration of viable organisms on milk and dairy 
products 
 pH 7.0 approx 
 Oxoid code  CM325 
 formula [per litre] 
  Yeast extract [Oxoid L21] 2.5g 
  Tryptone [Oxoid L42] 5g 
  Dextrose  1g 
  Agar No1 [Oxoid L11] 9g 
Table A.1
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A.2 Unedited graph from Method 2c 
Chitosan Vs S.epidermis & MRSA 9551
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55
0
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MRSA 9551 1
MRSA 9551 0.1
MRSA 9551 0.01
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S.epidermis 0.1
S.epidermis 0.01
 
Fig. A.2 
Unedited graph for method 2c including 1g chitosan suspension reading. 
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A.3 Data from Method 4b 
Method 4b 
07/10/03 Data 
Table A.3 
Chitosan and MRSA data 
06/10/03 
initial inoculum 
  
cell count mean 
48.2 
cells per ml 
1.93 x 10
-8
 
cells in 200µl inoculum 
3.86  x 10
-7
 
Results from 07/10/2003  
  
cell counts from plate count 
agars (by dilution) cells per ml for these values (by dilution) 
Average of cells per 
ml values 
  10
-6
 10
 -7
 10
 -8
 10
-6
 10
 -7
 10
 -8
  
c1        
c2   962   9.62 x 10
-10
  
c3  44092   4.41 x 10
-11
   
       2.69 x 10
-11
 
        
0.02 - 1   3504   3.50 x 10
-11
  
0.02 - 2  593 290  5.93  x 10
-9
 2.90 x 10
-10
  
0.02 - 3   457   4.57 x 10
-10
  
       1.08 x 10
-11
 
        
0.04 - 1   248   2.48 x 10
-10
  
0.04 - 2        
0.04 - 3   1572   1.57 x 10
-11
  
       9.10 x 10
-10
 
        
0.06 - 1   412   4.12 x 10
-10
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0.06 - 2   29   2.90 x 10
-9
  
0.06 - 3        
       2.21 x 10
-10
 
        
0.08 - 1   352   3.52 x 10
-10
  
0.08 - 2   351   3.51 x 10
-10
  
0.08 - 3   649   6.49 x 10
-10
  
       4.51 x 10
-10
 
        
0.1 - 1        
0.1 - 2   3044   3.04 x 10
-11
  
0.1 - 3        
       3.04 x 10
-11
 
 
 
Results from 08/10/2003 
 
 
 
  
cell counts from plate count 
agars (by dilution) cells per ml for these values (by dilution) 
Average of cells per 
ml values 
  10
-6
 10
 -7
 10
 -8
 10
-6
 10
 -7
 10
 -8
   
c1   1016   1.02 x 10
-11
  
c2   407   4.07 x 10
-10
  
c3   3992   3.99 x 10
-11
  
       1.81 x 10
-11
 
        
0.02 - 1   3364   3.36 x 10
-11
  
0.02 - 2   1616   1.62 x 10
-11
  
0.02 - 3   2216   2.22 x 10
-11
  
       2.40 x 10
-11
 
        
0.04 - 1   305   3.05 x 10
-10
  
0.04 - 2   2276   2.28 x 10
-11
  
0.04 - 3   105   1.05 x 10
-10
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       8.95 x 10
-10
 
        
0.06 - 1   1920   1.92 x 10
-11
  
0.06 - 2   1800   1.80 x 10
-11
  
0.06 - 3   1788   1.79 x 10
-11
  
       1.84 x 10
-11
 
        
0.08 - 1   958   9.58 x 10
-10
  
0.08 - 2   788   7.88 x 10
-10
  
0.08 - 3   3200   3.20 x 10
-11
  
       1.65 x 10
-11
 
        
0.1 - 1   2340   2.34 x 10
-11
  
0.1 - 2   6636   6.64 x 10
-11
  
0.1 - 3   2416   2.42 x 10
-11
  
       3.80 x 10
-11
 
Results from 09/10/2003  
  
cell counts from plate count 
agars (by dilution) cells per ml for these values (by dilution) 
Average of cells per 
ml values 
  10
-6
 10
 -7
 10
 -8
 10
-6
 10
 -7
 10
 -8
   
c1   2610   2.61 x 10
-11
  
c2   1990   1.99 x 10
-11
  
c3   563   5.63 x 10
-10
  
       1.72 x 10
-11
 
        
0.02 - 1   1610   1.61 x 10
-11
  
0.02 - 2   1618   1.62 x 10
-11
  
0.02 - 3   1380   1.38 x 10
-11
  
       1.54 x 10
-11
 
        
0.04 - 1   842   8.42 x 10
-10
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0.04 - 2   1262   1.26 x 10
-11
  
0.04 - 3   1484   1.48 x 10
-11
  
       1.20 x 10
-11
 
        
0.06 - 1   1996   2.00 x 10
-11
  
0.06 - 2   2050   2.05 x 10
-11
  
0.06 - 3   1760   1.76 x 10
-11
  
       1.94 x 10
-11
 
        
0.08 - 1   3094   3.09 x 10
-11
  
0.08 - 2   2766   2.77 x 10
-11
  
0.08 - 3   1182   1.18 x 10
-11
  
       2.35 x 10
-11
 
        
0.1 - 1   2644   2.64 x 10
-11
  
0.1 - 2      0  
0.1 - 3   2228   2.23 x 10
-11
  
       1.62 x 10
-11
 
 
20/10/03 Data 
Table A.4 
Chitosan and MRSA data  20/10/03 
initial inoculum   
cell count mean 20.6 
cells per ml 
8.24 x 10
-7
 
cells in 200µl inoculum 
1.65 x 10
-7
 
  
Each culture for this experimental 
run was plated out two times (a & b)  
Results from 21/10/03  
  
cell counts from plate 
count agars (by 
cells per ml for these values (by 
dilution) 
Average of cells 
per ml values 
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dilution) 
  10
-7
 10
-8
 10
-9
 10
-7
 10
-8
 10
-9
   
c1a 1 1  1.00 x 10
-7
 1.00 x 10
-8
   
c1b  3   3.00 x 10
-8
   
c2a 85 11  8.50 x 10
-8
 1.10 x 10
-9
   
c2b 65 6 1 6.50 x 10
-8
 6.00 x 10
-8
 1.00 x 10
-9
  
c3a 60 11 3 6.00 x 10
-8
 1.10 x 10
-9
 3.00 x 10
-9
  
c3b 82 10  8.20 x 10
-8
 1.00 x 10
-9
   
       8.56 x 10
-8
 
        
0.002-1a 32 1  3.20 x 10
-8
 1.00 x 10
-8
   
0.002-1b 51 3  5.10 x 10
-8
 3.00 x 10
-8
   
0.002-2a 64 4 1 6.40 x 10
-8
 4.00 x 10
-8
 1.00 x 10
-9
  
0.002-2b 68 2 1 6.80 x 10
-8
 2.00 x 10
-8
 1.00 x 10
-9
  
0.002-3a  12 2  1.20 x 10
-9
 2.00 x 10
-9
  
0.002-3b        
       6.96 x 10
-8
 
        
0.004-1a 55 5 2 5.50 x 10
-8
 5.00 x 10
-8
 2.00 x 10
-9
  
0.004-1b 93 6 1 9.30 x 10
-8
 6.00 x 10
-8
 1.00 x 10
-9
  
0.004-2a 104 10  1.04 x 10
-9
 1.00 x 10
-9
   
0.004-2b 142 14 2 1.42 x 10
-9
 1.40 x 10
-9
 2.00 x 10
-9
  
0.004-3a 130 8  1.30 x 10
-9
 8.00 x 10
-8
   
0.004-3b 118 3  1.18 x 10
-9
 3.00 x 10
-8
   
       1.07 x 10
-9
 
        
0.006-1a 131 21  1.31 x 10
-9
 2.10 x 10
-9
   
0.006-1b 92 16  9.20 x 10
-8
 1.60 x 10
-9
   
0.006-2a 103 19  1.03 x 10
-9
 1.90 x 10
-9
   
0.006-2b 95 11  9.50 x 10
-8
 1.10 x 10
-9
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0.006-3a 71   7.10 x 10
-8
    
0.006-3b 78   7.80 x 10
-8
    
       1.24 x 10
-9
 
        
0.008-1a 46 65  4.60 x 10
-8
 6.50 x 10
-9
   
0.008-1b  11  0.00 1.10 x 10
-9
   
0.008-2a 16 16  1.60 x 10
-8
 1.60 x 10
-9
   
0.008-2b 28 9  2.80 x 10
-8
 9.00 x 10
-8
   
0.008-3a 198 12 3 1.98 x 10
-9
 1.20 x 10
-9
 3.00 x 10
-9
  
0.008-3b 180 9 2 1.80 x 10
-9
 9.00 x 10
-8
 2.00 x 10
-9
  
       1.56 x 10
-9
 
        
0.01-1a 0 10   1.00 x 10
-9
   
0.01-1b 42 11  4.20 x 10
-8
 1.10 x 10
-9
   
0.01-2a 74 14  7.40 x 10
-8
 1.40 x 10
-9
   
0.01-2b 62 8  6.20 x 10
-8
 8.00 x 10
-8
   
0.01-3a 1 9  1.00 x 10
-7
 9.00 x 10
-8
   
0.01-3b 0 0      
       7.77 x 10
-8
 
Results from 22/10/03  
  
cell counts from plate 
count agars (by 
dilution) 
cells per ml for these values (by 
dilution) 
Average of cells 
per ml values 
  10
-7
 10
-8
 10
-9
 10
-7
 10
-8
 10
-9
   
c1a 67 7 1 6.70 x 10
-8
 7.00 x 10
-8
 1.00 x 10
-9
  
c1b 18 9  1.80 x 10
-8
 9.00 x 10
-8
   
c2a 6 6  6.00 x 10
-7
 6.00 x 10
-8
   
c2b 30  1 3.00 x 10
-8
  1.00 x 10
-9
  
c3a 1   1.00 x 10
-7
    
c3b 24   2.40 x 10
-8
    
       5.15 x 10
-8
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0.002-1a  5 15  5.00 x 10
-8
 1.50 x 10
-10
  
0.002-1b 10   1.00 x 10
-8
    
0.002-2a 362   3.62 x 10
-9
    
0.002-2b 248   2.48 x 10
-9
    
0.002-3a 179   1.79 x 10
-9
    
0.002-3b 156   1.56 x 10
-9
    
       3.58 x 10
-9
 
        
0.004-1a        
0.004-1b        
0.004-2a        
0.004-2b        
0.004-3a        
0.004-3b        
        
        
0.006-1a        
0.006-1b        
0.006-2a 39   3.90 x 10
-8
    
0.006-2b 38   3.80 x 10
-8
    
0.006-3a 59   5.90 x 10
-8
    
0.006-3b 48   4.80 x 10
-8
    
       4.60 x 10
-8
 
        
0.008-1a        
0.008-1b        
0.008-2a        
0.008-2b        
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0.008-3a        
0.008-3b        
        
        
0.01-1a        
0.01-1b        
0.01-2a        
0.01-2b        
0.01-3a        
0.01-3b        
        
Results from 23/10/03  
  
cell counts from plate 
count agars (by 
dilution) 
cells per ml for these values (by 
dilution) 
Average of cells 
per ml values 
  10
-6
 10
 -7
 10
 -8
 10
-6
 10
 -7
 10
 -8
   
c1a 70 10  7.00 x 10
-7
 1.00 x 10
-8
   
c1b 49 3 2 4.90 x 10
-7
 3.00 x 10
-7
 2.00 x 10
-8
  
c2a 148 11 2 1.48 x 10
-8
 1.10 x 10
-8
 2.00 x 10
-8
  
c2b 199 16 3 1.99 x 10
-8
 1.60 x 10
-8
 3.00 x 10
-8
  
c3a 88 6  8.80 x 10
-7
 6.00 x 10
-7
   
c3b 77 3 1 7.70 x 10
-7
 3.00 x 10
-7
 1.00 x 10
-8
  
       1.20 x 10
-8
 
        
0.002-1a 95 6  9.50 x 10
-7
 6.00 x 10
-7
   
0.002-1b 119 6  1.19 x 10
-8
 6.00 x 10
-7
   
0.002-2a 108 8  1.08 x 10
-8
 8.00 x 10
-7
   
0.002-2b 187 5 1 1.87 x 10
-8
 5.00 x 10
-7
 1.00 x 10
-8
  
0.002-3a 35 2  3.50 x 10
-7
 2.00 x 10
-7
   
0.002-3b 49 5  4.90 x 10
-7
 5.00 x 10
-7
   
       7.79 x 10
-7
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0.004-1a 82 2  8.20 x 10
-7
 2.00 x 10
-7
   
0.004-1b 149 1  1.49 x 10
-8
 1.00 x 10
-7
   
0.004-2a 215 14  2.15 x 10
-8
 1.40 x 10
-8
   
0.004-2b 192 12 3 1.92 x 10
-8
 1.20 x 10
-8
 3.00 x 10
-8
  
0.004-3a 441 30 1 4.41 x 10
-8
 3.00 x 10
-8
 1.00 x 10
-8
  
0.004-3b 366 35  3.66 x 10
-8
 3.50 x 10
-8
   
       1.99 x 10
-8
 
        
0.006-1a 49 9  4.90 x 10
-7
 9.00 x 10
-7
   
0.006-1b 42 11  4.20 x 10
-7
 1.10 x 10
-8
   
0.006-2a 393 56 3 3.93 x 10
-8
 5.60 x 10
-8
 3.00 x 10
-8
  
0.006-2b 457 67 2 4.57 x 10
-8
 6.70 x 10
-8
 2.00 x 10
-8
  
0.006-3a 102 8 3 1.02 x 10
-8
 8.00 x 10
-7
 3.00 x 10
-8
  
0.006-3b 94 1 3 9.40 x 10
-7
 1.00 x 10
-7
 3.00 x 10
-8
  
       2.35 x 10
-8
 
        
0.008-1a 207 12 1 2.07 x 10
-8
 1.20 x 10
-8
 1.00 x 10
-8
  
0.008-1b 234 16  2.34 x 10
-8
 1.60 x 10
-8
   
0.008-2a 829 106 4 8.29 x 10
-8
 1.06 x 10
-9
 4.00 x 10
-8
  
0.008-2b 816 75 13 8.16 x 10
-8
 7.50 x 10
-8
 1.30 x 10
-9
  
0.008-3a 39 1  3.90 x 10
-7
 1.00 x 10
-7
   
0.008-3b 118 4  1.18 x 10
-8
 4.00 x 10
-7
   
       4.12 x 10
-8
 
        
0.01-1a 306 1 2 3.06 x 10
-8
 1.00 x 10
-7
 2.00 x 10
-8
  
0.01-1b 298 13 2 2.98 x 10
-8
 1.30 x 10
-8
 2.00 x 10
-8
  
0.01-2a 65 31 3 6.50 x 10
-7
 3.10 x 10
-8
 3.00 x 10
-8
  
0.01-2b 177 24 3 1.77 x 10
-8
 2.40 x 10
-8
 3.00 x 10
-8
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0.01-3a 110 48 5 1.10 x 10
-8
 4.80 x 10
-8
 5.00 x 10
-8
  
0.01-3b 98 40  9.80 x 10
-7
 4.00 x 10
-8
   
       2.43 x 10
-8
 
Large portions of the data for this study were uncountable; therefore there is no graph 
for these data. 
 
04/11/03 Data 
Table A.5 
Chitosan and MRSA data 04/11/03 
initial inoculum   
cell count mean 12.2 
cells per ml 
4.88 x 10
-7
 
cells in 200µl inoculum 
9.76 x 10
-6
 
Each culture for this experimental 
run was plated out two times (a & b)  
Results from 5/11/03  
  
cell counts from plate 
count agars (by 
dilution) 
cells per ml for these values (by 
dilution) 
Average of cells 
per ml values 
  10
-7
 10
-8
 10
-9
 10
-7
 10
-8
 10
-9
   
c1a 10 11 1 1.00 x 10
-8
 1.10 x 10
-9
 1.00 x 10
-9
  
c1b 50  35 5.00 x 10
-8
  3.50 x 10
-10
  
c2a 24 4 2 2.40 x 10
-8
 4.00 x 10
-8
 2.00 x 10
-9
  
c2b 26 6 1 2.60 x 10
-8
 6.00 x 10
-8
 1.00 x 10
-9
  
c3a 68 13  6.80 x 10
-8
 1.30 x 10
-9
   
c3b 103 11  1.03 x 10
-9
 1.10 x 10
-9
   
       3.09 x 10
-9
 
        
0.02 - 1a 80 2  8.00 x 10
-8
 2.00 x 10
-8
   
0.02 - 1b 54   5.40 x 10
-8
    
0.02 - 2a 64 8 3 6.40 x 10
-8
 8.00 x 10
-8
 3.00 x 10
-9
  
0.02 - 2b 87 10 1 8.70 x 10
-8
 1.00 x 10
-9
 1.00 x 10
-9
  
0.02 - 3a 60 7  6.00 x 10
-8
 7.00 x 10
-8
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0.02 - 3b 66 8  
6.60 x 
10
-8
 
8.00 x 
10
-8
 
  
       8.93 x 10
-8
 
        
0.04 - 1a 27 5  2.70 x 10
-8
 5.00 x 10
-8
   
0.04 - 1b 40 6  4.00 x 10
-8
 6.00 x 10
-8
   
0.04 - 2a 257 33 1 2.57 x 10
-9
 3.30 x 10
-9
 1.00 x 10
-9
  
0.04 - 2b 181 32 2 1.81 x 10
-9
 3.20 x 10
-9
 2.00 x 10
-9
  
0.04 - 3a 149 17  1.49 x 10
-9
 1.70 x 10
-9
   
0.04 - 3b 168 24 3 1.68 x 10
-9
 2.40 x 10
-9
 3.00 x 10
-9
  
       1.73 x 10
-9
 
        
0.06 - 1a 62 2  6.20 x 10
-8
 2.00 x 10
-8
   
0.06 - 1b 41 8  4.10 x 10
-8
 8.00 x 10
-8
   
0.06 - 2a 4 2  4.00 x 10
-7
 2.00 x 10
-8
   
0.06 - 2b 24  2 2.40 x 10
-8
  2.00 x 10
-9
  
0.06 - 3a 79 3 2 7.90 x 10
-8
 3.00 x 10
-8
 2.00 x 10
-9
  
0.06 - 3b 93 8 2 9.30 x 10
-8
 8.00 x 10
-8
 2.00 x 10
-9
  
       8.09 x 10
-8
 
        
0.08 - 1a 196 21 2 1.96 x 10
-9
 2.10 x 10
-9
 2.00 x 10
-9
  
0.08 - 1b 212 26  2.12 x 10
-9
 2.60 x 10
-9
   
0.08 - 2a 59 5  5.90 x 10
-8
 5.00 x 10
-8
   
0.08 - 2b 78 4 3 7.80 x 10
-8
 4.00 x 10
-8
 3.00 x 10
-9
  
0.08 - 3a 346 40 4 3.46 x 10
-9
 4.00 x 10
-9
 4.00 x 10
-9
  
0.08 - 3b 350 33  3.50 x 10
-9
 3.30 x 10
-9
   
       2.29 x 10
-9
 
        
0.1 - 1a 83 2  8.30 x 10
-8
 2.00 x 10
-8
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0.1 - 1b 7 2  7.00 x 10
-7
 2.00 x 10
-8
   
0.1 - 2a 14 3  1.40 x 10
-8
 3.00 x 10
-8
   
0.1 - 2b 45 7 1 4.50 x 10
-8
 7.00 x 10
-8
 1.00 x 10
-9
  
0.1 - 3a 90 4  9.00 x 10
-8
 4.00 x 10
-8
   
0.1 - 3b 95 8 1 9.50 x 10
-8
 8.00 x 10
-8
 1.00 x 10
-9
  
       5.67 x 10
-8
 
Results from 6/11/03  
  
cell counts from plate 
count agars (by 
dilution) 
cells per ml for these values (by 
dilution) 
Average of cells 
per ml values 
  10
-6
 10
 -7
 10
 -8
 10
-6
 10
 -7
 10
 -8
   
c1a  25 4 0.00 2.50 x 10
-8
 4.00 x 10
-8
  
c1b 837 40 5 8.37 x 10
-8
 4.00 x 10
-8
 5.00 x 10
-8
  
c2a 693  3 6.93 x 10
-8
  3.00 x 10
-8
  
c2b 580 76 8 5.80 x 10
-8
 7.60 x 10
-8
 8.00 x 10
-8
  
c3a  79 4  7.90 x 10
-8
 4.00 x 10
-8
  
c3b  73 15  7.30 x 10
-8
 1.50 x 10
-9
  
       6.91 x 10
-8
 
        
0.02 - 1a 501 51 4 5.01 x 10
-8
 5.10 x 10
-8
 4.00 x 10
-8
  
0.02 - 1b 405 52 2 4.05 x 10
-8
 5.20 x 10
-8
 2.00 x 10
-8
  
0.02 - 2a  280 36  2.80 x 10
-9
 3.60 x 10
-9
  
0.02 - 2b  246 27  2.46 x 10
-9
 2.70 x 10
-9
  
0.02 - 3a  66 14  6.60 x 10
-8
 1.40 x 10
-9
  
0.02 - 3b 651 60  6.51 x 10
-8
 6.00 x 10
-8
   
       1.24 x 10
-9
 
        
0.04 - 1a 59 5  5.90 x 10
-7
 5.00 x 10
-7
   
0.04 - 1b  4   4.00 x 10
-7
   
0.04 - 2a  159 11  1.59 x 10
-9
 1.10 x 10
-9
  
0.04 - 2b  149 9  1.49 x 10
-9
 9.00 x 10
-8
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0.04 - 3a 3408 328 24 3.41 x 10
-9
 3.28 x 10
-9
 2.40 x 10
-9
  
0.04 - 3b 2984 321 26 2.98 x 10
-9
 3.21 x 10
-9
 2.60 x 10
-9
  
       1.78 x 10
-9
 
        
0.06 - 1a 208 32 2 2.08 x 10
-8
 3.20 x 10
-8
 2.00 x 10
-8
  
0.06 - 1b 186 60 6 1.86 x 10
-8
 6.00 x 10
-8
 6.00 x 10
-8
  
0.06 - 2a 724 96 8 7.24 x 10
-8
 9.60 x 10
-8
 8.00 x 10
-8
  
0.06 - 2b  43 14  4.30 x 10
-8
 1.40 x 10
-9
  
0.06 - 3a  104 10  1.04 x 10
-9
 1.00 x 10
-9
  
0.06 - 3b  117 12  1.17 x 10
-9
 1.20 x 10
-9
  
       7.23 x 10
-8
 
        
0.08 - 1a  330 38  3.30 x 10
-9
 3.80 x 10
-9
  
0.08 - 1b  371 44  3.71 x 10
-9
 4.40 x 10
-9
  
0.08 - 2a  95 10  9.50 x 10
-8
 1.00 x 10
-9
  
0.08 - 2b  118 12  1.18 x 10
-9
 1.20 x 10
-9
  
0.08 - 3a  403 42  4.03 x 10
-9
 4.20 x 10
-9
  
0.08 - 3b  399 39  3.99 x 10
-9
 3.90 x 10
-9
  
       2.97 x 10
-9
 
        
0.1 - 1a 506 23 8 5.06 x 10
-8
 2.30 x 10
-8
 8.00 x 10
-8
  
0.1 - 1b  58 9  5.80 x 10
-8
 9.00 x 10
-8
  
0.1 - 2a 183 17 4 1.83 x 10
-8
 1.70 x 10
-8
 4.00 x 10
-8
  
0.1 - 2b 120 16 3 1.20 x 10
-8
 1.60 x 10
-8
 3.00 x 10
-8
  
0.1 - 3a 92 11 2 9.20 x 10
-7
 1.10 x 10
-8
 2.00 x 10
-8
  
0.1 - 3b 125 15 3 1.25 x 10
-8
 1.50 x 10
-8
 3.00 x 10
-8
  
       3.13 x 10
-8
 
Results from 7/11/03  
  
cell counts from plate 
count agars (by 
dilution) 
cells per ml for these values (by 
dilution) 
Average of cells 
per ml values 
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  10
-6
 10
 -7
 10
 -8
 10
-6
 10
 -7
 10
 -8
   
c1a 79 21  7.90 x 10
-7
 2.10 x 10
-8
   
c1b  23   2.30 x 10
-8
   
c2a  89   8.90 x 10
-8
   
c2b  91   9.10 x 10
-8
   
c3a  183   1.83 x 10
-9
   
c3b  185   1.85 x 10
-9
   
       1.14 x 10
-9
 
        
0.02 - 1a 256 34  2.56 x 10
-8
 3.40 x 10
-8
   
0.02 - 1b 284 36  2.84 x 10
-8
 3.60 x 10
-8
   
0.02 - 2a  297   2.97 x 10
-9
   
0.02 - 2b  291   2.91 x 10
-9
   
0.02 - 3a 538 40  5.38 x 10
-8
 4.00 x 10
-8
   
0.02 - 3b 536 58  5.36 x 10
-8
 5.80 x 10
-8
   
       9.17 x 10
-8
 
        
0.04 - 1a 508 47  5.08 x 10
-8
 4.70 x 10
-8
   
0.04 - 1b 535 56  5.35 x 10
-8
 5.60 x 10
-8
   
0.04 - 2a 222 16  2.22 x 10
-8
 1.60 x 10
-8
   
0.04 - 2b 36 11  3.60 x 10
-7
 1.10 x 10
-8
   
0.04 - 3a 693 100  6.93 x 10
-8
 1.00 x 10
-9
   
0.04 - 3b 778 106  7.78 x 10
-8
 1.06 x 10
-9
   
       5.11 x 10
-8
 
        
0.06 - 1a 565   5.65 x 10
-8
    
0.06 - 1b 363   3.63 x 10
-8
    
0.06 - 2a 314 25  3.14 x 10
-8
 2.50 x 10
-8
   
0.06 - 2b 297 15  2.97 x 10
-8
 1.50 x 10
-8
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0.06 - 3a  30  0.00 3.00 x 10
-8
   
0.06 - 3b  41  0.00 4.10 x 10
-8
   
       2.65 x 10
-8
 
        
0.08 - 1a 477 23  4.77 x 10
-8
 2.30 x 10
-8
   
0.08 - 1b 350 19  3.50 x 10
-8
 1.90 x 10
-8
   
0.08 - 2a  190   1.90 x 10
-9
   
0.08 - 2b  101   1.01 x 10
-9
   
0.08 - 3a 992 79  9.92 x 10
-8
 7.90 x 10
-8
   
0.08 - 3b 673 62  6.73 x 10
-8
 6.20 x 10
-8
   
       7.23 x 10
-8
 
        
0.1 - 1a 588 71  5.88 x 10
-8
 7.10 x 10
-8
   
0.1 - 1b 708 90  7.08 x 10
-8
 9.00 x 10
-8
   
0.1 - 2a  50   5.00 x 10
-8
   
0.1 - 2b 657 47  6.57 x 10
-8
 4.70 x 10
-8
   
0.1 - 3a 543 60  5.43 x 10
-8
 6.00 x 10
-8
   
0.1 - 3b 394 50  3.94 x 10
-8
 5.00 x 10
-8
   
       5.97 x 10
-8
 
 
18/01/05 Data 
Chitosan and MRSA data 18/01/05 
initial inoculum   
cell count mean 23.5 
cells per ml 
9.40 x 10
-7
 
cells in 200µl inoculum 
1.88 x 10
-7
 
Results from the 19th Jan 05  
  
cell counts from plate 
count agars (by 
dilution) 
cells per ml for these values (by 
dilution) 
Average of cells 
per ml values 
  10
-6
 10
 -7
 10
 -8
 10
-6
 10
 -7
 10
 -8
   
c1  262 16  2.62 x 10
-9
 1.60 x 10
-9
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c2   105   1.05 x 10
-10
  
c3  572 62  5.72 x 10
-9
 6.20 x 10
-9
  
       5.33 x 10
-9
 
        
0.02 - 1  365 59  3.65 x 10
-9
 5.90 x 10
-9
  
0.02 - 2   139   1.39 x 10
-10
  
0.02 - 3   36   3.60 x 10
-9
  
       6.76 x 10
-9
 
        
0.04 - 1   179   1.79 x 10
-10
  
0.04 - 2  904   9.04 x 10
-9
   
0.04 - 3   166   1.66 x 10
-10
  
       1.45 x 10
-10
 
        
0.06 - 1  423 47  4.23 x 10
-9
 4.70 x 10
-9
  
0.06 - 2   145   1.45 x 10
-10
  
0.06 - 3   155   1.55 x 10
-10
  
       9.73 x 10
-9
 
        
0.08 - 1 5560   5.56 x 10
-9
    
0.08 - 2  268 36  2.68 x 10
-9
 3.60 x 10
-9
  
0.08 - 3 2984   2.98 x 10
-9
    
       3.71 x 10
-9
 
        
0.1 - 1   151   1.51 x 10
-10
  
0.1 - 2   173   1.73 x 10
-10
  
0.1 - 3  376 118  3.76 x 10
-9
 1.18 x 10
-10
  
       1.20 x 10
-10
 
Results from the 20th  
  cell counts from plate cells per ml for these values (by Average of cells 
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count agars (by 
dilution) 
dilution) per ml values 
  10
-7
 10
-8
 10
-9
 10
-7
 10
-8
 10
-9
   
c1 117 15 1 1.17 x 10
-9
 1.50 x 10
-9
 1.00 x 10
-9
  
c2  68 10  6.80 x 10
-9
 1.00 x 10
-10
  
c3 120 16 1 1.20 x 10
-9
 1.60 x 10
-9
 1.00 x 10
-9
  
       3.03 x 10
-9
 
        
0.02 - 1   34   3.40 x 10
-10
  
0.02 - 2  92 2  9.20 x 10
-9
 2.00 x 10
-9
  
0.02 - 3  40 6  4.00 x 10
-9
 6.00 x 10
-9
  
       1.10 x 10
-10
 
        
0.04 - 1  53 16  5.30 x 10
-9
 1.60 x 10
-10
  
0.04 - 2  300 13  3.00 x 10
-10
 1.30 x 10
-10
  
0.04 - 3  75 15  7.50 x 10
-9
 1.50 x 10
-10
  
       1.45 x 10
-10
 
        
0.06 - 1 447 54 8 4.47 x 10
-9
 5.40 x 10
-9
 8.00 x 10
-9
  
0.06 - 2        
0.06 - 3 507   5.07 x 10
-9
    
       5.74 x 10
-9
 
        
0.08 - 1  48 8  4.80 x 10
-9
 8.00 x 10
-9
  
0.08 - 2  32   3.20 x 10
-9
   
0.08 - 3  78 9  7.80 x 10
-9
 9.00 x 10
-9
  
       6.56 x 10
-9
 
        
0.1 - 1 471 57 6 4.71 x 10
-9
 5.70 x 10
-9
 6.00 x 10
-9
  
0.1 - 2 547 90 5 5.47 x 10
-9
 9.00 x 10
-9
 5.00 x 10
-9
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0.1 - 3  69 5  6.90 x 10
-9
 5.00 x 10
-9
  
       5.97 x 10
-9
 
Results from the 23rd  
  
cell counts from plate 
count agars (by 
dilution) 
cells per ml for these values (by 
dilution) 
Average of cells 
per ml values 
  10
-6
 10
 -7
 10
 -8
 10
-6
 10
 -7
 10
 -8
   
c1  17   1.70 x 10
-8
   
c2  89 11  8.90 x 10
-8
 1.10 x 10
-9
  
c3  22 3  2.20 x 10
-8
 3.00 x 10
-8
  
       5.36 x 10
-8
 
        
0.02 - 1   60   6.00 x 10
-9
  
0.02 - 2  285 34  2.85 x 10
-9
 3.40 x 10
-9
  
0.02 - 3        
       4.08 x 10
-9
 
        
0.04 - 1   24   2.40 x 10
-9
  
0.04 - 2   387   3.87 x 10
-10
  
0.04 - 3   66   6.60 x 10
-9
  
       1.59 x 10
-10
 
        
0.06 - 1   56   5.60 x 10
-9
  
0.06 - 2  111 6  1.11 x 10
-9
 6.00 x 10
-8
  
0.06 - 3   35   3.50 x 10
-9
  
       2.70 x 10
-9
 
        
0.08 - 1   66   6.60 x 10
-9
  
0.08 - 2   51   5.10 x 10
-9
  
0.08 - 3   36   3.60 x 10
-9
  
       5.10 x 10
-9
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0.1 - 1  80 4  8.00 x 10
-8
 4.00 x 10
-8
  
0.1 - 2  39 4  3.90 x 10
-8
 4.00 x 10
-8
  
0.1 - 3  135 12  1.35 x 10
-9
 1.20 x 10
-9
  
       7.57 x 10
-8
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B. PLA pore size data 
PLA pore size measurement data 
Table B.1 pore size measurement from fig 4.24 (PLA 1) 
 
Area of picture 
Width of printed out 
PLA image (cm) 
Real width of PLA 
image measured (µm) 
Height of printed out 
PLA image (cm) 
Real height of PLA 
image measured 
(µm) 
20.3 31.72 20.36 31.81 
       
Real area (µm
2
)= 1009.05     
 pore size measurements 
Diameter of pore on 
printout (cm) 
Real pore Diameter  
(µm) 
Area of pore (pie x 
(Diameter )) (µm
2
)  
0.9 1.41 4.42  
1.2 1.88 5.89  
1.5 2.34 7.36  
1.1 1.72 5.40  
0.9 1.41 4.42  
0.8 1.25 3.93  
1 1.56 4.91  
3.8 5.94 18.65  
1.3 2.03 6.38  
2 3.13 9.82  
0.7 1.09 3.44  
0.8 1.25 3.93  
1.4 2.19 6.87  
0.7 1.09 3.44  
4.3 6.72 21.11  
2.7 4.22 13.25  
2.5 3.91 12.27  
1 1.56 4.91  
2.7 4.22 13.25  
1.5 2.34 7.36  
0.7 1.09 3.44  
0.6 0.94 2.95  
0.6 0.94 2.95  
3.3 5.16 16.20  
1.5 2.34 7.36  
0.7 1.09 3.44  
0.6 0.94 2.95  
1 1.56 4.91  
0.8 1.25 3.93  
0.8 1.25 3.93  
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2.1 3.28 10.31  
2 3.13 9.82  
1.5 2.34 7.36  
2.1 3.28 10.31  
0.6 0.94 2.95  
2 3.13 9.82  
1.8 2.81 8.84  
1 1.56 4.91  
1.7 2.66 8.34  
2 3.13 9.82  
0.7 1.09 3.44  
0.6 0.94 2.95  
2 3.13 9.82  
1.3 2.03 6.38  
1.8 2.81 8.84  
3.2 5.00 15.71  
2.5 3.91 12.27  
1.3 2.03 6.38  
1 1.56 4.91  
1.8 2.81 8.84  
1.1 1.72 5.40  
1.3 2.03 6.38  
0.7 1.09 3.44  
2 3.13 9.82  
2.3 3.59 11.29  
0.7 1.09 3.44  
0.6 0.94 2.95  
1.7 2.66 8.34  
0.5 0.78 2.45  
0.4 0.63 1.96  
0.9 1.41 4.42  
1.4 2.19 6.87  
0.9 1.41 4.42  
1.3 2.03 6.38  
0.7 1.09 3.44  
2 3.13 9.82  
1.9 2.97 9.33  
1 1.56 4.91  
1.5 2.34 7.36  
0.7 1.09 3.44  
0.9 1.41 4.42  
1.3 2.03 6.38  
0.9 1.41 4.42  
2.4 3.75 11.78  
2 3.13 9.82  
0.7 1.09 3.44  
2.4 3.75 11.78  
1 1.56 4.91  
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1.7 2.66 8.34  
1.4 2.19 6.87  
       
  
Average Pore area 
(µm
2
) 7.04  
  
Total area of pores 
(µm
2
) 563.03  
  Percentage pores (%) 55.80  
   St Dev of pore area 3.88  
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Table B.2 pore size measurement from fig 4.25 (PLA 2) 
 
Area of picture 
Width of printed out 
PLA image (cm) 
Real width of PLA 
image measured (µm) 
Height of printed out 
PLA image (cm) 
Real height of PLA 
image measured 
(µm) 
20.3 31.72 20.36 31.81 
       
Real area (µm
2
)= 1009.05     
      
 pore size measurements 
Diameter of pore on 
printout (cm) 
Real pore Diameter  
(µm) 
Area of pore (pie x 
(Diameter )) (µm
2
)  
2.7 4.22 13.25  
2.8 4.38 13.74  
1.8 2.81 8.84  
2.2 3.44 10.80  
2 3.13 9.82  
0.9 1.41 4.42  
0.8 1.25 3.93  
2.5 3.91 12.27  
1.9 2.97 9.33  
1.8 2.81 8.84  
1.2 1.88 5.89  
1 1.56 4.91  
0.7 1.09 3.44  
0.9 1.41 4.42  
1.1 1.72 5.40  
2.9 4.53 14.24  
0.6 0.94 2.95  
0.5 0.78 2.45  
1.2 1.88 5.89  
3.6 5.63 17.67  
0.8 1.25 3.93  
3.3 5.16 16.20  
0.9 1.41 4.42  
1 1.56 4.91  
1.2 1.88 5.89  
0.5 0.78 2.45  
0.5 0.78 2.45  
0.6 0.94 2.95  
0.4 0.63 1.96  
2 3.13 9.82  
4.1 6.41 20.13  
1.7 2.66 8.34  
1 1.56 4.91  
0.6 0.94 2.95  
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0.5 0.78 2.45  
0.7 1.09 3.44  
1 1.56 4.91  
1.1 1.72 5.40  
1 1.56 4.91  
0.8 1.25 3.93  
4.3 6.72 21.11  
1.3 2.03 6.38  
0.7 1.09 3.44  
0.9 1.41 4.42  
1 1.56 4.91  
0.6 0.94 2.95  
0.9 1.41 4.42  
0.7 1.09 3.44  
0.5 0.78 2.45  
2.1 3.28 10.31  
5.5 8.59 27.00  
1.5 2.34 7.36  
1.5 2.34 7.36  
3.6 5.63 17.67  
      
  
Average Pore 
area(µm
2
) 7.44  
  
Total area of pores 
(µm
2
) 402.03  
  Percentage pores (%) 39.84  
   St Dev of pore area 5.56  
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TableB.3 pore size measurement from fig 4.26 (PLA 3) 
Area of picture 
Width of printed out 
PLA image (cm) 
Real width of PLA 
image measured (µm) 
Height of printed out 
PLA image (cm) 
Real height of PLA 
image measured 
(µm) 
20.3 31.72 20.36 31.81 
       
Real area (µm
2
)= 1009.05     
  
 pore size measurements 
Diameter of pore on 
printout (cm) 
Real pore Diameter  
(µm) 
Area of pore (pie x 
(Diameter )) (µm
2
)  
2.5 3.91 12.27  
1.7 2.66 8.34  
1.3 2.03 6.38  
1.3 2.03 6.38  
1.3 2.03 6.38  
1.8 2.81 8.84  
1.9 2.97 9.33  
0.9 1.41 4.42  
2 3.13 9.82  
4.7 7.34 23.07  
1.2 1.88 5.89  
1.8 2.81 8.84  
1.3 2.03 6.38  
6.1 9.53 29.94  
2 3.13 9.82  
0.6 0.94 2.95  
5.5 8.59 27.00  
3.2 5.00 15.71  
5 7.81 24.54  
7.2 11.25 35.34  
1.2 1.88 5.89  
1.5 2.34 7.36  
2.5 3.91 12.27  
1.1 1.72 5.40  
1.2 1.88 5.89  
5.9 9.22 28.96  
1.2 1.88 5.89  
0.6 0.94 2.95  
1.2 1.88 5.89  
3 4.69 14.73  
2.1 3.28 10.31  
1.4 2.19 6.87  
2.5 3.91 12.27  
1.1 1.72 5.40  
2.5 3.91 12.27  
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1.8 2.81 8.84  
5.8 9.06 28.47  
4.7 7.34 23.07  
      
  
Average Pore 
area(µm
2
) 12.22  
  
Total area of pores 
(µm
2
) 464.37  
  Percentage pores (%) 46.02  
   St Dev of pore area 8.71  
 
C. Tissue culture study  
C.1 Tissue culture study raw data 
Assumptions 
All of the samples measure 30mm in length.  Each sample was tested 9 times.  All 
plasma treatment work was performed on the Riccarton apparatus unless stated 
otherwise. 
 
Key 
Grey table cells, couldn‟t be seen clearly enough to measure.  Media Red = no 
change in the pH of the media.  This means that the media is not being metabolised 
much/ at all by viable cells.  Media Orange = slight change in the pH of the media.   
This means that the media is being metabolised by cells in the flask.  21/08/2005, no 
data for inoculum.  An oversight due to late working hours and heavy work load. 
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Polypropylene Data 
 
Inoculation 
/cell count 
day (cells 
per ml) Cell growth up biomaterial strip (mm) 
Day 0 8 15 22 29 
Date 20/06/2006 28/06/2006 05/07/2006 12/07/2006 19/07/2006 
Polypropylene 1 140000 0.00 0.00 0.00 0.00 
Polypropylene 2 140000 0.00 0.00 0.00 0.00 
Polypropylene 3 140000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Argon plasma 1 140000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Argon plasma 2 140000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Argon plasma 3 140000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Ammonia plasma 1 140000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Ammonia plasma 2 140000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Ammonia plasma 3 140000 0.00 0.00 0.00 0.00 
Polypropylene coated with 
0.1% Chitosan solution 1 140000 0.00 0.00 0.00 0.00 
Polypropylene coated with 
0.1% Chitosan solution 2 140000 1.00 1.20 2.80 2.80 
Polypropylene coated with 
0.1% Chitosan solution 3 140000 3.50 2.50 5.00 5.00 
Polypropylene treated with 
Argon plasma then coated with 
0.1% Chitosan solution 1 140000 0.00 0.20 0.00 0.00 
Polypropylene treated with 140000 0.00 0.00 0.00 0.00 
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Argon plasma then coated with 
0.1% Chitosan solution 2 
Polypropylene treated with 
Argon plasma then coated with 
0.1% Chitosan solution 3 140000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 1 140000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 2 140000         
Polypropylene treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 3 140000 0.00 0.00 0.00 0.00 
 
Day 0 8 15 22 29 
Date 18/07/2006 26/07/2006 02/08/2006 09/08/2006 16/08/2006 
Polypropylene 1 330000 0.00 0.00 0.00 0.00 
Polypropylene 2 330000 0.00 0.00 0.00 0.00 
Polypropylene 3 330000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Argon plasma 1 330000 0.00 16.00 19.00 24.00 
Polypropylene treated with 
Argon plasma 2 330000 0.75 7.00 15.50 24.00 
Polypropylene treated with 
Argon plasma 3 330000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Ammonia plasma 1 330000 1.50 10.00 16.00 28.00 
Polypropylene treated with 
Ammonia plasma 2 330000 5.00 8.00 15.00 26.00 
Polypropylene treated with 
Ammonia plasma 3 330000 1.00 24.00 15.00 20.00 
Polypropylene coated with 
0.1% Chitosan solution 1 330000 0.00 0.00 0.00 0.00 
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Polypropylene coated with 
0.1% Chitosan solution 2 330000 4.50 11.50 19.00 19.00 
Polypropylene coated with 
0.1% Chitosan solution 3 330000 0.50 1.00 0.00 0.00 
Polypropylene treated with 
Argon plasma then coated with 
0.1% Chitosan solution 1 330000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Argon plasma then coated with 
0.1% Chitosan solution 2 330000 2.00 0.00 0.00 0.00 
Polypropylene treated with 
Argon plasma then coated with 
0.1% Chitosan solution 3 330000 0.50 4.00 2.00 2.00 
Polypropylene treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 1 330000 1.00 9.00 16.00 30.00 
Polypropylene treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 2 330000 0.00 10.00 15.50 15.50 
Polypropylene treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 3 330000 0.00 0.00 0.00 0.00 
 
Day 0 8 15 22 29 
Date 25/08/2006 02/09/2006 09/09/2006 16/09/2006 23/09/2006 
Polypropylene 1 190000 0.00 0.00 0.00 0.00 
Polypropylene 2 190000 0.00 0.00 30.00 30.00 
Polypropylene 3 190000 0.00 3.13 30.00 30.00 
Polypropylene treated with 
Argon plasma 1 190000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Argon plasma 2 190000 0.00 2.00 30.00 30.00 
Polypropylene treated with 
Argon plasma 3 190000 0.00 0.00 12.00 30.00 
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Polypropylene treated with 
Ammonia plasma 1 190000 3.00 0.50 20.00 30.00 
Polypropylene treated with 
Ammonia plasma 2 190000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Ammonia plasma 3 190000 1.50 4.00 5.00 30.00 
Polypropylene coated with 
0.1% Chitosan solution 1 190000 0.00 4.00 30.00 30.00 
Polypropylene coated with 
0.1% Chitosan solution 2 190000 1.00 3.75 22.50 30.00 
Polypropylene coated with 
0.1% Chitosan solution 3 190000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Argon plasma then coated with 
0.1% Chitosan solution 1 190000 9.00 14.00 30.00 30.00 
Polypropylene treated with 
Argon plasma then coated with 
0.1% Chitosan solution 2 190000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Argon plasma then coated with 
0.1% Chitosan solution 3 190000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 1 190000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 2 190000 0.00 0.00 0.00 0.00 
Polypropylene treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 3 190000 0.00 4.00 4.00 4.00 
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Polyurethane Data 
Day 0 8 15 22 29 
Date 14/07/2005 22/07/2005 29/07/2005 05/08/2005 12/08/2005 
Tuftane® Polyurethane 1 170000 0.00 0.00 0.00 0.00 
Tuftane® Polyurethane 2 170000 0.00 0.00 4.00 14.00 
Tuftane® Polyurethane 3 170000 0.00 0.00 0.00 0.00 
Tuftane® Polyurethane treated 
with Argon plasma 1 170000 5.20 24.00 30.00 30.00 
Tuftane® Polyurethane treated 
with Argon plasma 2 170000 4.00 30.00 30.00 30.00 
Tuftane® Polyurethane treated 
with Argon plasma 3 170000 0.00 1.00 6.00 10.00 
Tuftane® Polyurethane treated 
with Ammonia plasma 1 170000 0.00 0.00 30.00 26.00 
Tuftane® Polyurethane treated 
with Ammonia plasma 2 170000 5.00 9.00 11.00 16.00 
Tuftane® Polyurethane treated 
with Ammonia plasma 3 170000 0.50 6.25 28.00 30.00 
Tuftane® Polyurethane dusted 
with Chitosan powder then 
treated with Argon plasma 1 170000 2.50 6.00 30.00 30.00 
Tuftane® Polyurethane dusted 
with Chitosan powder then 
treated with Argon plasma 2 170000 0.00 0.00 0.00 0.00 
Tuftane® Polyurethane dusted 
with Chitosan powder then 
treated with Argon plasma 3 170000 0.00 0.00 0.00 2.25 
 
Day 0 8 15 22 29 
Date 21/08/2005 29/08/2005 05/09/2005 12/09/2005 19/09/2005 
Tuftane® Polyurethane 1   0.00 0.00 0.00 0.00 
Tuftane® Polyurethane 2   2.00 4.50 14.00 30.00 
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Tuftane® Polyurethane 3   0.00 0.20 4.50 24.00 
Tuftane® Polyurethane treated 
with Argon plasma 1   7.75 30.00 30.00 30.00 
Tuftane® Polyurethane treated 
with Argon plasma 2   0.00 0.40 0.00 0.00 
Tuftane® Polyurethane treated 
with Argon plasma 3   6.50 30.00 30.00 30.00 
Tuftane® Polyurethane treated 
with Ammonia plasma 1   0.00 30.00 30.00 30.00 
Tuftane® Polyurethane treated 
with Ammonia plasma 2   0.00 2.00 15.00 30.00 
Tuftane® Polyurethane treated 
with Ammonia plasma 3   0.00 6.00 30.00 30.00 
Tuftane® Polyurethane dusted 
with Chitosan powder then 
treated with Argon plasma 1   0.00 30.00 30.00 30.00 
Tuftane® Polyurethane dusted 
with Chitosan powder then 
treated with Argon plasma 2   2.00 0.00 1.00 0.00 
Tuftane® Polyurethane dusted 
with Chitosan powder then 
treated with Argon plasma 3   0.00 0.00 0.00 0.00 
Tuftane® Polyurethane treated 
with Argon plasma on the 
Europlasma machine 1   14.00 30.00 30.00 30.00 
Tuftane® Polyurethane treated 
with Argon plasma on the 
Europlasma machine 2   0.00 6.00 0.00 6.00 
Tuftane® Polyurethane treated 
with Argon plasma on the 
Europlasma machine 3   0.00 0.00 0.00 0.00 
Tuftane® Polyurethane treated 
with Argon plasma on the 
Europlasma machine 4   0.00 0.00 0.00 0.00 
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Tuftane® Polyurethane treated 
with Argon plasma on the 
Europlasma machine 5   7.00 30.00 30.00 30.00 
Tuftane® Polyurethane treated 
with Argon plasma on the 
Europlasma machine 6   0.00 0.00 0.00 0.00 
Tuftane® Polyurethane treated 
with Oxygen plasma on the 
Europlasma machine 1   0.00 0.00 0.00 0.00 
Tuftane® Polyurethane treated 
with Oxygen plasma on the 
Europlasma machine 2   0.00 0.00 0.00 0.00 
Tuftane® Polyurethane treated 
with Oxygen plasma on the 
Europlasma machine 3   0.00 0.00 0.00 0.00 
Tuftane® Polyurethane treated 
with Oxygen plasma on the 
Europlasma machine 4   0.00 9.00 30.00 30.00 
Tuftane® Polyurethane treated 
with Oxygen plasma on the 
Europlasma machine 5   4.00 8.50 23.00 30.00 
Tuftane® Polyurethane treated 
with Oxygen plasma on the 
Europlasma machine 6   0.00 0.00 0.00 0.00 
 
Day 0 8 15 22 29 
Date 25/08/2005 02/09/2005 09/09/2005 16/09/2005 23/09/2005 
Tuftane® Polyurethane 1 240000 4.00 4.00 21.00 25.00 
Tuftane® Polyurethane 2 240000 0.00 0.00 0.00 0.00 
Tuftane® Polyurethane 3 240000 0.00 0.00 0.00 0.00 
Tuftane® Polyurethane treated 
with Argon plasma 1 240000 0.00 0.00 0.00 2.00 
Tuftane® Polyurethane treated 
with Argon plasma 2 240000 0.00 0.00 0.00 0.00 
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Tuftane® Polyurethane treated 
with Argon plasma 3 240000 5.00 18.00 30.00 30.00 
Tuftane® Polyurethane treated 
with Ammonia plasma 1 240000 1.00 2.50 6.00 5.25 
Tuftane® Polyurethane treated 
with Ammonia plasma 2 240000 5.50 16.00 25.75 30.00 
Tuftane® Polyurethane treated 
with Ammonia plasma 3 240000 3.00 8.00 24.00 30.00 
Tuftane® Polyurethane dusted 
with Chitosan powder then 
treated with Argon plasma 1 240000 0.00 8.00 13.50 13.50 
Tuftane® Polyurethane dusted 
with Chitosan powder then 
treated with Argon plasma 2 240000 0.00 0.00 0.00 0.00 
Tuftane® Polyurethane dusted 
with Chitosan powder then 
treated with Argon plasma 3 240000 0.00 0.00 0.00 0.00 
Tuftane® Polyurethane treated 
with Argon plasma on the 
Europlasma machine 1 240000 0.00 0.00 0.00 0.00 
Tuftane® Polyurethane treated 
with Argon plasma on the 
Europlasma machine 2 240000 0.00 0.00 0.00 0.00 
Tuftane® Polyurethane treated 
with Argon plasma on the 
Europlasma machine 3 240000 0.00 0.00 0.00 0.00 
Tuftane® Polyurethane treated 
with Oxygen plasma on the 
Europlasma machine 1 240000 8.00 3.00 16.00 12.00 
Tuftane® Polyurethane treated 
with Oxygen plasma on the 
Europlasma machine 2 240000 0.00 0.00 0.00 0.00 
Tuftane® Polyurethane treated 
with Oxygen plasma on the 
Europlasma machine 3 240000 4.00 16.00 28.00 30.00 
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Polyester Data 
Day 0 8 15 22 29 
Date 16/07/2005 24/07/2005 31/07/2005 07/08/2005 14/08/2005 
Vascutek Polyester 1 100000 3.00 3.00 4.20 6.00 
Vascutek Polyester 2 100000 3.00 4.25 12.00 30.00 
Vascutek Polyester 3 100000 4.40 5.50 8.00 30.00 
Vascutek Polyester treated with 
Argon plasma 1 100000 0.00 0.00 0.00 0.00 
Vascutek Polyester treated with 
Argon plasma 2 100000 4.00 5.00 6.00 6.00 
Vascutek Polyester treated with 
Argon plasma 3 100000 0.00 0.00 0.00 0.00 
Vascutek Polyester treated with 
Ammonia plasma 1 100000 0.00 0.00 0.00 0.00 
Vascutek Polyester treated with 
Ammonia plasma 2 100000 0.00 0.00 0.00 0.00 
Vascutek Polyester treated with 
Ammonia plasma 3 100000 0.00 0.00 0.00 0.00 
 
Day 0 8 15 22 29 
Date 03/08/2005 11/08/2005 18/08/2005 25/08/2005 01/09/2005 
Vascutek Polyester 1 235000 2.50 4.00 5.00 7.50 
Vascutek Polyester 2 235000 0.00 0.00 0.00 0.00 
Vascutek Polyester 3 235000 2.20 3.00 4.00 6.88 
Vascutek Polyester treated with 
Argon plasma 1 235000 0.00 0.00 2.50 4.00 
Vascutek Polyester treated with 
Argon plasma 2 235000 0.00 0.00 0.00 0.00 
Vascutek Polyester treated with 
Argon plasma 3 235000 0.00 0.00 0.00 0.00 
Vascutek Polyester treated with 
Ammonia plasma 1 235000 0.00 0.00 0.00 0.00 
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Vascutek Polyester treated with 
Ammonia plasma 2 235000 0.00 0.00 0.00 0.00 
Vascutek Polyester treated with 
Ammonia plasma 3 235000 0.00 0.00 3.00 7.20 
 
Day 0 8 15 22 29 
Date 21/08/2005 29/08/2005 05/09/2005 12/09/2005 19/09/2005 
Vascutek Polyester 1   2.75 3.50 8.00 30.00 
Vascutek Polyester 2   4.00 4.00 9.00 26.00 
Vascutek Polyester 3   3.00 4.00 5.00 7.00 
Vascutek Polyester treated with 
Argon plasma 1   0.00 0.00 0.00 0.00 
Vascutek Polyester treated with 
Argon plasma 2   0.00 0.00 0.00 0.00 
Vascutek Polyester treated with 
Argon plasma 3   3.00 5.50 6.50 8.00 
Vascutek Polyester treated with 
Ammonia plasma 1   4.00 7.00 6.00 9.00 
Vascutek Polyester treated with 
Ammonia plasma 2   0.00 0.00 5.75 7.00 
Vascutek Polyester treated with 
Ammonia plasma 3   4.00 5.20 30.00 30.00 
 
Poly-ε-caprolactone Data 
Day 0 8 15 22 29 
Date 14/07/2005 20/07/2005 29/07/2005 05/08/2005 12/08/2005 
Poly-ε-caprolactone 6400 1 170000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 2 170000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 3 170000 0.00 0.00 0.00 0.40 
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Poly-ε-caprolactone 6400 
treated with Argon plasma 1 170000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 
treated with Argon plasma 2 170000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 
treated with Argon plasma 3 170000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 
treated with Ammonia plasma 1 170000 0.00 2.00 4.00 6.00 
Poly-ε-caprolactone 6400 
treated with Ammonia plasma 2 170000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 
treated with Ammonia plasma 3 170000 0.00 0.00 0.00 0.00 
 
Day 0 8 15 22 29 
Date 18/07/2005 26/07/2005 02/08/2005 09/08/2005 16/08/2005 
Poly-ε-caprolactone 6400 1 330000 1.00 2.00 0.00 0.00 
Poly-ε-caprolactone 6400 2 330000 2.00 8.00 9.00 6.00 
Poly-ε-caprolactone 6400 3 330000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 
treated with Argon plasma 1 330000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 
treated with Argon plasma 2 330000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 
treated with Argon plasma 3 330000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 
treated with Ammonia plasma 1 330000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 
treated with Ammonia plasma 2 330000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 
treated with Ammonia plasma 3 330000 0.00 0.00 0.00 0.00 
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Day 0 8 15 22 29 
Date 25/08/2005 02/09/2005 09/09/2005 16/09/2005 23/09/2005 
Poly-ε-caprolactone 6400 1 240000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 2 240000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 3 240000 0.00 0.00 0.00 0.00 
Poly-ε-caprolactone 6400 
treated with Argon plasma 1 240000 0.00 8.00 8.00 8.00 
Poly-ε-caprolactone 6400 
treated with Argon plasma 2 240000         
Poly-ε-caprolactone 6400 
treated with Argon plasma 3 240000         
Poly-ε-caprolactone 6400 
treated with Ammonia plasma 1 240000 0.00 5.00 10.00 30.00 
Poly-ε-caprolactone 6400 
treated with Ammonia plasma 2 240000         
Poly-ε-caprolactone 6400 
treated with Ammonia plasma 3 240000 0.00 5.00 10.00 30.00 
 
Solanyl Flexibilitis Data 
Day 0 8 15 22 29 
Date 20/06/2005 28/06/2005 05/07/2005 12/07/2005 19/07/2005 
Solanyl Flexibilitis 1 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis 2 140000 1.50 0.00 0.00 0.00 
Solanyl Flexibilitis 3 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Argon plasma 1 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Argon plasma 2 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Argon plasma 3 140000 0.00 0.00 0.00 0.00 
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Solanyl Flexibilitis treated with 
Ammonia plasma 1 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Ammonia plasma 2 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Ammonia plasma 3 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis extruded 
with 2% Chitosan powder 
(w/w) 1 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis extruded 
with 2% Chitosan powder 
(w/w) 2 140000 0.50 0.00 0.00 0.00 
Solanyl Flexibilitis extruded 
with 2% Chitosan powder 
(w/w) 3 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis coated with 
0.1% Chitosan solution 1 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis coated with 
0.1% Chitosan solution 2 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis coated with 
0.1% Chitosan solution 3 140000 0.00 0.00 0.00 2.00 
Solanyl Flexibilitis treated with 
Argon plasma then coated with 
0.1% Chitosan solution 1 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Argon plasma then coated with 
0.1% Chitosan solution 2 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Argon plasma then coated with 
0.1% Chitosan solution 3 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 1 140000 0.00 0.00 0.00 0.00 
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Solanyl Flexibilitis treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 2 140000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 3 140000 0.00 0.00 0.00 0.00 
 
Day 0 8 15 22 29 
Date 03/08/2005 11/08/2005 18/08/2005 25/08/2005 01/09/2005 
Solanyl Flexibilitis 1 235000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis 2 235000 0.00 0.00 0.00 21.00 
Solanyl Flexibilitis 3 235000 0.00 0.00 7.00 0.00 
Solanyl Flexibilitis treated with 
Argon plasma 1 235000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Argon plasma 2 235000 0.00 0.50 27.00 19.00 
Solanyl Flexibilitis treated with 
Argon plasma 3 235000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Ammonia plasma 1 235000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Ammonia plasma 2 235000 2.00 16.00 24.00 30.00 
Solanyl Flexibilitis treated with 
Ammonia plasma 3 235000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis extruded 
with 2% Chitosan powder 
(w/w) 1 235000 0.00 0.00 15.00 30.00 
Solanyl Flexibilitis extruded 
with 2% Chitosan powder 
(w/w) 2 235000 0.00 1.75 15.00 30.00 
Solanyl Flexibilitis extruded 
with 2% Chitosan powder 
(w/w) 3 235000 0.00 0.00 0.00 0.00 
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Solanyl Flexibilitis coated with 
0.1% Chitosan solution 1 235000 0.00 1.00 0.00 0.00 
Solanyl Flexibilitis coated with 
0.1% Chitosan solution 2 235000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis coated with 
0.1% Chitosan solution 3 235000 0.00 7.00 7.00 17.50 
Solanyl Flexibilitis treated with 
Argon plasma then coated with 
0.1% Chitosan solution 1 235000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Argon plasma then coated with 
0.1% Chitosan solution 2 235000 0.00 0.00 0.00 4.00 
Solanyl Flexibilitis treated with 
Argon plasma then coated with 
0.1% Chitosan solution 3 235000 0.00 6.00 6.00 26.00 
Solanyl Flexibilitis treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 1 235000 0.00 4.00 2.00 21.00 
Solanyl Flexibilitis treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 2 235000 0.00 0.25 5.00 30.00 
Solanyl Flexibilitis treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 3 235000 0.00 1.00 16.00 30.00 
 
Day 0 8 15 22 29 
Date 25/08/2005 02/09/2005 09/09/2005 16/09/2005 23/09/2005 
Solanyl Flexibilitis 1 190000 14.50 24.00 30.00 30.00 
Solanyl Flexibilitis 2 190000 0.00 6.00 0.00 0.00 
Solanyl Flexibilitis 3 190000  n/a n/a  n/a  n/a 
Solanyl Flexibilitis treated with 
Argon plasma 1 190000  n/a n/a  n/a  n/a 
Solanyl Flexibilitis treated with 
Argon plasma 2 190000  n/a n/a  n/a  n/a 
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Solanyl Flexibilitis treated with 
Argon plasma 3 190000  n/a n/a  n/a  n/a 
Solanyl Flexibilitis treated with 
Ammonia plasma 1 190000  n/a n/a  n/a  n/a 
Solanyl Flexibilitis treated with 
Ammonia plasma 2 190000  n/a n/a  n/a  n/a 
Solanyl Flexibilitis treated with 
Ammonia plasma 3 190000  n/a n/a  n/a  n/a 
Solanyl Flexibilitis extruded 
with 2% Chitosan powder 
(w/w) 1 190000  n/a n/a  n/a  n/a 
Solanyl Flexibilitis extruded 
with 2% Chitosan powder 
(w/w) 2 190000  n/a n/a  n/a  n/a 
Solanyl Flexibilitis extruded 
with 2% Chitosan powder 
(w/w) 3 190000  n/a n/a  n/a  n/a 
Solanyl Flexibilitis coated with 
0.1% Chitosan solution 1 190000 0.00 0.00 8.00 10.00 
Solanyl Flexibilitis coated with 
0.1% Chitosan solution 2 190000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis coated with 
0.1% Chitosan solution 3 190000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Argon plasma then coated with 
0.1% Chitosan solution 1 190000 0.00 0.00 0.00 0.00 
Solanyl Flexibilitis treated with 
Argon plasma then coated with 
0.1% Chitosan solution 2 190000 0.00 0.00 13.25 8.00 
Solanyl Flexibilitis treated with 
Argon plasma then coated with 
0.1% Chitosan solution 3 190000 3.00 30.00 30.00 30.00 
Solanyl Flexibilitis treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 1 190000 0.00 0.00 0.00 0.00 
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Solanyl Flexibilitis treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 2 190000 2.00 28.00 30.00 30.00 
Solanyl Flexibilitis treated with 
Ammonia plasma then coated 
with 0.1% Chitosan solution 3 190000 0.00 0.00 0.00 0.00 
 
Poly-L-Lactic acid Data 
Day 0 8 15 22 29 
Date 16/07/2005 24/07/2005 31/07/2005 07/08/2005 14/08/2005 
Poly-L-Lactic acid 1 100000 0.00 17.50 17.50 30.00 
Poly-L-Lactic acid 2 100000 2.00 0.00 0.00 0.00 
Poly-L-Lactic acid 3 100000 0.50 0.00 0.00 0.00 
Poly-L-Lactic acid treated with 
Argon plasma 1 100000 0.00 0.00 0.00 0.00 
Poly-L-Lactic acid treated with 
Argon plasma 2 100000 0.00 0.00 0.00 0.00 
Poly-L-Lactic acid treated with 
Argon plasma 3 100000 6.00 30.00 30.00 30.00 
Poly-L-Lactic acid treated with 
Ammonia plasma 1 100000 0.00 2.50 0.00 0.00 
Poly-L-Lactic acid treated with 
Ammonia plasma 2 100000 0.00 0.00 0.00 0.00 
Poly-L-Lactic acid treated with 
Ammonia plasma 3 100000 3.00 3.00 30.00 30.00 
 
Day 0 8 15 22 29 
Date 21/08/2005 29/08/2005 05/09/2005 12/09/2005 19/09/2005 
Poly-L-Lactic acid 1   Can‟t 
measure. 
Cells 
growing on 
Cell 
attachment, 
can't 
measure. 
Cell 
attachment, 
can't 
measure. 
Cell 
attachment 
at both 
ends. Can't 
202 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. 
Media 
remained 
red 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. Media 
turned 
orange 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. 
Media 
turned 
orange 
measure, 
probably 
all the 
way. Cells 
growing 
on 
capillary 
tube + 
cells 
growing 
on tissue 
culture 
flask. 
Media 
turned 
orange 
Poly-L-Lactic acid 2   Can‟t 
measure. 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. 
Media 
turned 
orange 
Cell 
attachment, 
can't 
measure. 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. Media 
turned 
orange 
Cell 
attachment, 
can't 
measure. 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. 
Media 
turned 
orange 
Cell 
attachment 
at both 
ends. Can't 
measure, 
probably 
all the 
way. + 
Cells 
growing 
on 
capillary 
tube + 
cells 
growing 
on tissue 
culture 
flask. 
Media 
turned 
orange 
Poly-L-Lactic acid 3   Can‟t 
measure. 
Cell 
attachment, 
Cell 
attachment, 
Cell 
attachment 
203 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. 
Media 
remained 
red 
can't 
measure. 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. Media 
turned 
orange 
can't 
measure. 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. 
Media 
turned 
orange 
at both 
ends. Can't 
measure, 
probably 
all the 
way. + 
Cells 
growing 
on 
capillary 
tube + 
cells 
growing 
on tissue 
culture 
flask. 
Media 
turned 
orange 
Poly-L-Lactic acid treated with 
Argon plasma 1 
  Can‟t 
measure. 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. 
Media 
turned 
orange 
Cell 
attachment, 
can't 
measure. 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. Media 
turned 
orange 
Cell 
attachment, 
can't 
measure. 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. 
Media 
turned 
orange 
Cell 
attachment 
at both 
ends. Can't 
measure, 
probably 
all the 
way. + 
Cells 
growing 
on 
capillary 
tube + 
cells 
growing 
on tissue 
culture 
flask. 
Media 
turned 
orange 
204 
Poly-L-Lactic acid treated with 
Argon plasma 2 
  0 0 0 0 
Poly-L-Lactic acid treated with 
Argon plasma 3 
  Can‟t 
measure 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. 
Media 
remained 
red 
Few Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. Media 
turned 
orange. 
Cell 
attachment, 
can't 
measure. 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. 
Media 
turned 
orange 
Cell 
attachment 
at one end, 
can't 
measure + 
cells 
growing 
on 
capillary 
tube + 
cells 
growing 
on tissue 
culture 
flask. 
Media 
turned 
orange 
Poly-L-Lactic acid treated with 
Ammonia plasma 1 
  Cell 
attachment. 
No cells 
growing on 
capillary 
tube or 
tissue 
culture 
flask. 
Media 
remained 
red 
Cell 
attachment, 
cells 
growing on 
capillary 
tube. Media 
turned 
orange 
Cell 
attachment, 
can't 
measure. 
Cells 
growing on 
capillary 
tube + cells 
growing on 
tissue 
culture 
flask. 
Media 
turned 
orange 
Cell 
attachment 
at one end, 
possibly 
the  other, 
can't 
measure + 
cells 
growing 
on 
capillary 
tube + 
cells 
growing 
on tissue 
culture 
flask. 
Media 
turned 
205 
orange 
Poly-L-Lactic acid treated with 
Ammonia plasma 2 
  0 0 0 0 
Poly-L-Lactic acid treated with 
Ammonia plasma 3 
  Cell 
attachment. 
No cells 
growing on 
capillary 
tube or 
tissue 
culture 
flask. 
Media 
remained 
red 
Cell 
attachment, 
cells 
growing on 
capillary 
tube + cells 
growing on 
tissue 
culture 
flask. 
Media 
turned 
orange 
Cell 
attachment, 
can't 
measure, 
cells 
growing on 
capillary 
tube + cells 
growing on 
tissue 
culture 
flask. 
Media 
turned 
orange 
Cell 
attachment 
at one end, 
possibly 
the  other, 
can't 
measure + 
cells 
growing 
on 
capillary 
tube + 
cells 
growing 
on tissue 
culture 
flask. 
Media 
turned 
orange 
 
Day 0 8 15 22 29 
Date 25/08/2005 02/09/2005 09/09/2005 16/09/2005 23/09/2005 
Poly-L-Lactic acid 1 240000 Few cells 
growing 
on 
capillary 
tube. 
sample 
came off 
Cell 
attachment. 
Free 
floating. 
Possibly 
confluent. 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
Cell 
attachment, 
can't 
measure. 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
Can‟t 
measure. 
(Free 
floating. 
Both ends 
have cells. 
Few cells 
growing 
on tissue 
culture 
flask, + 
cells 
206 
growing on 
capillary 
tube. Media 
turned 
orange 
tube. 
Media 
turned 
orange 
growing 
on 
capillary 
tube. 
Media 
turned 
orange 
Poly-L-Lactic acid 2 240000 Few Cells 
growing 
on tissue 
culture 
flask. No 
cells 
growing 
on 
capillary 
tube. 
Cell 
attachment, 
free 
floating. 
Cells 
growing on 
capillary 
tube. Media 
remained 
red 
Cell 
attachment, 
can't 
measure. 
Cells 
growing on 
tissue 
culture 
flask, + 
cells 
growing on 
capillary 
tube. 
Media 
turned 
orange 
Cells on 
one end 
contracting 
sample. 
Can't 
measure. 
Probably 
not on 
other end. 
Cells 
growing 
on tissue 
culture 
flask. 
Media 
turned 
orange 
Poly-L-Lactic acid 3 240000 0 0 0 0 
Poly-L-Lactic acid treated with 
Argon plasma 1 
240000 0 0 0 0 
Poly-L-Lactic acid treated with 
Argon plasma 2 
240000 0 0 0 0 
Poly-L-Lactic acid treated with 
Argon plasma 3 
240000 0 0 0 0 
Poly-L-Lactic acid treated with 
Ammonia plasma 1 
240000 0 0 0 0 
Poly-L-Lactic acid treated with 
Ammonia plasma 2 
240000 0 0 0 0 
Poly-L-Lactic acid treated with 
Ammonia plasma 3 
240000 0 0 0 0 
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C.2 Fluorescence images 
 
Below, a list of tissue culture samples with the measurements from the last day of 
measuring growth along the sample, with corresponding fluorescence images and 
descriptions from the last day of each sample.  Where there are no fluorescence 
images, there was either nothing to see, or no good image could be obtained. 
 
 Sample Growth measured on 
previous day and 
observations 
Notes recorded 
during 
fluorescence 
measurement 
Fluorescence microscopy images 
(and image number) 
Day 0 29 30  
Date 20/06/2005 19/07/2005 20/07/2005  
Polypropylene 1 0.0 mm no visible cells No image 
Polypropylene 2 0.0 mm no visible cells No image 
Polypropylene 3 0.0 mm no visible cells No image 
Polypropylene + 
Argon 1 
0.0 mm no visible cells 
No image 
Polypropylene + 
Argon 2 
0.0 mm no visible cells 
No image 
Polypropylene + 
Argon 3 
0.0 mm no visible cells 
No image 
Polypropylene + 
ammonia 1 
0.0 mm no visible cells 
No image 
Polypropylene + 
ammonia 2 
0.0 mm no visible cells 
No image 
Polypropylene + 
ammonia 3 
0.0 mm no visible cells 
No image 
Polypropylene  + 
Chitosan 1 
0.0 mm no visible cells 
No image 
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Polypropylene  + 
Chitosan 2 
2.8 mm  + cells 
growing on capillary 
tube 
 
2.1 
2.2 
2.3 
Polypropylene  + 
Chitosan 3 
5 mm  + cells 
growing on capillary 
tube 
 
3.1 
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3.2 
3.3 
3.4 
3.5 
210 
 
Polypropylene + 
Argon + Chitosan 1 
0.0 mm  
1.1 
1.2 
Polypropylene + 
Argon + Chitosan 2 
0.0 mm  
2.1 
2.2 
Polypropylene + 0.0 mm no visible cells No image 
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Argon + Chitosan 3 
Polypropylene + 
ammonia + Chitosan 
1 
0.0 mm no visible cells 
No image 
Polypropylene + 
ammonia + Chitosan 
2 
0.0 mm no visible cells 
No image 
Polypropylene + 
ammonia + Chitosan 
3 
0.0 mm no visible cells 
No image 
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Day 0 29.0   
Date 20/06/2005 19/07/2005 20/07/2005  
Solanyl  1 0.0 mm no visible cells No image 
Solanyl 2 0.0 mm no visible cells No image 
Solanyl  3 0.0 mm no visible cells 
3.1 
3.2 
Solanyl + Argon 1 0.0 mm no visible cells No image 
Solanyl + Argon 2 0.0 mm no visible cells No image 
Solanyl + Argon 3 0.0 mm no visible cells No image 
Solanyl + ammonia 1 0.0 mm no visible cells No image 
Solanyl + ammonia 2 0.0 mm no visible cells No image 
Solanyl + ammonia 3 0.0 mm no visible cells No image 
Solanyl  2% Chitosan 
1 
0.0 mm no visible cells No image 
Solanyl  2% Chitosan 
2 
0.0 mm no visible cells No image 
Solanyl  2% Chitosan 0.0 mm no visible cells No image 
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3 
Solanyl  + Chitosan 1 0.0 mm no visible cells No image 
Solanyl  + Chitosan 2 0.0 mm no visible cells No image 
Solanyl  + Chitosan 3 2 mm  + cells 
growing on capillary 
tube 
no visible cells No image 
Solanyl + Argon + 
Chitosan 1 
0.0 mm no visible cells No image 
Solanyl + Argon + 
Chitosan 2 
0.0 mm no visible cells No image 
Solanyl + Argon + 
Chitosan 3 
0.0 mm no visible cells No image 
Solanyl + ammonia + 
Chitosan 1 
0.0 mm no visible cells No image 
Solanyl + ammonia + 
Chitosan 2 
0.0 mm no visible cells 
No image 
Solanyl + ammonia + 
Chitosan 3 
0.0 mm no visible cells 
No image 
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Day 0.0 29.0 31.0  
Date 14/07/2005 12/08/2005 14/08/2005  
Polyurethane 1 0 mm   Media 
remained red 
no visible cells 
No image 
Polyurethane  2 14 mm + cells 
growing on capillary 
tube. Media turned 
orange. 
2 pictures 
3.1 
3.2 
Polyurethane  3 0 mm   Media 
remained red 
no visible cells 
No image 
Polyurethane  + 
Argon 1 
30 mm + cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange. 
4 pictures 
1.1 
215 
 
1.2 
1.3 
1.4 
Polyurethane  + 
Argon 2 
30 mm + cells 
growing on capillary 
tube    + cells 
growing on tissue 
culture flask.  Media 
turned orange. 
5 pictures 
2.1 
216 
 
2.2 
2.2 
2.3 
2.4 
217 
 
Polyurethane  + 
Argon 3 
10 mm + cells 
growing on capillary 
tube    + cells 
growing on tissue 
culture flask. Media 
turned orange. 
cells 1/4 way 
up 
3.1 
3.2 
Polyurethane  + 
ammonia 1 
26 mm + cells 
growing on capillary 
tube    + cells 
growing on tissue 
culture flask. Media 
turned orange. 
 
1.1 
Polyurethane  + 
ammonia 2 
16 mm + cells 
growing on capillary 
tube    + cells 
growing on tissue 
culture flask. Media 
turned orange. 
 
2.1 
218 
 
2.2 
2.3 
2.4 
Polyurethane  + 
ammonia 3 
30 mm + cells 
growing on capillary 
tube    + cells 
growing on tissue 
culture flask. Media 
turned orange. 
 
3.1 
219 
 
3.2 
3.3 
Polyurethane  + 
Argon + Chitosan 
powder  1 
30 mm + cells 
growing on capillary 
tube    + cells 
growing on tissue 
culture flask. Media 
turned orange. 
  
1.1 
1.2 
220 
 
1.3 
1.4 
1.5 
1.6 
221 
 
Polyurethane  + 
Argon + Chitosan 
powder  2 
0  mm  Media 
remained red 
no visible cells 
2.1 
Polyurethane  + 
Argon + Chitosan 
powder  3 
2.25 mm  + cells 
growing on capillary 
tube   Media 
remained red 
Growth ¼ 
along the 
length of 
sample? No image 
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Day 0.0 29.0 31.0  
Date 14/07/2005 12/08/2005 14/07/2005  
polycaprolactone  1 0 mm   Media 
remained red 
no visible cells 
No image 
polycaprolactone  2 0  mm  Media 
remained red 
no visible cells 
No image 
polycaprolactone  3 0.4 mm + cells 
growing on capillary 
tube    + cells 
growing on tissue 
culture flask. Media 
turned orange. 
one end of 
sample 
3.1 
3.2 
polycaprolactone  + 
Argon 1 
0 mm   Media 
remained red 
no visible cells 
No image 
polycaprolactone  + 
Argon 2 
0  mm  Media 
remained red 
Growth at both 
ends.  
2.1= one end 
2.1 
223 
 
2.2 
2.3 
2.4 
polycaprolactone  + 
Argon 3 
0 mm   Media 
remained red 
Cells span 1/3 
of sample from 
one end and ½ 
way along 
sample from 
other end 
3.1 
224 
 
3.2 
3.3 
3.4 
polycaprolactone  + 
ammonia 1 
6 mm + cells growing 
on capillary tube    + 
cells growing on 
tissue culture flask. 
Media turned orange. 
1/4 to 1/2 
1.1 
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polycaprolactone  + 
ammonia 2 
0.0 mm   Media 
remained red 
no visible cells 
2.1 
polycaprolactone  + 
ammonia 3 
0 mm   Media 
remained red 
1/3 to 1/2 
3.1 
 
226 
 
Day 0.0 29.0 30.0  
Date 16/07/2005 14/08/2005 15/08/2005  
Polyester  1 6 mm + cells growing 
on capillary tube    + 
cells growing on 
tissue culture flask. 
Media turned orange. 
Cells visible 
all the way 
along sample 
or fibres 
fluorescing 
1.1 
1.2 
1.2 zoom 
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Polyester  2 11 mm dense, 30 mm 
total + cells growing 
on capillary tube    + 
cells growing on 
tissue culture flask. 
Media turned orange. 
Cells visible 
all the way 
along sample 
or fibres 
fluorescing 
2.1 
2.1 zoom 
2.2 
Polyester  3 8 mm dense, 30 mm 
total + cells growing 
on capillary tube    + 
cells growing on 
tissue culture flask. 
Media turned orange. 
Cells visible 
all the way 
along sample 
or fibres 
fluorescing 
3.1 
228 
 
3.2 
3.3 
3.3 zoom 
Polyester  + Argon 1 0 mm   Media 
remained red 
Cells visible 
all the way 
along sample 
or fibres 
fluorescing 
1.1 
229 
 
1.2 zoom 
Polyester  + Argon 2 6 mm + cells growing 
on capillary tube    + 
cells growing on 
tissue culture flask. 
Media turned orange. 
Cells visible 
all the way 
along sample 
or fibres 
fluorescing 
2.1 
2.2 zoom 
Polyester  + Argon 3 0 mm   Media 
remained red 
Cells visible 
all the way 
along sample 
or fibres 
fluorescing 
3.1 
230 
 
3.2 zoom 
Polyester  + ammonia 
1 
0 mm   Media 
remained red 
Cells visible 
all the way 
along sample 
or fibres 
fluorescing 
1.1 
1.2 zoom 
Polyester  + ammonia 
2 
0 mm   Media 
remained red 
Cells visible 
all the way 
along sample 
or fibres 
fluorescing 
2.1 
231 
 
2.2 zoom 
Polyester  + ammonia 
3 
0 mm   Media 
remained red 
Cells visible 
all the way 
along sample 
or fibres 
fluorescing 
3.1 
3.1 zoom 
3.2 
232 
 
Day 0.0 29.0 30.0  
Date 16/07/2005 14/08/2005 15/08/2005  
Polylactic acid  1 Cells growing on 
capillary tube    + 
cells growing on 
tissue culture flask, 
possibly all the way.  
Cells visible 
all the way 
along sample 
1.1 
1.2 
1.3 
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1.4 
Polylactic acid  2 Cells growing on 
capillary tube    + 
cells growing on 
tissue culture flask, 
possibly all the way.  
no visible cells 
No image 
Polylactic acid  3 Cells growing on 
capillary tube   + 
cells growing on 
tissue culture flask, 
possibly all the way.  
0.7 
3.1 
3.2 
234 
 
Polylactic acid  + 
Argon 1 
0 mm   Media 
remained red 
no visible cells 
1.1 
Polylactic acid  + 
Argon 2 
0 mm   Media 
remained red 
no visible cells 
No image 
Polylactic acid  + 
Argon 3 
Cells growing on 
capillary tube   + 
cells growing on 
tissue culture flask, 
possibly all the way.  
Cells visible 
all the way 
along sample 
3.1 
3.2 
235 
 
3.3 
3.4 
3.5 
3.6 
236 
 
Polylactic acid  + 
ammonia 1 
Cells growing on 
capillary tube.  Media 
remained red 
no visible cells 
No image 
Polylactic acid  + 
ammonia 2 
0 mm   Media 
remained red 
no visible cells 
2.1 
Polylactic acid  + 
ammonia 3 
Cells growing on 
capillary tube   + 
cells growing on 
tissue culture flask, 
possibly all the way.  
Cells visible 
all the way 
along sample 
3.1 
3.2 
237 
 
3.3 
3.4 
 
238 
 
Day 0.0 29.0 31.0  
Date 18/07/2005 16/08/2005 17/08/2005  
Polypropylene 1 0 mm   Media 
remained red 
no visible cells No image 
Polypropylene 2 0 mm   Media 
remained red 
no visible cells No image 
Polypropylene 3 0 mm   Media 
remained red 
no visible cells No image 
Polypropylene  + 
Argon 1 
Cells growing on 
capillary tube    + 
cells growing on 
tissue culture flask 
can't measure 
improvement. Media 
turned orange. 
24.0 
1.1 
1.2 
1.3 
239 
 
1.4 
1.5 end 
Polypropylene  + 
Argon 2 
Cells growing on 
capillary tube   + 
cells growing on 
tissue culture flask 
can't measure 
improvement. Media 
turned orange. 
24.0mm pic22 
at end, pic23 is 
start end 
2.1 
2.2 end 
240 
 
2.3 
2.4 
Polypropylene + 
Argon 3 
0 mm  Media 
remained red 
Cells can be 
seen growing 
along the edge 
of the material 
only. 
3.1 
Polypropylene + 
ammonia 1 
Cells growing on 
capillary tube    + 
cells growing on 
tissue culture flask 
can't measure 
improvement. Media 
turned orange. 
28.0 
1.1 
241 
 
1.2 
Polypropylene + 
ammonia 2 
Cells growing on 
capillary tube   + 
cells growing on 
tissue culture flask 
can't measure 
improvement. Media 
turned orange. 
26.0 
2.1 
2.2 
2.3 
242 
 
Polypropylene + 
ammonia 3 
Cells growing on 
capillary tube   + 
cells growing on 
tissue culture flask 
can't measure 
improvement. Media 
turned orange. 
20 picture 36 
3.1 
Polypropylene  + 
Chitosan 1 
0 mm.  Piece of 
detached film 
floating in media.  
Media remained red 
 
1.1 
1.2 
1.3 
243 
 
1.4 
Polypropylene + 
Chitosan 2 
Cells growing on 
capillary tube    + 
cells growing on 
tissue culture flask 
can't measure 
improvement. Media 
turned orange. 
16.0 
2.1 
2.2 
244 
 
2.3 
2.4 
Polypropylene + 
Chitosan 3 
0mm? Cells growing 
on capillary tube    + 
cells growing on 
tissue culture flask. 
Media turned orange. 
no visible cells No image 
Polypropylene + 
Argon + Chitosan 1 
0 mm   Media 
remained red 
Sample 
destroyed 
No image 
Polypropylene + 
Argon + Chitosan 2 
Cells growing on 
capillary tube   + 
cells growing on 
tissue culture flask 
can't measure 
improvement. Media 
turned orange. 
no visible cells No image 
Polypropylene + 
Argon + Chitosan 3 
1/4 mm? Remaining 
length looks empty. 
Media turned orange. 
cells growing on 
tissue culture flask 
patches along 
edge 
3.1 
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Polypropylene + 
ammonia + Chitosan 
1 
Cells growing on 
capillary tube + cells 
growing on tissue 
culture flask can't 
measure 
improvement. Media 
turned orange. 
not consistent 
1.1 
1.2 
1.3 
1.4 
246 
 
Polypropylene + 
ammonia + Chitosan 
2 
Cells growing on 
capillary tube + cells 
growing on tissue 
culture flask can't 
measure 
improvement. Media 
turned orange. 
 
2.1 
2.2 
2.3 
 
247 
 
Polypropylene + 
ammonia + Chitosan 
3 
0mm. cell debris no visible cells 
No image 
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Day 0 29.0 30.0  
Date 18/07/2005 16/08/2005 17/08/2005  
polycaprolactone  1 0 mm   Media 
remained red 
Unclear, but 
unlikely to be 
cell growth 
1.1 
polycaprolactone  2 6 mm plus + cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange. cell debris 
Unclear, but 
unlikely to be 
cell growth 
2.1 
polycaprolactone  3 0 mm   Media 
remained red 
Unclear, but 
unlikely to be 
cell growth 
3.1 
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polycaprolactone  + 
Argon 1 
0 mm   Media 
remained red 
Unclear, but 
unlikely to be 
cell growth 
1.1 
polycaprolactone  + 
Argon 2 
Few cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange. 
Unclear, but 
unlikely to be 
cell growth 
2.1 
polycaprolactone  + 
Argon 3 
0 mm   Media 
remained red 
Unclear, but 
unlikely to be 
cell growth 
3.1 
polycaprolactone  + 
ammonia 1 
0 mm   Media 
remained red 
Unclear, but 
unlikely to be 
cell growth 
1.1 
250 
 
polycaprolactone  + 
ammonia 2 
0 mm   Media 
remained red 
Unclear, but 
unlikely to be 
cell growth 
2.1 
polycaprolactone  + 
ammonia 3 
0 mm   Media 
remained red 
Unclear, but 
unlikely to be 
cell growth 
3.1 
 
251 
 
Day 0 29.0 30.0  
Date 03/08/2005 01/09/2005 02/09/2005  
Polyester  1 7.5 mm (patches of 5, 
2 and .5 mm, + cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange. 
Cells visible 
all the way 
along sample? 
(Error 
reading?) 
1.1 
1.2 
1.3 
252 
 
1.4 zoom 
1.5 
Polyester  2 0 mm   Media 
remained red 
Cells visible 
all the way 
along sample? 
(Error 
reading?) 
2.1 
2.2 
253 
 
Polyester  3 5 - 8.75 mm + cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange. 
Cells visible 
all the way 
along sample 
(error 
reading?)  
3.1 
Polyester  + Argon 1 4 mm. Media turned 
orange. 
Cells visible 
all the way 
along sample? 
(Error 
reading?) 
1.1 
1.2 
Polyester  + Argon 2 0 mm   Media 
remained red 
Cells visible 
all the way 
along sample? 
(Error 
reading?) 
2.1 
254 
 
2.2 
Polyester  + Argon 3 0 mm   Media 
remained red 
Cells visible 
all the way 
along sample? 
(Error 
reading?) 
3.1 
Polyester  + ammonia 
1 
Few  cells growing 
on tissue culture flask 
Media remained red 
Cells visible 
all the way 
along sample? 
(Error 
reading?) 
1.1 
255 
 
1.2 zoom 
Polyester  + ammonia 
2 
0  mm  Media 
remained red 
Cells visible 
all the way 
along sample? 
(Error 
reading?) 
2.1 
Polyester  + ammonia 
3 
7.2 mm (2 one end, 5 
other). Media turned 
orange. 
Cells visible 
all the way 
along sample? 
(Error 
reading?) 
3.1 
3.2 
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Day 0 29 30  
Date 21/08/2005 19/09/2005 20/09/2005  
Polyurethane 1 0  mm  Media 
remained red 
no visible cells 
No image 
Polyurethane  2 30 mm  (dense and 
loose bits, 2mm d, 
4mm l, 6mm d, 8mm 
l, 4mm d, 2,2mm l) + 
cells growing on 
capillary tube  + cells 
growing on tissue 
culture flask. Media 
turned orange. 
no growth 
beyond 1/3 
(2.1 very 
difficult to 
visualise) 
patchy, non-
confluent 
No image 
Polyurethane  3 24 mm  (1mm dense, 
6mm gap/loose, 23 
mm dense or can't 
see) + cells growing 
on capillary tube  + 
cells growing on 
tissue culture flask. 
Media turned orange. 
(5 cells, 
nothing else) 
No image 
Polyurethane  + 
Argon 1 
30 mm (confluent) + 
cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange. 
Cells visible 
all the way 
along sample. 
Good growth. 
Confluent, 
gaps where 
removed from 
dish 
No image 
Polyurethane  + 
Argon 2 
0  mm  Media 
remained red 
no visible cells No image 
Polyurethane  + 
Argon 3 
30 mm (confluent) + 
cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
Good growth. 
Continuous 
along edge 
both sides. 
Plenty in 
No image 
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turned orange. middle. All the 
way 
Polyurethane  + 
ammonia 1 
30 mm (confluent) + 
cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange. 
Good growth. 
Confluent all 
the way 
No image 
Polyurethane  + 
ammonia 2 
30 mm (confluent) + 
cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange. 
Gap from 6-
12mm. Good 
growth. Non-
confluent. 
Gaps 
surrounded by 
cells 
No image 
Polyurethane  + 
ammonia 3 
30 mm (confluent) + 
cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange. 
Patchy growth. 
Mostly along 
edge. Not 
dense. All the 
way 
No image 
Polyurethane  + 
Argon + Chitosan 
powder 1 
30 mm (confluent) + 
cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange. 
Very good 
growth. 
Confluent all 
the way, both 
sides. 
Excellent 
No image 
Polyurethane  + 
Argon + Chitosan  
powder 2 
0 mm   Media 
remained red 
no visible cells No image 
Polyurethane  + 
Argon + Chitosan 
powder  3 
0  mm (signs of dead 
cells)  Media 
remained red 
no visible cells No image 
Polyurethane  + 
Argon @ Galashiels 
1 
30 mm (confluent) + 
cells growing on 
capillary tube + cells 
Cells confluent 
all the way 
along sample. 
No image 
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growing on tissue 
culture flask. Media 
turned orange. 
Dense 
Polyurethane  + 
Argon @ Galashiels 
2 
6mm v. loose, v. little 
clump of cells 
growing on tissue 
culture flask, no cells 
growing on capillary 
tube. Media turned 
orange. 
no visible cells No image 
Polyurethane  + 
Argon @ Galashiels 
3 
0 mm  signs of dead 
cells at one end  
Media remained red 
no visible cells No image 
Polyurethane  + 
Argon @ Galashiels 
4 
0 mm   Media 
remained red 
no visible cells No image 
Polyurethane  + 
Argon @ Galashiels 
5 
30 mm (confluent) + 
cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange. 
Cells confluent 
all the way 
along sample. 
Very dense all 
the way 
No image 
Polyurethane  + 
Argon @ Galashiels 
6 
0  mm  Media 
remained red 
no visible cells No image 
Polyurethane  + 
Oxygen @ Galashiels 
1 
0  mm  Media 
remained red 
no visible cells No image 
Polyurethane  + 
Oxygen @ Galashiels 
2 
0  mm  Media 
remained red 
no visible cells No image 
Polyurethane  + 
Oxygen @ Galashiels 
3 
0  mm  Media 
remained red 
no visible cells No image 
Polyurethane  + 
Oxygen @ Galashiels 
30 mm (confluent) + 
cells growing on 
Dense for first 
5mm. Cells 
No image 
259 
 
4 capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange. 
thick to 12mm. 
Not very dense 
to 28mm. 
Confluent for 
last 2mm. 
Cells probably 
ripped off in 
places 
Polyurethane  + 
Oxygen @ Galashiels 
5 
30 mm (confluent) + 
cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange. 
cells confluent 
on other side 
(outward 
facing side, 
very dense 
No image 
Polyurethane  + 
Oxygen @ Galashiels 
6 
0 mm   Media 
remained red 
no visible cells No image 
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Day 0 29 30  
Date 21/08/2005 19/09/2005 20/09/2005  
Polyester  1 30 mm  (dense for 
first 6mm, cells 
everywhere + cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange. 
1.2 is one end. 
Other end 
damaged by 
removal. 1/4 
from other end 
is picture 1.3. 
all the way 
1.1 
1.2 
1.3 
261 
 
Polyester  2 26 mm  (4mm gap 
16mm from one end, 
10mm from other. 
5mm very dense + 
cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange. 
2.2 is one end. 
Vas 2.3 is the 
other end. 
Very dense for 
about 6mm. 
2.4 is past 
dense bit 
2.1 
2.2 
2.3 
2.4 
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Polyester  3 7 mm (5.5mm dense, 
0.5mm less dense, 
1mm other end. Rest 
mostly gap with one 
or two cells + cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange. 
3.1 is very 
dense section. 
3.2 is ~ 6mm 
from end. Like 
3.3 for rest. 
Little 
clumping 8mm 
from 3.1 
3.1 
3.2 
3.3 
Polyester  + Argon 1 0 mm  traces of dead 
cells,  Media 
remained red 
no visible cells 
1.1 
263 
 
Polyester  + Argon 2 0 mm  traces of dead 
cells, Media 
remained red 
no visible cells 
2.1 
Polyester  + Argon 3 8 mm (7.25mm one 
end, 0.75mm the 
other end) + cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange. 
3.1 is one end, 
gap 
for~10mm, 
picture 3.2, 
loose until 
10mm from 
end (picture 
3.3) then 
confluent and 
dense until 
end. 
3.1 
3.2 
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3.3 
3.4 
3.5 
Polyester  + ammonia 
1 
9mm (7mm one end, 
dense, other end, 
1.25mm, 5.75mm gap 
then 0.75mm) + cells 
growing on tissue 
culture flask. Media 
turned orange. 
1.1 is one end. 
All the way, 
but mostly not 
very dense, 
like 1.4 &1.5. 
1.3 is mid, 1.4 
and 1.5 is 
either side 
1.1 
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1.2 
1.3 
1.4 
1.5 
Polyester  + ammonia 
2 
7 mm. Media turned 
orange 
2.1 is 10mm 
from dense 
end, then 
nothing (like 
picture 2.2) to 
other end. 
266 
 
2.1 
2.2 
Polyester  + ammonia 
3 
30  mm ( 9mm v. 
dense, dense all the 
way) + cells growing 
on capillary tube + 
cells growing on 
tissue culture flask 
3.1 is one end, 
like that for 
5mm, then less 
dense like 3.2 
for 2mm, then 
more dense 
like 3.3 for last 
5mm 
3.1 
3.2 
267 
 
3.3 
3.4 
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Day 0 29 30  
Date 21/08/2005 19/09/2005 20/09/2005  
Polylactic acid  1 Cell attachment at 
both ends. Can't 
measure, probably all 
the way. Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
fluorescence 
indicates 
nothing 
resembling 
live cells 
present 
1.1 
1.2 
1.3 
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Polylactic acid  2 Cell attachment at 
both ends. Can't 
measure, probably all 
the way. + Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
if this is cell 
growth, then 
its all the way , 
patchy in 
places(see  
picture) 
2.1 
2.2 
2.3 
2.4 
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2.5 
2.6 
2.7 
Polylactic acid  3 Cell attachment at 
both ends. Can't 
measure, probably all 
the way. + Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
Picture 3.2 = 
one end, 3.4 = 
the other, 
picture 3.7 = 
dense bit. 
Cells visible 
all the way 
3.1 
271 
 
3.2 
3.3 
3.4 
3.5 
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3.6 
3.7 
Polylactic acid  + 
Argon 1 
Cell attachment at 
both ends. Can't 
measure, probably all 
the way. + Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
All the way, 
mostly on edge 
(avoiding 
artefacts) 
picture 1.4 and 
picture 1.5. 
spanning 
width 
occasionally 
1.1 
1.2 
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1.3 
1.4 
1.5 
Polylactic acid  + 
Argon 2 
0 mm   Media 
remained red 
1st  picture is 
cells between 
14-18mm 
(approximately
) that is all 
2.1 
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Polylactic acid  + 
Argon 3 
Cell attachment at 
one end, can't 
measure + cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
Picture 33 is 
typical density. 
Picture 3.2 is 
1/4 way up. 
Cells all the 
way, but not 
very dense. 
One or two 
gaps on the 
other end. 
Probably 
ripped off 
from removal 
from the glass 
3.1 
3.2 
3.3 
Polylactic acid  + 
ammonia 1 
Cell attachment at 
one end, possibly 
other, can't measure + 
cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange 
Cells grew all 
the way, but 
have been lost 
due 
mechanical 
removal of 
sample from 
capillary tube. 
1.1 
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1.2 
Polylactic acid  + 
ammonia 2 
0  mm  Media 
remained red 
no visible cells 
2.1 
2.2 
Polylactic acid  + 
ammonia 3 
Cell attachment at 
one end, possibly 
other, can't measure + 
cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange 
Picture 3.1 is 
one end, 
confluent, 
same all the 
way. 
3.1 
276 
 
3.2 
3.3 
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Day 0 29 30  
Date 25/08/2005 23/09/2005 24/09/2005  
Polypropylene 1 0 or 6 mm (possibly 
6mm patch 6mm 
from one end, or no 
cells.)  Media 
remained red 
no visible cells 
No image 
Polypropylene 2 Cells attached and 
growth along sample. 
Can't see clearly 
enough to measure. + 
Cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange /red 
There were 
more cells. 
Appears a lot 
have been 
ripped off.  
Picture 2.2 is 
ripped site. 
5mm from one 
end; 12mm is 
empty/ ripped 
off. Cells 
remain on 
10mm of other 
end. 
2.1 
2.2 
2.3 
278 
 
2.4 
Polypropylene 3 Cells attached and 
growth up. Can't see 
clearly enough to 
measure. Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
Looks like 
what cells 
were there are 
dead by now. 
Similar 
appearance to 
pp2. No live 
cells left. 
No image 
Polypropylene + 
Argon 1 
0 mm? Media 
remained red 
no visible cells 
No image 
Polypropylene + 
Argon 2 
Definite attachment 
one end. Can't see 
well enough to 
measure. + Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
Confluent. 
Some cells still 
alive. 2.1 are 
live and dying 
cells, 2.2 are 
also live and 
dying cells. 
2.1 
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2.2 
Polypropylene  + 
Argon 3 
Can‟t see attachment. 
Can tell tomorrow. + 
Cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange 
Confluent and 
not very 
populated bits. 
3.1 is empty 
bit. 3.2 is 
better bit, 3.3 
is as clear as it 
gets I think. 
Reasonable. 
3.3 for 7mm, 
virtually 
empty for 
13mm, like 34 
for next 7mm, 
last 3mm 
pretty empty. 
Probably 
mechanical 
damage from 
removal of 
sample from 
capillary tube. 
3.1  
3.2 
3.3 
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3.4 
Polypropylene + 
ammonia 1 
Definite attachment 
one end. Can't see 
well enough to 
measure. + Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
Confluent. 
Cells start 
dying due to 
length of time 
required to 
examine all of 
the samples.  
Picture 1.1 
shows some 
cells alive on 
the other side 
with a gap 
from removal 
from the 
capillary tube. 
1.1 
1.2 
Polypropylene + 
ammonia 2 
0 mm   Media 
remained red 
no visible cells 
No image 
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Polypropylene + 
ammonia  3 
Definite attachment 
both ends. Can't see 
well enough to 
measure. + Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
3.1 and 3.2 
unclear 
(external side). 
Confluent but 
cells dying on 
external side. 
Cells still alive 
on inner side. 
3.1 
3.2 
3.3 
Polypropylene  + 
chitosan 1 
Definite attachment 
both ends. Can't see 
well enough to 
measure. + Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
Confluent but 
for gaps where 
removal from 
capillary tube 
caused holes. 
1.1 and 1.2 
1.1 
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1.2 
Polypropylene  + 
Chitosan 2 
Definite attachment 
both ends. Can't see 
well enough to 
measure. + Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
Confluent in 3 
bits. Looks 
like rest has 
been ripped 
off. 2.1 and 2.2 
are ripped bits. 
2.1 
2.2 
Polypropylene  + 
Chitosan 3 
0  mm  Media 
remained red 
no visible cells 
No image 
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Polypropylene + 
Argon + Chitosan 1 
Definite attachment 
both ends. Can't see 
well enough to 
measure. Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange /red 
0 (practically) 
like 1.1 and 
1.2 for all. V. 
poor) 
1.1 
1.2 
Polypropylene + 
Argon + Chitosan 2 
0 mm (peeling 
chitosan film. Think, 
almost def, none  
Media remained red 
no visible cells 
No image 
Polypropylene + 
Argon + Chitosan 3 
0 mm.  Media 
remained red 
no visible cells 
No image 
Polypropylene + 
ammonia  + Chitosan 
1 
0 mm.  Media 
remained red 
no visible cells 
No image 
Polypropylene + 
ammonia + Chitosan 
2 
0 mm.  Media 
remained red 
no visible cells 
No image 
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Polypropylene + 
ammonia  + Chitosan 
3 
Definite attachment 
both ends. Can't see 
well enough to 
measure. cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
just along edge 
(like bottom 
right of 3.1 
and 3.2 except 
for 2mm (3.1) 
3.1 
3.3 
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Day 0 29 30  
Date 25/08/2005 23/09/2005 24/09/2005  
Polycaprolactone  1 0. Very few cells 
growing on capillary 
tube (~12 cells max).  
Media remained red 
no visible cells 
No image 
Polycaprolactone  2 Possible attachment. 
Measure next day. 
Cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange /red 
Very few cells. 
2.1 
2.2 
polycaprolactone  3 0 mm.  Media 
remained red 
no visible cells 
No image 
polycaprolactone  + 
Argon 1 
8 mm + cells growing 
on capillary tube + 
cells growing on 
tissue culture flask. 
Media turned orange 
10mm not very 
dense. 1.1 is 
end of cells, 
1.2 is middle 
of cells 
1.1 
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1.2 
polycaprolactone  + 
Argon 2 
 Contaminated 
therefore discarded 
  
No image 
polycaprolactone  + 
Argon 3 
 Contaminated 
therefore discarded 
  
No image 
polycaprolactone  + 
ammonia  1 
30 mm + cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
confluent all 
the way 
1.1 
1.2 
polycaprolactone  + 
ammonia  2 
    
No image 
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polycaprolactone  + 
ammonia  3 
30 mm (lots of 
attachment both ends, 
all the way. (Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask). Media turned 
orange 
Cells grew all 
the way. 
Mostly 
confluent. 1.2 
is healthy bit. 
3.1 
3.2 
Solanyl  2% Chitosan  
2 
30 mm Lots of cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
16 definitely 
cells, a lot 
(optical 
microscope) 
No image 
Solanyl  2% Chitosan  
3 
0 mm.  Media 
remained red 
no visible cells 
No image 
Solanyl  + Chitosan 1 Few cells growing on 
capillary tube + cells 
growing on tissue 
culture flask, 
probably 0. Media 
turned orange 
4 or 5 clusters 
of cells, 
nothing 
directly 
measurable 
1.1 
288 
 
1.2 
Solanyl  + Chitosan 2 Few cells growing on 
capillary tube, lots of 
floating cells, 
probably 0. Media 
turned orange 
no visible cells 
No image 
Solanyl  + Chitosan 3 17.5 mm in clusters 
(6.3, 4& 4.5 mm) + 
cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange 
Clusters of 
cells 
No image 
Solanyl  + Argon + 
Chitosan 1 
Nothing visible.  
Media remained red 
no visible cells 
No image 
Solanyl  + Argon + 
Chitosan 2 
4 mm in clusters (1.5, 
0.5, 2 mm) + cells 
growing on capillary 
tube. Media turned 
orange 
Clusters of 
cells 
2.1 
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2.2 
Solanyl  + Argon + 
Chitosan 3 
26 mm in two 
clusters (8, 2mm gap 
then 18 mm) + cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
Cells visible 
all the way 
along sample. 
3.1 
3.2 
Solanyl + ammonia  
+ Chitosan 1 
12-30 mm + cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
Cells visible 
all the way 
along sample 
with little gaps 
probably from 
removal from 
glass tube) No image 
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Solanyl + ammonia  
+ Chitosan 2 
30 mm, lots of cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
Cells visible 
all the way 
along sample 
with little gaps 
probably from 
removal from 
glass tube) 
2.0 
Solanyl  + ammonia  
+ Chitosan 2 
30 mm lots of cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
Cells visible 
all the way 
along sample 
with little gaps 
probably from 
removal from 
glass tube) No image 
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Day 0 29 30  
Date 25/08/2005 23/09/2005 24/09/2005 No image 
Solanyl 1 Sample detached at 
one end. Cells 
growing all the way 
along sample. Cells 
at both ends, + cells 
growing on capillary 
tube + cells growing 
on tissue culture flask  
Media remained red 
Confluent for 
all but last part 
of sample. Still 
plenty of cells, 
just not all the 
way. Possibly 
ripped off. 
No image 
Solanyl 2 Cells present on 
detached end, not 
much else + cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask.  Media 
remained red 
no visible cells 
No image 
Solanyl  3 Contaminated 
therefore discarded 
 
No image 
Solanyl  + Argon 1 Contaminated 
therefore discarded 
 
No image 
Solanyl + Argon 2 Contaminated 
therefore discarded 
 No image 
Solanyl  + Argon 3 Contaminated 
therefore discarded 
 No image 
Solanyl + ammonia  
1 
Contaminated 
therefore discarded 
 No image 
Solanyl + ammonia  
2 
Contaminated 
therefore discarded 
 No image 
Solanyl  + ammonia  
3 
Contaminated 
therefore discarded 
 No image 
Solanyl  2% Chitosan  Contaminated  No image 
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1 therefore discarded 
Solanyl  2% Chitosan  
2 
Contaminated 
therefore discarded 
 No image 
Solanyl  2% Chitosan  
3 
Contaminated 
therefore discarded 
 No image 
Solanyl + Chitosan 1 4mm gap, 2mm, 
2mm gap, 2mm, 
2mm gap, 2mm. 
4mm other end + 
cells growing on 
capillary tube + cells 
growing on tissue 
culture flask . Media 
turned orange 
Picture 1.1 is 
dead bit, 1.2 is 
part of 
confluent bit. 
 1.1 
 1.2 
Solanyl  + Chitosan 2 0 mm.  Media 
remained red 
no visible cells No image 
Solanyl + Chitosan 3 0 mm.  Media 
remained red 
no visible cells No image 
Solanyl + Argon + 
Chitosan 1 
0  mm. Media has 
remained red 
no visible cells No image 
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Solanyl  + Argon + 
Chitosan 2 
8 mm (8mm dense, 
then can't see well 
enough. Probably a 
lot more) + cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange /red 
Mostly 
confluent (2.1 
is loose bit, 2.2 
is confluent 
bit. 
 2.1 
 2.2 
Solanyl + Argon + 
Chitosan 3 
30 mm confluent all 
the way. Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange /red. 
Confluent all 
the way. 
No image 
Solanyl + ammonia  
+ Chitosan 1 
0 mm.  Media 
remained red 
No visible 
cells. 
No image 
Solanyl + ammonia  
+ Chitosan 2 
30 mm (confluent all 
the way I think, 
pretty sure) + cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media is 
orange/ red. 
3x2mm gaps 
in confluence. 
Still cells. 
Probably due 
to removal. 
(Picture 2.2, 
cells conf) 
No image 
sol + ammonia  + 0 mm.  Media no visible cells No image 
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Chitosan 2 remained red 
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Day 0 29 30  
Date 25/08/2005 23/09/2005 24/09/2005  
Polyurethane 1 25 mm (5 mm gap, 
2mm from one end. 
Rest is confluent. 
Cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange 
1.1 is one end. 
Patchy like 1.1 
for 4mm, gap 
for next 
10mm, patchy 
for last 16mm. 
Confluent and 
loose bits like 
1.2, 1.3 & 1.4 
1.1 
1.2 
1.3 
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1.4 
Polyurethane  2 0 mm.  Media 
remained red 
no visible cells 
No image 
Polyurethane  3 0 mm.  Media 
remained red 
no visible cells 
No image 
Polyurethane  + 
Argon 1 
2mm + cells growing 
on capillary tube, no 
cells growing on 
tissue culture flask.  
Media remained red 
2mm 
1.1 
Polyurethane  + 
Argon 2 
0 mm.  Media 
remained red 
no visible cells 
No image 
Polyurethane  + 
Argon 3 
30 mm (confluent all 
the way.) Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
Confluent 
except for rips. 
Live and dying 
bits. 3.1 has 
both, 3.2 is 
dying bit, 3.3 
is clear bit 
3.1 
297 
 
3.2 
3.2 
3.4 
Polyurethane  + 
ammonia  1 
5.25 mm (4mm 
confluent. Other end, 
2mm gap, 0.75mm, 
0.5mm gap, 0.5mm) 
+ cells growing on 
capillary tube + cells 
growing on tissue 
culture flask. Media 
turned orange 
1.1 is isolated 
patch at one 
end. Like 1.2 
for first 6mm 
other end. 
Cells only 1/3 
way up width. 
Probably the 
strip was tight 
1.1 
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against the 
tube 
prohibiting 
further 
spreading. 
1.2 
Polyurethane  + 
ammonia  2 
30 mm (confluent all 
the way.) cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
All the way. 
Mostly 
confluent. 
Gaps both 
sides, but cells 
on both sides. 
All the way. 
2.2 is gap/ 
ripped bit 2.1 
2.2 
Polyurethane  + 
ammonia  3 
30 mm (confluent all 
the way.) + Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
confluent for 
first 7mm, 
4mm ripped 
but with cells, 
2mm 
confluent, 
14mm mostly 
empty/ few 
cells 
3.1 
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3.2 
Polyurethane  + 
Argon + Chitosan 
powder  1 
Can‟t measure 
accurately. Plenty of 
cells, but some ripped 
off from moving 
flask. + Cells 
growing on capillary 
tube + cells growing 
on tissue culture 
flask. Media turned 
orange 
Mostly empty. 
Either poor 
growth or lost 
due to ripping. 
1.1 is best bit; 
the rest is 
almost empty/ 
scattered. 
4x2mm one at 
each end, 1.1 
and other 
dying bit. 
Mostly empty. 
Rest like 1.2 at 
best. 
1.1 
1.2 
Polyurethane  + 
Argon + Chitosan  
powder 2 
0 mm.  Media 
remained red 
no visible cells No image 
Polyurethane  + 
Argon + Chitosan  
powder 3 
0 mm.  Media 
remained red 
no visible cells No image 
Polyurethane  + 
Argon @ Galashiels 
0 mm.  Media 
remained red 
no visible cells No image 
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1 
Polyurethane  + 
Argon @ Galashiels 
2 
0 mm.  Media 
remained red 
no visible cells No image 
Polyurethane  + 
Argon @ Galashiels 
3 
0 mm (little cells 
growing on capillary 
tube & cells growing 
on tissue culture 
flask).  Media 
remained red 
no visible cells No image 
Polyurethane  + 
Oxygen @ Galashiels 
1 
12 mm + (12mm 
confluent/ patchy. 
6mm gap, then can't 
tell. Plenty on other 
end.) + Cells growing 
on capillary tube + 
cells growing on 
tissue culture flask. 
Media turned orange 
4.5mm 
confluent to 
not (1.1 is 
bloody 
unclear.), 6mm 
form other end 
is 3mm 
cluster. Poorly 
stained. 
1.1 
Polyurethane  + 
Oxygen @ Galashiels 
2 
0 mm (2-3cells on 
flask, little + cells 
growing on capillary 
tube. Media turned 
orange 
no visible cells 
No image 
Polyurethane  + 
Oxygen @ Galashiels 
3 
30 mm (all the way 
confluent except 
2mm patchy 2mm 
from one end). Media 
turned orange 
28 (2mm gap 
2mm from one 
end. Some 
cells still alive 
8hrs after 
staining) 
3.1 
301 
 
3.2 
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Day 0 29 30  
Date 25/08/2005 23/09/2005 24/09/2005  
Polylactic acid 1 Can‟t measure. (Free 
floating. Both ends 
have cells. Few cells 
growing on tissue 
culture flask, + cells 
growing on capillary 
tube. Media turned 
orange 
confluent all 
the way 
No image 
Polylactic acid 2 Cells on one end 
contracting sample. 
Can't measure. 
Probably not on other 
end. Cells growing 
on tissue culture 
flask. Media turned 
orange 
11mm. 
Confluent to 
not dense. 1.1 
is healthy bit, 
1.2 where cells 
have started 
dying 
No image 
Polylactic acid 3 0 mm.  Media 
remained red 
no visible cells No image 
Polylactic acid + 
Argon 1 
0 mm.  Media 
remained red 
no visible cells No image 
Polylactic acid + 
Argon 2 
0 mm.  Media 
remained red 
no visible cells No image 
Polylactic acid + 
Argon 3 
0 mm.  Media 
remained red 
no visible cells No image 
Polylactic acid + 
ammonia  1 
0 mm. Media 
remained red 
no visible cells No image 
Polylactic acid + 
ammonia  2 
0 mm.  Media 
remained red 
no visible cells No image 
Polylactic acid + 
ammonia 3 
0 mm.  Media 
remained red 
no visible cells No image 
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